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While much is known about the macrophage receptors important for the
phagocytosis of apoptotic cells, little is known about how macrophages first
"sense" and then move toward dying cells. Work presented here investigates the
chemoattractant molecules released by dying cells in the "Come-get-me" stage
of apoptotic cell clearance.
The CD 14 knockout mouse (CD 14-/-) was observed to have increased
numbers of free apoptotic cells in the thymus. It was hypothesised that this was
due to a defect in macrophage clearance of dying cells. In vitro assays revealed
that macrophages from the CD 14-/- mouse had a partial defect in the
phagocytosis of apoptotic cells. Clearance also involves macrophage movement
towards the apoptotic corpse. Therefore, it was hypothesised that, in addition to
a phagocytosis defect, CD 14-/- had impaired chemotaxis to apoptotic cells.
An in vitro transmigration assay was developed using the Burkitt's
lymphoma (BL) cells as a source of apoptotic cells. In this assay, monocytes
and macrophages, but not neutrophils, migrated preferentially to apoptotic BL,
and chemotaxis correlated to phosphatidylserine exposure on apoptotic cells.
Chemotaxis was abolished when BL were transfected with the anti-apoptotic
protein bcl-2. Although CD 14 was up regulated on the surface of the migrating
macrophages, experiments with knockout cells revealed that chemotaxis did not
require either CD 14 or the scavenger receptor CD36.
Experiments using a viral chemokine antagonist (vMIPII) suggested that
fractalkine (CX3CL1) was a candidate "come-get-me" signal released from
dying cells. Fractalkine was expressed by apoptotic cells and in chemotaxis
assays, CX3CL1 competitively inhibited macrophage migration to apoptotic
cells but not to CCL5 (RANTES). Monoclonal antibodies that blocked the
chemokine domain of CX3CL1 also inhibited macrophage chemotaxis to
apoptotic cells.
This is the first demonstration of the involvement of a known chemokine,
CX3CL1 in the clearance of apoptotic cells. In this novel process, cells dying by
apoptosis release fractalkine that recruits macrophages primed to efficiently
engulf the cell corpse.
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In order to ensure their timely removal, it is known that apoptotic cells
release chemoattractive molecules that attract phagocytes. This thesis will investigate
the of role macrophage receptors in the chemotaxis to, and engulfment of apoptotic
cells.
1.2 Apoptosis
When a cell dies it usually goes quietly, by a process of programmed cell
suicide called apoptosis. But when it is faced by overwhelming infection or damage,
the cell may simply explode in an un-planned pattern of death (Cotran, 1989).
Accidental death is called necrosis, it happens without warning and cells may have
limited time to signal their distress. First the cell swells, and then it bursts releasing
organelles like mitochondria, proteolytic granules and lysosomes. Cellular debris can
sometimes be detected in healthy tissues and this can be due to "secondary" or late
necrosis. Unlike apoptotic cell contents, the organelles released during necrosis are
not wrapped in a cover of plasma membrane (Savill, 2002).
Critically, throughout apoptosis, the plasma membrane appears to remain
intact and cell contents do not leak out and attract the attention of the immune
system. The name "apoptosis" is coined from the Greek meaning "leaves falling off
the trees," and was first described by Kerr, Wyllie and Currie in 1972 (Kerr, 1972). It
is a physiological process that regulates cell numbers and maintains homeostasis.
During apoptosis, the cell carefully packages up its nuclear material and safely
recycles intracellular constituents. This is done in a step-wise manner and the
accompanying morphological changes can be monitored microscopically. First the
lipids in the plasma membrane are rearranged. Best known of the apoptotic signals is
the translocation of the phospholipid, phosphatidylserine (PS) from the inner to the
outer leaflet of the plasma membrane (Fadok, 1992); This rearrangement is
coordinated by scramblase and translocase enzymes (Williamson, 2002). The
exposure of PS can be measured by the calcium-dependent binding of AnnexinV
(Koopman, 1994). Next, the cytoskeleton collapses and consequently the cell
shrinks, the nuclear envelope is dismantled and the DNA becomes fragmented. The
different lengths of DNA resulting from this enzymatic process give a typical
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"ladder" pattern when the DNA is run out on a gel. Small blebs appear on the plasma
membrane often containing nuclear material and sometimes, autoantigens (Casciola-
Rosen, 1994).
Apoptosis is essential for the remodelling of tissues, for example, the
dissolution of the inter-digital finger webs during embryogenesis. It is also important
during lymphocyte development and in response to infection. Germinal-centres are
sites of intense B cell proliferation and programmed cell death, and here, apoptotic
cells are seen frequently, alongside the "tingible body" macrophages that are busy
engulfing them. Likewise, apoptotic cells are found in the thymus and bone marrow,
two sites where self-reactive clones are deleted. In the periphery, apoptosis is
important in the control of viral and intracellular infections. The proteases and
nucleases that are activated during apoptosis also destroy viral DNA and so limit the
spread of infection. Therefore, apoptosis is a safer method of disposing of cells than
necrosis. It is not surprising that cytotoxic T lymphocytes (CTL) can initiate
programmed cell death through the extrinsic pathway.
A number of extracellular signals (extrinsic) and intracellular (intrinsic)
pathways can trigger apoptosis (Figure 1.1). CTL expresses Fas ligand that binds the
Fas (CD95) death receptor on target cells (Trauth, 1989). Fas is a member of the
Tumour Necrosis Factor receptor family (TNFR) and is an example of how the
extrinsic pathway is triggered. Upon CTL induction, the receptor clusters at the
plasma membrane and recruits adaptor proteins able to trigger an enzyme cascade
resulting in cell death. The proteases that are responsible for the disassembly of the
cell are called caspases, "C" because they have cysteine at their active site and "asp"
because they cleave proteins at specific aspartic acid residues (Nicholson, 1977;
Nicholson, 1999;Cohen, 1997). Caspases are not synthesized de novo, but lie in pro¬
enzyme form "waiting" for the pro-apoptotic signals. Each caspase sequentially
activates another in the chain, and so the number of active protease enzymes is
amplified at each step of the process. The intracellular pathway is often recruited
during the activation of the extrinsic pathway. p53, the most commonly mutated gene
in human malignancies, induces apoptosis in damaged cells in order to prevent the
replication of faulty genes (Lowe, 1993). Under the control of genes targeted by p53,
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mitochondria release cytochrome C. This activates caspase 3, the executor enzyme,
which is the common to both pathways.
Caspases are closely regulated by a set of genes in the Bcl-2 (B cell
lymphoma) family (Chao, 1998). Bcl-2 inhibits apoptosis by blocking the release of
cytochrome c (Wang, 1993). Bcl-2 is a 24kDa membrane protein that was cloned in
1986 (Cleary, 1986). Cell lines used in the present work have been transfected with
Bcl-2 in order to prevent apoptosis (Henderson, 1991;Milner, 1992). Two other
members, Bax and Bak also stimulate cytochrome c release, whereas Bad, is pro-
apoptotic because it binds and inactivates bcl-2. Another family member, Bid is able
to insert the lipid lysophosphatidylcholine (LPC) in to the mitochondrial membranes
and this membrane perturbation promotes the leakage of cytochrome c
(Goonesinghe, 2004). Interestingly, LPC can also be released from apoptotic cells
and is chemoattractive to monocytes (Lauber, 2003).
Many of the phases of apoptosis can be viewed under a microscope, except
from very early on in the apoptotic programme when dying cells may be
indistinguishable from their live neighbours. However, new techniques have been
developed to help spot these fresh corpses (Leers, 2002). Even so, apoptotic cells are
vanishingly rare except for at the lymphoid sites mentioned previously. The reason
for their scarcity is that they are swiftly removed by either neighbouring cells or by
the "professional phagocytes", the macrophages. The process of engulfment of
apoptotic cells is the last, but sometimes forgotten stage of the apoptotic process in
situ (Fadok, 1999).
1.3 Clearance of apoptotic cells
Apoptotic cells are rarely seen in vivo because their clearance is so quick and
efficient. Over 100 years ago, Elias Metchnikoff first described macrophages
phagocytosing dying cells (Karnovsky, 1981 ;Shafrir, 1995). When apoptotic cells are
seen in histological tissue sections, they are nearly always associated with a
macrophage (Kerr, 1972). Therefore, macrophages have been named the
"professional" phagocytes. It is likely that the macrophage's main role is to remove
apoptotic cells from areas with high death rate, as happens during inflammation or
development (reviewed in Gregory, 2004). Although not studied as deeply, non-
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specialised neighbouring cells also have a role in the clearance of cell corpses
(Parnaik, 2000). Removal of dead cells by these "amateur" phagocytes may account
for the majority of the day-to-day clearance required to keep up with the pace of
physiological cell turnover. Amateur phagocytes, like retinal epithelium and
mesenchymal cells are less mobile than macrophages and so on-the-spot
phagocytosis proceeds more slowly in these cells (Marmorstein, 1998; Wood, 2000).
Local removal of dead cells is very efficient. The PU1 knockout mice have no
macrophages and yet develop normally because of the work of these amateur
phagocytes (McKercher, 1996). The nematode worm, Caenorhabditis elegans
(C.elegans), also has no macrophages and uses unspecialised neighbours to remove
apoptotic cells efficiently (Wu, 1998).
Caenorhabditis elegans
The study of the worm C.elegans revealed a link between the genes
mediating apoptotic cell-clearance and those that signalled death. When a cell dies by
programmed cell death it has the foresight to activate undertaker genes that are
required for the removal of its cell corpse. These seven ced (Cell Death Defective)
genes are there to allow development to proceed smoothly or more simply, in order
to recycle cell parts. Mutations in the ced genes leads to the persistence of 131
"extra" cells. None of the ced genes is essential because the worm can tolerate the
presence of these persistent apoptotic cells (Devitt, 2004 66;Ellis, 1991). However,
600 million years of evolution has insured that even primitive organisms have
developed mechanisms to remove dying cells swiftly and quietly. The more complex
fruit-fly, Drosophila melanogaster, cannot survive without apoptosis and has
developed haemocytes that are able to remove dying cells in order for development
to proceed normally (Franc, 1996). Haemocytes may be the forerunners of
mammalian macrophages, the so-called "professional" phagocytes.
All seven ced-genes have human homologs with a conserved function in both
the clearance of apoptotic cells and in cell migration (Yuan, 1993; Hengartner,
1994). The ced genes are grouped into two separate cassettes and function as two
pathways that possibly interact. The first pathway contains the genes (CED1, CED6
and CED7) and their human homologs (LRP/CD91, hCed6/GULP and ABCA1)
respectively (Liu, 1998;Wu, 1998;Zhou, 2001). Cedl, like CD91 is a transmembrane
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receptor for apoptotic cells and Ced 6 is an adaptor protein that aids clustering of this
receptor (Su, 2002). Indeed, CD91 also forms clusters when interacting with
apoptotic cells (Ogden, 2001). Ced 7 facilitates the distribution of lipids on both the
macrophage and the apoptotic-cell membranes. The human homolog, the ABCA1
transporter also alters the local composition of lipids in the plasma membranes.
ABCA1 is required to be on both the apoptotic cell and the phagocyte for engulfment
to occur (Wang, 2003;Williamson, 2002). By moving phosphatidylserine, ABCA1
affects the overall fluidity of the plasma membranes of both cells and increases cell
mobility and so enhances clearance (Hamon, 2000;Hamon, 2002).
The second pathway or cassette contains four genes (CED2, CED5, CED 12
and CED10) and their human homologs (crkll, DOCK 180, ELMO and Rac/GTPase
respectively), (Wu, 1998; Zhou, 2001; Reddien, 2000). These are genes important for
both cell mobility and chemotaxis (Wu, 2001). The group consists of an adaptor
protein (ced2/crkll), a protein GEF (guanine-exchange-factor) complex. Together
ced5 and ced6 remove GDP that allows GTP to bind to cedlO/Rac (Brugnera, 2002).
The human homolog of ced 10, is the Rho-family-member Rac, that promotes the
extension of the actin cytoskeleton. This is important for both the outgrowth of
pseudopodia for engulfment and also for macrophage migration through tissues
towards apoptotic cells. The upstream receptor for the second pathway is not known
but it could be either an integrin-like receptor or perhaps a chemokine receptor
(Albert, 2000).
Removal of apoptotic cells
A brief glance at the number of receptors implicated in apoptotic cell-
clearance in Figure 1.2, confirms that mammals are far more complicated than
worms. Even so, the question of why so many molecules are needed for engulfment
cannot be avoided. Suggestions of receptor redundancy have been put forward to
explain these vast numbers, reasoning that engulfment of apoptotic cells is a critical
process that needs fail-safe back up molecules. In support of a redundancy theory,
some knockouts (clq-/- and MFG-E8-/-) show very specific defects that are limited
to a single organ for example in the MFG-E8-/- mouse apoptotic cells accumulate in
germinal centres (Hanayama, 2004); And others, for example, CD 14-/-, display no
adverse effects to the persistence of apoptotic cells (Devitt, 2004). Undoubtedly,
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clearance is important, but perhaps this view has been overstated particularly as
many of the receptors like Clq and CD14 have other immunological jobs to do. It is
likely that different strains of mice and different tissues have a preferred method of
clearance. In addition, these molecules do the clearing up together, as a team. A
model has been proposed where some molecules simply anchor the apoptotic cell to
the phagocyte e.g. CD 14 (Devitt, 2004) and others signal for engulfment e.g. MFG-
E8 (Hanayama, 2004). This has been described as "tethering" and "tickling (Henson,
2001; Hoffmann, 2001). This may be too simplistic because clearance of apoptotic
cells can be divided into at least six phases: "Come-get-me", "eat-me", "don't-eat-
me", "tether", "tickle" and finally the immunological "consequences" of engulfment.
With such complexity, one or two examples, pertinent to the work of this thesis will
be chosen to illustrate each of the five steps.
"Come-get-me"
Lysophosphatidylcholine, SI 9, EMAPlIandfractalkine
A cell that is in the process of committing suicide will release
chemoattractive molecules that advertise its presence to phagocytic cells.
Lysophosphatidylcholine, is an example of a chemoattractive molecule released by
apoptotic cells (Lauber, 2003) and will be discussed in Section 1.6. If neighbouring
cells within are within range, these "come-get-me" signals need not travel too far and
may help direct tissue macrophages towards the target cell. The longer-range signals,
such as the chemokines released by endothelial cells, like RANTES (CCL5), are able
to recruit monocytes from the circulation into organs. The role of fractalkine
(CX3CL1) in macrophage chemotaxis to apoptotic cells will be discussed separately















































"Eat-me" and "don't eat me" signals require the phagocyte and the apoptotic
cell to be in close proximity. Phosphatidylserine (PS) is the most famous of all the
"eat-me" signals (Fadok, 1992). PS normally resides on the inner leaflet of the
plasma membrane but during apoptosis this asymmetry is lost and membrane lipids
become redistributed through the actions of two enzymes a flipase and a scramblase
(Bratton, 1993; Williamson, 2002). The detailed mechanisms that control PS
redistribution are not fully understood to date. But PS is one of the earliest steps in
apoptosis and precedes morphological events like cell-shrinkage and bleb formation.
FITC-labelled annexin V, that binds to surface PS in the presence of calcium
is commonly used for detecting apoptotic cells by flow cytometry (Koopman, 1994).
During apoptosis the dying cell transports a related annexin, annexin 1 from the
cytoplasm to the external leaflet of the plasma membrane alongside PS (Arur, 2003).
If antibodies or RNA silencing inhibits the translocation of annexin 1, this prevents
engulfment of the apoptotic cell. Annexin 1 has a role in both tethering and
engulfment. It is unknown whether annexin 1 binds directly to a phagocytic receptor.
The fMLP (formylated Methionine-Leucine-Phenylalanine) chemokine receptor
expressed on monocytes but especially on neutrophils can bind annexin 1 (Walther,
2000). The fMLP receptor binds to N-formylated peptides produced by bacteria and
guides leukocytes to sites of infection.
Alternatively, annexin 1 may not bind to a receptor but attach directly to PS
on the apoptotic cell surface. As for annexin V, this binding is calcium dependent.
Early on in apoptosis there is a spike in intracellular calcium levels that triggers the
mobilisation of annexin 1 from the cytoplasm to the plasma membrane. When faced
with the lower calcium concentration of the extracellular space, annexin tends to
aggregate. This may pull PS and other apoptotic cell-ligands into clusters that can be
recognised by the Clq-calreticulin-CD91 complex (Ogden, 2001).
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A receptor for phosphatidylserine
No macrophage surface receptor had been shown to bind directly to PS until
2000 when Fadok and colleagues described the phosphatidylserine receptor (PSR)
(Fadok, 2000). However, doubts about the identity of the PSR have recently come to
light (Williamson, 2004). PSR was discovered through screening a panel of
monoclonal antibodies that could block the uptake of apoptotic cells. The same
unbiased strategy was used when CD 14 was found to be a receptor for apoptotic cells
(Devitt, 1998). The monoclonal antibody 217G8E9 blocked engulfment and
stimulated the release of TGFp (Fadok, 1998). Using phage display, the peptide
recognised by mab 217G8E9 was sequenced and cloned. Later studies showed that
the psr-gene product was a nuclear protein, and it seemed unlikely that it was
involved in apoptotic cell clearance at the periphery of the cell (Cui, 2004).
Two mouse PSR knockouts on the mixed 129 (agouti brown
mouse)/C57BL/6 (black mouse) backgrounds were produced (Li, 2003; Kunisaki,
2004). Both of these psr-/- reported perinatal lethality and a failure of apoptotic cell-
clearance. In particular, the lungs of the PSR-/- embryos were abnormal. Lungs
develop by extension and branching, not by involution and apoptosis, as occurs
during mammary development. It again seemed unlikely that a failure to engulf
apoptotic cells was driving this phenotype. Around the same time the worm homolog
of the psr, the upstream receptor for pathway two, was knocked out in C.elegans.
Again, there was persistence of apoptotic cells but unexpectedly, the mutation was
less severe than deletions of other ced genes (Wang, 2003).
A third group made a psr-/- on the C57BL/6 background and again this
mouse had gross embryological malformations, but importantly, there was no defect
in the removal of apoptotic cells (Bose, 2004). Furthermore, the antibody,
mab217G8E9 bound to both wild type and psr-/- cells. It seems that the discovery of
the psr gene was a case of mistaken identity and that mab217G8E9 may cross react
with another surface protein. The spectrum of persistence of apoptotic cells shown
across the knockouts from different backgrounds is a warning to interpret differences




Recently it has been shown that live cells express "don't eat me" signals to
prevent them being engulfed by macrophages. A homotypic interaction between
CD31 / (PECAM) allows the important discrimination of live from apoptotic cells.
CD31 normally repels CD31 on a phagocyte, or more correctly, it signals the
macrophage to "go-away" (Brown, 2002). However, during apoptosis, CD31 is
somehow disabled and the CD31's signal is no longer "go away". How CD31
becomes altered is unknown, it may involve changes in the carbohydrate moieties as
may happen to ICAM3, perhaps before being recognised by CD 14 (Moffatt, 1999;
Gregory, 2000; Gregory, 1998). Red blood cells escape destruction in the spleen by
expressing CD47 that signals "don't-eat-me" to splenic macrophages expressing SIP-
Ra. (Oldenberg, 2000). Signals from live cells may be more important in vivo where
clearance is a swift and early event. If a macrophage recognises an altered apoptotic
ligand, tethering and engulfment of the apoptotic cell will ensue.
"Tether"
CD14
The lipopolysaccharide (LPS) -receptor CD 14 is an example of a protein that
tethers apoptotic cells (Devitt, 1998; Devitt, 2004). Indeed, soluble CD 14 that is
abundant in plasma can discriminate between live and apoptotic cells by opsonising
LPS-like motifs (Devitt, 2004). Similar to CD 14, other important immunoregulatory
proteins also bind to apoptotic cells. This group of well-characterised proteins
including antibodies and complement proteins have been shown to opsonise
apoptotic cells (Ogden et al 2001). IgM binds lysophosphatidylcholine on the surface
of dead cells, and auto-antibodies from patients with Systemic Lupus Erythematosus
(SLE) were shown to bind to the surface blebs of apoptotic cells (Casciola-Rosen,
1994). These opsonins can bridge the gap between the apoptotic cell and phagocyte
by binding Fc and complement receptors on macrophages (Hart, 2004).
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Apoptotic cells are often recognised by pattern-recognition-receptors (PRR)
like CD14 and collectins (Vandivier, 2002; Gregory, 2000; Ogden, 2001). PRR are
conserved germ line-encoded receptors that recognise repetitive molecular patterns
on pathogens. One example of a pathogen-associated-molecular pattern (PAMP) is
lipopolysaccharide (LPS). PAMPS are essential for pathogen survival and the PRR's
that recognise them have evolved over millions of years. In fact the PRR "Toll"
genes are conserved between plants and humans (Medzhitov, 1997). This has led to
some of the "altered" PAMP-like ligands found on apoptotic cells to be called,
perhaps indiscriminately, ACAMPS (Apoptotic-cell-associated-molecular patterns,
(reviewed in Gregory, 2004).
Although many molecules like CD36, complement and CD68, can recognise
apoptotic cells, but there is very little evidence these bind to PS directly (Kodama,
1996; Ogden, 2001; Savill, 1992; Ren, 1995). The vitronectin receptor (av|33), the
integrin receptor avp5 and MER all employ bridging molecules that first opsonise
apoptotic cells before gathering them in (Scott, 2001). The importance of CD 14 in
macrophage interaction with apoptotic cells is discussed in more detail in a later
section of this chapter.
"Tickle"
MFG-E8 and CD36
MFG-E8 (Milk fat globule epidermal growth factor protein 8) is an example
of a bridge that connects PS to avP3 and avP5 (Hanayama, 2002). As its name
suggests, it is found secreted in breast milk. It binds to PS via a clotting factor VIII-
homology domain and it has an RGD (Arginine, Glycine and Aspartate) motif at its
amino-terminus that enables it to bind to integrins. MFG-E8 is expressed by "tingible
body" macrophages in germinal centres, where it is important in the receptor
mediated-phagocytosis of apoptotic cells. MFG-E8 knockout macrophages tethered
apoptotic cells but could not engulf or "tickle" them (Hanayama, 2004). In addition
these knockout mice have enlarged spleen, but the cell ratios are normal. This bulk is
not simply due to the persistence of apoptotic cells but may be related to MFG-E8's
effect on the lymphocytes life span. Alternatively MFG-E8 may affect B and T cell
recruitment and retention in the spleen.
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CD36 is another phagocyte receptor that uses integrin receptors to engulf
apoptotic cells (Savill, 1992). It is a well-characterised class B scavenger receptor for
oxidised low-density lipoprotein that also recognises altered lipid on the surface of
apoptotic cells (Ren, 1995). Scavenger receptors are mainly expressed on
macrophages and bind negatively-charged, acetylated and oxidised low density
lipoproteins (LDL) (Krieger, 1994; Chang, 1999). Like wise, CD36 is expressed by
macrophages and platelets and recognises apoptotic cells in a complex of
thrombospondin and avp3 (Savill, 1992).
Monoclonal antibodies raised against LDL on apoptotic cells inhibited
macrophage clearance, whereas over-expression of CD36 in a non- phagocytic cell
line allowed the phagocytosis of apoptotic cells. Only "altered" or oxidised LDL (but
not native LDL) and anti-CD36 antibodies could inhibit uptake of apoptotic cells
(Ren, 1995). Although CD36 will bind to PS, it binds to the apoptotic-cell indirectly
through a thrombospondin bridge, that links to an unknown ligand. Whether or not it
binds PS directly, CD36 is required for the PS dependent uptake of apoptotic cells
(Fadok, 1998). Recently, it was discovered that CD36, like TLR2, binds Lipoteichoic
acid (LTA) and diacylglycerides, both PAMPs displayed by Gram-positive cells
(Hoebe, 2005). Antibodies against PAMPS like LPS and LTA have been used to
identify novel apoptotic cell-associated patterns (Tennant, 2004).
CD36 appears to have a choice of which integrin receptor to bind, either
aVp3 or aVp5. CD36 interacts with aVp3 on macrophages to engulf apoptotic cells
quietly, but when CD36 associated with aVp5 on dendritic cells, it can lead to cross
presentation of self-antigens. This interaction could potentially result in
autoimmunity (Albert, 1998;Kodama, 1996).
The immunological consequences of engulfing apoptotic cells
Autoimmunity and TGF-ft
The many different types of receptor implicated in the phagocytosis of
apoptotic cells are striking (Figure 1.2a). It is intriguing that such a diverse group of
receptors is involved in the phagocytosis of apoptotic cells and yet, despite this
variety, the outcome of engulfment is almost always non-inflammatory (reviewed in
(Savill, 2002; Henson, 2001; Grimsley, 2003).
31
The macrophage is not simply a waste disposal and recycling outfit, although
the consequences of it engulfing a dying cell may be neutral and environmentally
sound (Kurosaka, 2003). The phagosome is a secure place to break-up apoptotic cells
and it is said, to prevent the environmental damage caused by necrotic cells. In order
to prevent such damage the accepted wisdom is that the apoptotic-cell membrane
must be intact before "secondary necrosis" has occurred. However, in vitro
observations show that macrophages prefer to eat leaky cells. It may not be the mode
of cell death, but the type of cell that is dying that is critical (Gregory, 2004). The
membranes of both necrotic and apoptotic cells can stimulate the release of TGFp by
macrophages (Fadok, 2001). When a neutrophil dies it is more likely to trigger
inflammation than an apoptotic lymphocyte. It may be that necrotic death of short¬
lived granulocytes early on in the immune response may help to amplify the immune
response early. However, a proinflammatory reaction to the death of a lymphocyte
(present during the later stage of an infection) might delay healing and even promote
chronic inflammation. In addition, elastases released from apoptotic neutrophils
could cleave the putative anti-inflammatory PSR, but conceivably pro-inflammatory
receptors could be cleaved by the same mechanism (Vandivier, 2002).
Most often, the clearance of apoptotic cells by mononuclear phagocytes
results in anti-inflammatory effects, with the production of TGFp, IL-10 and PGE2
(Voll, 1997; Fadok, 1998; McDonald, 1999). In addition, apoptotic cells can release
these mediators themselves (Ogden, 2005; Gao, 1998; Chen, 2001).
However, when apoptotic cells are fed to macrophages in the presence of LPS
it must be remembered that the natural cell's response to LPS alone may be to
balance the early release of TNFa by a later, perhaps more sustained, production of
IL10. This is why it is not surprising to see that apoptotic cells do not completely
quench the initial inflammatory response to LPS (Lucas, 2003). The simple binding
of apoptotic neutrophils to monocyte produced IL-10 in response to LPS (Byrne,
2002). A cuff of apoptotic cells, that can't be phagocytosed, surrounds macrophages
in the spleen of the MFG-E8 -/- mouse. Despite binding apoptotic cells these mice
still develop inflammatory autoimmune disease at 40 weeks (Hanayama,
2004;Hanayama, 2002). Other knockouts like Clq and MER and also have
autoimmune disease in the presence of apoptotic cells (Botto, 1998; Scott, 2001).
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However, apoptotic cells persist in CD 14-/- without any inflammatory consequences
(Devitt, 2004). One mechanism for the autoimmunity may be the cross-presentation
of self-antigens on MHC by dendritic cells (Albert, 1998; Albert, 2004).
Autoantibodies against cell membrane-phospholipids can direct pro-inflammatory
responses through Fc-receptor signalling (Kim, 2003; Hart, 2004). The interpretation
that all necrotic cells are pro-inflammatory whereas apoptotic cells are not, over¬
simplifies the complex interaction between the dead cell and the phagocyte (Gregory,
2004).
CD14
CD14 is a 55kDa transmembrane receptor that binds the phospholipids PS
and PC and also lipopolysaccharide (LPS) from gram-negative bacteria (Jack, 2000;
Ulevitch, 1999). CD 14 is predominantly expressed on myeloid cells, monocytes and
macrophages. CD 14 has a short glycosylphosphatidylinositol GPl-linked
cytoplasmic tail that contains no signalling elements and therefore, CD 14 is thought
to pair up with other receptors, like the Toll-Like Receptors (TLRs) and complement
receptor, CD1 lb, in order to signal (Akashi, 1999; Perera, 2001).
CD14's most famous role is that of a receptor for bacterial endotoxin, LPS,
where it is responsible for the production of TNFa that can lead to septic shock
(Wright, 1990; Beutler, 2001). The discovery that CD 14 is also a receptor for
apoptotic cells was initially surprising. The importance of CD 14, in this context was
discovered by screening a panel of "orphan" antibodies against leukocyte surface
structures for their capacity to inhibit macrophage and apoptotic cell interactions.
The monoclonal antibody 61D3 was shown to block recognition and phagocytosis of
apoptotic cells and after transient expression cloning and probing, it was revealed
that 61D3 bound to CD 14 (Devitt, 1998). What is more, epitope-mapping
experiments showed that 61D3 bound close to the LPS binding pocket. In fact this
binding was so close that the antibody could block TNFa production after LPS
stimulation (Devitt, 1998). Because of the close proximity of 61D3 binding to the
LPS binding site, an intriguing question arises: Do apoptotic cells display LPS-like
ligands on their surface? If so, it would be predicted that the CD14-mediated
clearance of apoptotic cells pro-inflammatory. However, apoptotic cells persist
without causing inflammation in the CD 14-/- mouse (Devitt, 2004).
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In addition to LPS, CD 14 binds many other ligands, such lectins and different
phospholipids (Yu, 1997; Wang, 1998; Chow, 1999; Poltorak, 2000; Sugiyama,
2001). Therefore Devitt and colleagues investigated whether CD 14 was an
alternative receptor for PS (Devitt, 2003). CD14 could bind to PS but it had a higher
affinity for phosphatidylinositol (PI), phosphatidylcholine (PC) and preferred to bind
to phosphatidylethanolamine (PE) most of all. Although PI liposomes were able to
block LPS binding they had no effect on the phagocytosis of apoptotic cells (Akashi,
1999). PS liposomes also had no effect on the CD14-dependent clearance of
apoptotic cells (Devitt, 2003). These results show that CD 14 is not an alternative
receptor for the recognition of phosphatidylserine on apoptotic cells. Later
experiments showed that CD 14 is a tethering molecule and does not have a
phagocytic role. Tethering events can be measured in isolation from phagocytosis by
lowering the temperature below 20C. At this temperature, macrophages tether but do
not phagocytose apoptotic cells (Devitt, 2004).
ICAM-3 (CD50) has been proposed to be an apoptotic ligand that CD 14
recognises. ICAM-3 is a highly glycosylated leukocyte marker that may become
"alternatively glycosylated" during apoptosis. These apoptotic changes to the
carbohydrate structure of ICAM-3 appear to be recognised by CD 14. Surface ICAM-
3 on live cells normally binds LFA-1 and not CD 14. During programmed-cell death,
ICAM-3 loses some of its affinity for LFA-1 and seems to bind to CD 14 instead
(Gregory, 1998; Moffatt, 1999). However, direct binding between ICAM-3 and
CD 14 has not been demonstrated.
CD14 and Toll-like Receptors (TLR)
TLR4 is a well-described member of the important Toll-like receptor family,
which appears to bind to LPS in co-operation with its co-receptor CD 14, and signals
through NFkB to up-regulate the transcription of pro-inflammatory cytokines like
TNFa and chemokines like CXCL8 (IL-8) (Medzhitov, 1997; Chow, 1999; Poltorak,
2000; Ulevitch, 1999). The transfection of a constitutively active toll receptor into
the monocyte cell-line THP-1 was able to up-regulate the co-stimulatory molecule
CD86 (Medzhitov, 1997). This showed that TLRs formed an important link between
the innate and adaptive immune systems. Rather that just being an ancient relic, quite
separate from the adaptive response, innate pathogen recognition receptors may
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instruct the adaptive system (Medzhitov, 1997; Medzhitov, 2003). Additionally,
TLRs may set the "flavour" of the consequent adaptive response, for example TH1
versus TH2 (Medzhitov, 2000; Chow, 1999; Fearon, 1996). Although CD 14 binds to
TLRs when it has bound to LPS, when CD 14 has bound to an apoptotic cell it does
not signal through a TLR (Shiratsuchi, 2004). However if CD 14 is associated with a
necrotic cell it may signal through TLR2 (Li, 2001). Significantly, phagocytosis of
apoptotic cells appears not to require TLR signalling (Blander, 2004).
CD14|0W and CD14high monocyte subsets
The heterogeneous lymphocyte lineage has been divided into subsets each
with specific phenotypes and individual functions. There is growing evidence that
monocyte subsets also exist (Ziegler-Heitbrock, 1996). Large monocytes were
separated from small monocytes be elutriation and were shown to have different
phenotypes. Smaller monocytes had higher antigen-presenting ability but produced
fewer reactive oxygen species than the larger cells (Ziegler-Heitbrock, 1991).
Ziegler-Heitbrock first described CD14lllgh and CD14low human monocyte subsets in
1988 (Ziegler-Heitbrock, 1988). Cells in the CD14hlgh subset are typical monocytes.
The minority, CD14low-subset, normally represents only 5% of circulating monocytes
but numbers can dramatically increase during sepsis and in HIV infection
(Blumenstein, 1997; Skrzeczynska, 2002; Fischer-Smith, 2001; Thieblemont, 1995).
These CD14low monocytes also express the Fcylll receptor, CD16. Because the
CD 14+/CD16+ subset expressed high levels of MHCII molecules, it was thought that
these monocytes were in fact, dendritic cells (DC). Phenotypic and functional
analysis have shown both similarities and differences between the monocytes and the
DCs (Ancuta, 2000; Almeida, 2002; Thomas, 1994). It is likely that both the
CD14hlgh and CD 14|0W monocytes have the potential to differentiate into DCs in vivo
as was found to be the case in the mouse (Geissmann, 2003; Sallusto, 1994). In a
reverse-transmigration, in vitro model of leukocyte-trafficking across endothelium,
CD14+/CD16+ human monocytes were able to develop into migratory dendritic cells
(Randolph, 2002).
The exact role of CD14low/CD16+ monocytes remains an enigma. There is
evidence that CD14low/CD16+ monocytes have a "pro-inflammatory" phenotype.
CD14low/CD16+ monocytes were major producers of TNFa and their numbers were
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increased during sepsis (Beige, 2002; Blumenstein, 1997). The CD14hlgh and
CD14low human monocytes each expressed different chemokine receptors and had
the potential to migrate to different compartments of the body. CD14hlgh monocytes
migrated preferentially to CCL2 (MCP-1) in vitro compared to the CD14low subset,
which expressed higher levels of CCR5 mRNA, and accordingly, preferentially
migrated to RANTES (CCL5) and MlP-la (CCL3) (Weber, 2000). The receptor for
fractalkine (CX3CR1) is highly expressed on the CD14low /CD16+ subset and
mediates the arrest of these monocytes to HUVEC transfected with fractalkine
(CX3CL1) whereas the CD14hlgh/CD16- cells responded to CCL2 but not CX3CL1
(Ancuta, 2003). Mice have an equivalent subset to humans that is
CX3CRlhigh/CCR2-/Grl-. Geissmann et al used an elegant adoptive transfer
approach to show that CX3CRlhlgl7CD14low monocytes migrated into non-inflammed
sites whilst the CX3CR1|0W subset trafficked to the peritoneum (Geissmann, 2003).
This paper suggested that fractalkine receptor could be important in the constitutive
migration of monocytes out of the blood into tissue.
In addition to chemokine receptors, CD14hlgh and CD14low human monocytes
have different phagocytic receptors. The FcyRIII receptor CD16 on CD14low
monocytes has been mentioned, but these monocytes also have increased class A
scavenger receptors I/II (ScR-AI/II) on their surface, that controls the types of lipid
they bind (Draude, 1999). Interestingly there was no difference in CD36 expression
between the subsets. The CD14low macrophages had impaired uptake of acetylated-
oxidised LDL but both the CD14h,gh and CD14l0W monocytes bound oxidised LDL
equally well.
There was also differential expression of the glucocorticoid receptor (GCR)
between the subsets. The CD14low/CD16+ subset disappeared from the circulating
monocyte pool after infusion of high-dose glucocorticoids because these GCR-
expressing cells were more susceptible to steroid-induced apoptosis (Dayyani, 2003).
Steroid treatment is known to promote monocyte maturation into macrophages and to
enhance the phagocytosis of apoptotic cells (Heasman, 2003; Giles, 2001).
Monocytes have a very low ability to phagocytose apoptotic cells that improves as
they mature into macrophages. It is not known whether CD14hlgh and CD14low
monocytes mature into specific macrophage subsets. Two macrophage well
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described subsets are the "classically-activated/Ml" and the "alternatively-
activated/M2" macrophages (Gordon, 2003). However macrophages exhibit
plasticity and are less fixed in there function for example, compared to T cells.
Although CD14low/CD16+/ CX3CRlhlgh monocytes have a phenotype more similar to
alveolar macrophages than to peritoneal macrophages, it is not known if they
precursors for an "alternatively activated" macrophage.
It is unknown whether CD14low monocytes subsequently develop into
CD14low macrophages. In vitro experiments would predict that CD14low macrophages
would be impaired in their ability to phagocytose apoptotic cells and this was the
case in vivo where a tethering defect led to the accumulation of apoptotic cells in the
CD14 deficient mouse (Devitt, 2004). However, paradoxically, the CD14low/CD16+
monocytes produce more TNFa in response to LPS compared to CD14hlgh monocytes
(Draude, 1999). This was not due to the absolute levels of CD 14, but to an increase
in the expression of TLR in the CD14low/CD16+ subset. The phenotype of human
CD14low macrophages will be investigated in Chapter 3.
Experiments using a CD 14 -/- knockout mouse have given a clearer picture of
the physiological role of CD 14 in the phagocytosis of apoptotic cells (Devitt, 2004).
Future experiments using the CD14-/- mouse will show whether CD14 is a
functional marker of this small- CD14low /CD 16+ monocyte subset or simply an
incidentally expressed phenotypic label.
The CD14 knockout mouse (CD14-/-).
The first CD 14-/- knockout mouse was created in 1997 on a C57BL/6
background using a targeted gene approach. A frame-shift in the CD 14 gene was
caused by replacing a 272 base-pairs section within CD14 with a neo' gene. The
disrupted gene was then expressed in embryonic stem cells, injected into blastocysts
and the resulting mice were bred to homozygosity (Haziot, 1996). CD14-/- animals
were fertile, produced normal-sized litters and had no developmental defects.
Naturally, the first studies on the knockout mice concentrated on how the loss
of CD 14 affected the immune system and defects in the clearance of apoptotic cells
were not studied initially. CD 14-/- mice were resistant to LPS and could survive up
to 10 times the LDioo than the wild type, and secreted virtually no TNFa (Haziot,
1996). CD14-/- mice were also resistant to very high inoculations of gram-negative
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bacteria. In a model of Salmonella typhimurium peritonitis there was some
impairment of neutrophil chemotaxis into the peritoneum in the CD 14-/- animals but
the recruitment of F4/80-positive monocytes was unaffected (Yang, 2002). These
results suggested that CD 14 was not strictly required for the neutrophil influx, but in
the absence of CD 14, neutrophil recruitment was delayed and there was no local
inflammatory response. Despite a normal ability to phagocytose whole bacteria, the
CD 14-/- mice were able to tolerate a higher bacteraemia than their wild type
littermates and were slower to eliminate infections (Yang, 2002). However, in
pathogen-free conditions, CD14-/- mice had a comparable lifespan to wild type
controls. The fact that CD 14-/- mice bred successfully was of interest, to the Gregory
laboratory that was studying how the loss of CD 14-/- might affect the clearance of
apoptotic cells.
Apoptotic cell clearance in the CD14-/- mouse
Previous work from the Gregory laboratory, showing that CD 14 is involved
in the clearance of apoptotic cells by human macrophages in vitro, has been extended
to show that CD 14 is also involved in clearance by murine macrophages in vivo
(Devitt, 1998; Devitt, 2004). CD 14 appears to be a tethering molecule for apoptotic
cells. Histological examination of the CD 14-/- mouse revealed that there were
increased numbers of apoptotic cells in the spleen and thymus of the CD14-/-
(Devitt, 2004; Gregory, 2002). When the number of apoptotic cells that were in
contact with macrophages was compared to the number of non-associated or "free"
apoptotic cells; the CD14-/- mouse had a greater number of "free" apoptotic corpses
compared to wild type controls. Examination of the finger webs of the developing
CD 14-/- embryo showed that the macrophages were gorged-full of apoptotic bodies
and were qualitatively different to wild type macrophages (Gregory, unpublished
observation). This suggested that the clearance of apoptotic cells during development
in the CD14-/- mouse was somehow different to the wild type but the outcome was
the same, namely, a healthy live birth.
The accumulation of apoptotic cells in multiple tissues of CD14-deficient
mice may be the result of a defect in apoptotic-cell removal resulting in the
persistence of apoptotic cells that are not associated with phagocytes in situ. Both the
wild type and the CD14-/- mice had comparable numbers of macrophages and the
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rate of apoptosis was also shown to be equal (compared to the wild type) (Devitt,
2004). There are at least two explanations for the accumulation of dying cells in the
CD 14-/- animals in relation to their interactions with macrophages: Either,
phagocytosis of apoptotic cells was impaired in the CD 14-/- animals; or, the absence
of CD 14 caused a chemotactic defect leading to a reduced efficiency in the
recruitment of macrophages to apoptotic-cells.
1.4 Chemokines and their receptors
The finding that loss of CD14 resulted in the accumulation of apoptotic cells
led to the examination of apoptotic cells as a source of chemoattractant molecules for
macrophages. Chemotaxis is the directional movement of a cell up a chemoattractant
concentration gradient and is important in a number of biological processes including
leukocyte recruitment to sites of inflammation and into tumours, neurogenesis and
fibroblast migration during wound healing (reviewed in Zlotnik, 2000; Singer, 1986).
Chemotaxis of a circulating leukocyte through the endothelium into an inflammed
tissue progresses step-wise through primary adhesion and rolling, activation and
arrest, firm adhesion and finally, diapedesis (Springer, 1994; Lasky, 1992; Butcher,
1996; Webb, 1993). A mixture of in vitro and condition-of-flow studies has shown
that a cell first senses the chemical gradient using 7-transmembrane-spanning, G-
protein coupled, chemokine receptors. It next orientates itself along the axis of the
concentration gradient (Singer, 1986) and extends pseudopodia from the edge of the
cell facing the highest chemokine concentration and retracts its trailing edge away
from the lowest concentration (Zigmond, 1974). Next the leukocyte binds weakly to
the endothelium through cell-surface lectins called selectins. The adherence is so
weak that the force of passing blood is able to propel leukocytes forwards in a rolling
motion (Muller, 1999). Once a chemokine gradient has been sensed, cells become
activated to bind more firmly through adherence to integrin receptors (Thompson,
2000).
Chemokines
Chemokines are small (8-l7kDa), positively charged "chemotactic cytokines"
that induce cell migration. The development of EST (expressed sequence tag)
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databases that can pick out small proteins from the genome suggests that it is likely
that most of the human chemokines have already been discovered (Zlotnik, 2003).
To date, the human chemokine-family contains 42 chemokine ligands and 18
chemokine receptors in all. Many other molecules like bacterial fMLP, C5a and
platelet-derived lipids can also attract cells but are not strictly classed as chemokines
and will be referred to as chemoattractant molecules.
The chemokine superfamily has been divided into four groups and renamed
according to the distribution of conserved cysteine residues (C) found at the amino
terminal (Zlotnik, 2000). The four groups are: C, CC, CXC and CX3C where X
represents an amino acid separating two disulphide bonds. Chemokines are given the
suffix "L" to denote ligand (CX3CL1 (fractalkine) for example), and receptors have
the suffix "R". Cellular expression of receptors and ligands from these groups
broadly represent function. CCR are expressed on monocytes and lymphocytes and
CXCL chemokines, like CXCL8 (IL-8) also contain additional ELR (glutamic acid,
leucine and arginine) tripeptide sequence that attracts CXCR-expressing neutrophils.
Most of the chemokines fall into either an inflammatory group or a non¬
inflammatory group usually expressed in a tissue specific manner (Kurth, 2001). The
first chemokines to be identified were all pro-inflammatory and had important roles
in recruiting leukocytes to sites of inflammation (DeVreis, 1999). Inflammatory
chemokines like CXCL8 (IL-8) and CCL2 (MCP-1) are found in gene clusters.
These genes may have divided in response to evolutionary pressures, perhaps from
viruses (like cytomegalovirus (CMV) and Herpes) that can produce chemokine
antagonists. These gene clusters produce chemokines that can bind to more than one
receptor. For example, CCL5 (RANTES) binds to three receptors, CCR1, CCR3 and
CCR5.
In contrast, homeostatic chemokines, (like CCL21) are found at isolated
chromosomal locations and have a monogamous relationship to their receptors.
CCL21 is expressed by high endothelial venules and by lymphatic endothelial cells,
and its job is to recruit T cells into lymph nodes (Gunn, 1999). Loss of CCL21
function results in the pit (paucity of lymph node T cells) mouse, which has grossly
abnormal secondary lymphoid organs (Nakano, 1998).
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Chemokines can perform other diverse functions in addition to directing cell
migration. They can regulate haematopoiesis and angiogenesis (Kunkel, 1999;
Chensue, 2001) and many are also antimicrobial peptides. At high concentrations
they can lyse bacteria in a similar way to defensins (Chensue, 2001).
CX3CL1 (fractalkine) and CXCL16 (SR-PSOX) are two unusually large
chemokines that are also cell adhesion molecules. They both have long mucin stalks
that are cleaved to release their N-terminal chemokine domains. Fractalkine and
CXCL16 can arrest the cells expressing their cognate receptors (CX3CR1 /fractalkine
receptor and CXCR6/Bonzo respectively) under flow conditions. Pathogens like
malaria, E.coli, S aureus respiratory syncitial virus (RSV) and CMV all take
advantage of this binding opportunity (Chensue, 2001; Kledal, 1998; Tripp, 2001;
Hatabu, 2003). CXCL16 is a scavenger receptor that not only binds to
phosphatidylserine but also participates in the phagocytosis of a wide variety of
bacteria (Shimaoka, 2003; Minami, 2001). A recent publication has shown that many
other chemokines share this scavenger receptor activity and suggests that there is a
close evolutionary relationship between chemokines and scavenger receptors like
CD36 (Shimaoka, 2004).
1.5 Fractalkine and its receptor
Fractalkine (CX3CL1) has an unusual structure of a "chemokine on a stalk"
which is shared by only one other chemokine CXCL16, a member of the CXC group.
As discussed above, CXC 16 has scavenger receptor activity, binds oxidised
phospholipids and is involved in phagocytosis of bacteria (Shimaoka, 2003;
Shimaoka, 2004). No similar scavenger activity or phagocytic role for fractalkine has
been identified to date. The fractalkine knockout mouse and its receptor knockout
(CX3CL1-/- and CX3CR1-/- respectively) had no overt phenotype and there was no
mention of an accumulation of apoptotic cells in the organs of these mice (Jung,
2000; Cook, 2001).
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CX3CL1 structure and tissue distribution
Fractalkine was discovered as an experimental offshoot from research on the
C branch of chemokine genes that contains XCL1 (lymphotactin) and XCL2 (single
cell motif-1 (3 (SCM-ip)). Fractalkine has now been given the systematic name
CX3CL1 (Zlotnik, 2000). Bazan talks about why he called the new chemokine
fractalkine in the original paper, quoted below.
As closer inspection of one branch of the chemokine superfamily, the C
branch, yielded evidence of another, the CX3C, rather as in fractal geometry (where
dynamic, self-referential branch patterns in chaotic systems are revealed at
increasing scales of magnification), we have dubbed this new CX3C chemokine
fractalkine' (Bazan, 1997)
Fractalkine is a large (373 amino acid) membrane-bound, chemokine with a
unique CXXXC motif originally found in (but not restricted to) non-haemopoietic
cells, like neurons and epithelial cells (Pan, 1997; Harrison, 1998; Lucas, 2001).
Fractalkine expression on endothelial cells and human umbilical endothelial cells
(HUVECs), can be induced by proinflammatory cytokines like TNFa and it is also
up-regulated during brain inflammation (Pan, 1997). There was some initial
confusion about the tissue distribution of fractalkine until elegant studies by Lucas et
al revealed that this was due to an antibody cross-reacting with CD84 (Lucas, 2001).
Fractalkine is a gene directly targeted by p53 and so potentially may be expressed by
tumours where this promotor is active (Shiraishi, 2000).
CX3CL1 chemokine and adhesion molecule
The 90-100kDa, full-length transmembrane form of fractalkine is an adhesion
molecule that is cleaved to release the soluble chemokine domain (Garton, 2001;
Tsou, 2001; Hundhausen, 2003). Antibodies to both the N and C-terminals of
fractalkine have identified many different-sized bands by western blotting. Pulse
chase analysis of cells that were over-expressing fractalkine, showed that CX3CL1
was synthesized as a 50-75 kDa precursor that was further glycosylated to yield the
lOOkDa mature protein found at the cell surface. The mature lOOkDa fractalkine was
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then cleaved to release the 85kDa chemokine domain and to leave behind a 20kDa
C-terminal stalk on the cell surface (Garton, 2001; Lucas, 2001).
ADAM10 and ADAM17 (a disintegrin and metalloproteinase) are two
distinct metalloproteinases that cleave fractalkine (Garton, 2001; Tsou, 2001;
Hundhausen, 2003). ADAM10 is a disintegrin-like metalloproteinase that is
responsible for the constitutive shedding of fractalkine and ADAM 17 (also known as
TACE, Tumour necrosis factor-a-Converting Enzyme) was responsible for the
induced release of fractalkine after treatment with a phorbol ester (PMA). It is not
known how important the individual contributions of ADAM-10 and ADAM 17 are
to chemokine release in vivo but it is likely that they coordinate the release of soluble
fractalkine. Dual regulation of fractalkine would direct cell adhesion and local cell
trafficking
Full-length, membrane-bound fractalkine binds its receptor via the N-terminal
domain. It is the chemokine domain, and not the stalk, that is responsible for firm
adhesion of CX3CR1 positive cells under flow conditions. The stalk simply presents
the chemokine to its receptor partner in an advantageous aspect (Haskell, 2000). Two
basic residues in the chemokine domain of fractalkine are responsible for interaction
with the receptor, Lysine-7 and Arginine-47. Replacement of either residue by
alanine affected cell-cell adhesion, but only the Arginine-47 position was important
for chemokine activity (Harrison, 2001).
Interestingly, firm adhesion of CXCRl-positive cells did not require G-
protein signalling and was not inhibited by pertussis toxin (PTX) (Haskell, 1999).
However, chemotaxis to soluble fractalkine did require G-protein signalling.
Fractalkine signalling through CX3CR1, could boost cell adhesion to ICAM-1 and
fibronectin indirectly, by increasing integrin avidity, this time in a PTX-sensitive
manner (Goda, 2000). Fractalkine is generally believed to be a weak chemokine that
induced a variable chemotactic response in monocytes and monocyte-cell lines.
Monocyte chemotaxis to CX3CL1 (fractalkine) was a fraction (5%) of that to CCL2
(MCP-1) (Imai, 1997). Overall, leukocyte-adhesion may be fractalkine's primary
function (Umehara, 2001). Gene targeting of fractalkine generated CX3CL1 -/- mice
that had a remarkably normal phenotype (Cook, 2001). CX3CL1-/- animals had no
reproductive, behavioural or gross histological abnormalities compared to wild type
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mice. Fractalkine-deficient mice had a slight decrease in the number of F4/80
circulating monocytes and an increased number of CD4 T cells in the gut epithelium.
However, CX3CL1-/- reacted normally to i.p thioglycollate and efficiently cleared
away a Listeria monocytogenes infection.
Fractalkine receptor
The fractalkine receptor (CX3CR1) is a typical 7-transmembrane G-protein-
coupled, chemokine-receptor (Imai, 1997). It is primarily expressed by monocytes
and macrophages but not neutrophils (Beck, 2003). Cytotoxic lymphocytes, NK
cells, y5-T cells, and terminally differentiated CD8+ T cells, all expressed CX3CR1
(Nishimura, 2002). IFNy, but not IL-4 or IL-13, was able to induce the release of
soluble fractalkine and CX3CR1 was predominately expressed by TH1-polarised
CD4+ cells (Fraticelli, 2001).
Fractalkine-receptor-positive smooth muscle cells responded to fractalkine
produced by inflammatory cells within the atherosclerotic plaque (Lucas, 2003).
CX3CR1+ smooth muscle cells reinforced the plaque and prevented it rupturing. This
reparative role suggested that cells expressing CX3CR1 had a constitutive, non¬
inflammatory role. The human CD 16+ monocyte subsets, which are likely to be
equivalent to the mouse CX3CRlhlgh monocytes, were able to migrate across
unstimulated endothelium (Randolph, 2002).
CX3CR1 polymorphisms and disease
The fraction of human CD16+ monocytes is increased in the blood of HIV
patients and fractalkine was up-regulated in patients with HIV and AIDS-related
encephalitis (Tong, 2000; Erichsen, 2003). It is likely that the CDl6+ monocytes in
this study would have also been CX3CRl+ since CDl6+ monocytes preferentially
migrate to fractalkine (Ancuta, 2003). As well as being recruited into HIV-infected
brain, two isoforms of CX3CR1 were discovered to be co-receptors for the HIV virus
(Garin, 2003). Fractalkine receptor also binds to another viral component, a
glycoprotein from RSV (Tripp, 2001).
Fractalkine and its receptor have an important role in atherosclerosis, which
is the chief cause of ischemic heart disease. V/I249 and T/M280 are two relatively
common polymorphisms of the human fractalkine receptor that form the I249/M280
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haplotype present in about 28% of the population. The 1249 mutation protects
carriers from cardiovascular disease independently of smoking and other acquired
risk factors (McDermott, 2001; McDermott, 2003; Moatti, 2001). Where as the
M280 mutation is associated with an increase in the risk for a brain infarct
(Combadiere, 2003). The difference between 1249 and M280 in causing monocyte
adhesion in these two clinical syndromes is not well understood. It is possible that
they separate cell pathways. Alternatively, the M280 polymorphism that was more
adherent than 1249 in an in vitro flow chamber assay, might allow for tight monocyte
adherence in the lower-pressure cerebral system, that is not relevant to pathogenesis
of arteriosclerosis in the high-pressure vessels
CX3CR1 knockout mice had no obvious phenotype, just like fractalkine
knock out mice (Jung, 2000). Monocyte recruitment and DC maturation and
migration were normal and microglial accumulation at the site of a facial nerve
injury was similar to wild type. The biological function of fractalkine was exposed
when Christophe Combadiere crossed CX3CR1-/- with the Apolipoprotein E (apoE)
knockout mouse. The apoE mouse is a model used to study vascular disease because
these mice succumb early to atherosclerosis. The phenotype of the CX3CR1-/- /apoE
-/- double knockout-mice was striking because they had less atherosclerosis
(Combadiere, 2003). The absence of fractalkine receptor resulted in far smaller
plaques that contained more smooth muscle cells that were less likely to rupture.
These results showed that fractalkine played a direct role in atherosclerotic lesion
development on this mouse model.
The importance of fractalkine in graft rejection has been studied, because of
the high levels of fractalkine-receptor expression on mouse NK cells. Cardiac
allografts in CX3CR1-/- mice survived longer than wild type mice treated with a sub¬
therapeutic dose of cyclosporin (Haskell, 2001).
The CX3CR-/- mouse has not been studied in the context of lymphoma or
any other tumour to date but fractalkine receptor has been identified in glioblastoma
multiforme (Zlotnik, 2003).
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1.6 Macrophage chemotaxis towards apoptotic cells
Cells dying by apoptosis release chemoattractive molecules in order to attract
macrophages that will subsequently engulf them (Ravichandran, 2003). The cell
surface changes on apoptotic cells that make apoptotic cells more "palatable" to
macrophages have been studied in detail but only recently have the chemokines that
attract macrophages been investigated. Apoptotic cells release chemokines when the
plasma membrane is intact, whereas necrotic cells can leak out many potential
chemotactic molecules, like platelet activating factor (PAF) (Bratton, 1993).
Three chemotactic molecules have been described that are released from
apoptotic cells: l) RNA protein dimer S19 (RNA-S19) (Horino et al., 1998), 2)
Endothelial Monocyte-Activating Polypeptide II (EMAPII) (Wakasugi, 2003) and 3)
lysophosphatidylcholine (LPC) (Lauber, 2003). In addition, blebs, shed from the
surface of apoptotic germinal centre B cells were also shown to have chemotactic
activity, or were an effective system for distributing the chemotactic molecules on
their surface (Segundo, 1999). Interestingly, none of these molecules belonged to the
classical chemokine families.
S19 ribosomal protein dimer is a monocyte chemoattractant
S19 is a subunit of the ribosomal protein that was isolated from the synovium
of a patient with rheumatoid arthritis and shown to be chemoattractant for monocytes
(Nishiura, 1996). A large number of apoptotic cells have been shown to persist in
patients with rheumatoid arthritis (Firestein, 1995). During apoptosis, 45kDa S19
homodimers were released that were chemotactic to monocytes but not to neutrophils
at a concentration of 10"9M (Horino, 1998). S19 was responsible for the
predominantly monocyte infdtration that was found commonly in chronic
inflammation (Yamamoto, 2000). A transglutaminase enzyme that was induced
during the process of apoptosis catalysed the homodimerisation of S19 between
Gin 1378 and Lysl22. The homodimers did not form in live cells and were
specifically released from dying cells. SI9 was detected in the supernatants of
apoptotic cells 24-30 hours after heat treatment and by 48 hours the activity of SI9
was quenched in vivo by a serine protease. SI9 was released from two different cell
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types, an epithelial and a myeloid cell-line (AsPC-1 and HL-60 respectively)
suggesting it was a mechanism common to many cells (Nishimura, 2001).
S19 homodimers bound to the G-protein-linked complement receptor for C5a
9Shibuya, 2001). Indeed, S19-dimers competed with C5a for the C5a-receptor
binding despite there being only 4% homology between the protein sequences. The
dimerisation process seems to have brought together residues critical for interacting
with the receptor. The C5a receptor has two binding sites for the attachment of either
the S19-dimer or C5a, the first pocket (basic residues 41-43) was allowed for firm
adhesion of S19 but did not trigger G-protein signalling. Only after the ligand had
bound to the second site (aal31-133) did the receptor trigger a chemotaxis signal
(Shibuya, 2001). The late appearance of S19 dimers, 24 hours after the heat
treatment, suggests that this chemoattractive molecule may not be released as a result
of apoptosis. It is probable that S19 had leaked out from disintegrating cells. This is
contrast to EMAPII and LPC that are released very early on in the process of
apoptotic cell death.
Endothelial monocyte-activating polypeptide II (EMAPII)
EMAPII was identified as a chemotactic molecule released from cells early
on during apoptosis while the plasma membrane remained intact (Kao, 1994).
EMAPII was isolated from (methylcholanthrene-A-induced) apoptotic fibrosarcoma
cells and was found to be chemotactic to both monocytes and neutrophils. Like SI9,
EMAPII was also proinflammatory. It stimulated monocytes to release TNFa and
also induced neutrophils to make myeloperoxidase (Kao, 1994). This was
unexpected, since apoptotic-cell clearance is usually anti-inflammatory, although
there have been a few reports of apoptotic cells generating a pro-inflammatory
response (Albert, 1998). It is controversial as to whether mature EMAPII itself
induces apoptosis or is cleaved from the enzyme complex by caspase-3 and caspase-
7 during the process of apoptosis (Zhang, 2002).
Pro-EMAPII is homologous to the p43 subunit of the multi-enzyme complex,
aminoacyl-tRNA synthetase (RS). Aminoacyl-tRNA synthetases are a family of
enzymes that catalyse the attachment of specific amino acids to their cognate tRNAs
and are vital for protein synthesis. The p43/proEMAPII subunit contains the RNA-
binding portion of the complex. And similarly, Tyrosine-RS, Methionine-RS and
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Phenylalanine-RS also contain EMAPII appendices. Tyr-RS was found in
supernatants from apoptotic cells but Ala, lie, Lys, Val-RS were not (Wakasugi,
2003). Proteolytic cleavage of p43/proEMAPII halted cellular protein synthesis and
produced two fragments, both of which had chemokine activity. The C-terminal
fragment of p43 (mature EMAPII) was chemotactic to monocytes and neutrophils.
The other N-terminal-fragment, contained an ELR tripeptide sequence that was
chemotactic for CXCR1-expressing neutrophils (Wakasugi, 2003). The N-terminal
fragments of two other aminoacyl-tRNA transferases, Histidine-RS and Asparagine-
RS, were also chemoattractant to activated (but not to resting) monocytes and
immature DC's. Interestingly, Histidine-RS and Asparagine-RS are both
autoantigens found in the autoimmune connective-tissue diseases: myositis and
dermatomyositis (Howard, 2002). When aminoacyl-tRNA synthetases were released
from damaged cells they might attract the very monocytes able to induced
autoimmunity.
Lysophosphatidylcholine (LPC)
LPC is a phospholipid that was shown to be released from intact apoptotic
cells, crucially, before disintegration of the plasma membrane. LPC was chemotactic
to both monocyte cell lines and primary macrophages, although it attracted
macrophages more efficiently (Lauber, 2003). Before its discovery as a chemotactic
molecule, LPC was known to have a pro-inflammatory function. LPC is a major
component of oxidised low-density lipoprotein and (like fractalkine) it may be an
aetiological factor in arteriosclerosis. LPC caused inflammation associated with
atherosclerotic plaques (Huynh, 2002) and it activated NFkB when it bound to its
receptor, G2A (Kabarowski, 2001).
LPC appears to link together the caspase enzymes that regulate apoptosis, to
the process of clearance of apoptotic cells. Lauber et al showed that LPC release
depended on caspase 3. Although macrophages were able to engulf cells that died in
the absence of caspase-3 (Turner, 2003), they did not move towards apoptotic MCF7
breast cancer-cells that lack casapse-3 (Lauber, 2003).Lauber et al showed that the
apoptotic MCF7 cells could not attract monocytes, but chemotaxis was restored
when Caspase-3 was transfected into MCF7 cells. The chemokine isolated from the
supernatants of apoptotic cells was found to be the phospholipid,
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lysophosphatidylcholine (LPC) already known to be a chemotactic molecule
(Hoffman, 1982). Phospholipase A2 (PLA2) is the enzyme that catalyses the
hydrolysis of membrane phosphatidylcholine into LPC and arachadonic acid. The
PLA2 enzyme has many isoforms, but the cytosolic, calcium-independent form of
PLA2 was the only one to be cleaved by caspases and so activated during apoptosis.
No doubt, LPC is an important link between apoptosis and macrophage
chemotaxis to dying cells, but it is unlikely to be the only factor involved. Only a
very small amount of LPC was found in the supernatants derived from apoptotic
cells. In fact, much higher levels of LPC were required to attract macrophages than
were found in the more potent supernatants.
Chemoattractive molecules and chemokines have important roles in directing
the movement of macrophages. It has been seen that the persistence of apoptotic cells
in the CD 14-/- mouse did not cause inflammation. Indeed the high rates of apoptosis
in Burkitt's lymphoma (BL) may benefit tumour growth. Whether the
chemoattractive properties of apoptotic cells are able to draw in macrophages into
tumours, like BL, will be discussed in the next section.
1.7 Macrophage infiltration of tumours
Macrophages are common cell components of tumours and their presence is
associated with a poorer prognosis and a reduced 5 year-survival (Sikorsa, 2000).
Resident macrophages in tumours and are generally referred to as Tumour-
Associated-Macrophages (TAM) (Mantovani, 1992). Even though a
"lymphoreticular infiltrate" was first noticed in tumours by Virchow in 1863 the role
of TAM in tumourogenesis was not immediately apparent (Balkwill, 2001). Until
recently, the tumour-associated macrophages found so commonly in Burkitt's
lymphoma (BL) were described as "benign" in a standard pathology textbook
(Cotran, 1989). Rather than being simply bystanders, TAM can influence the
pathogenesis of tumours by multiple means. It has been suggested that "The
inflammatory cells and cytokines found in tumours are more likely to contribute to
tumour growth, progression and immunosuppression than they are to mount an
effective host anti-tumour response" (Balkwill, 2001). This may be why it has
proved so difficult to harness the immune system to destroy neoplastic cells.
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TAMS produce many different factors that support all stages of tumour
development from cell growth, longevity and survival, through proliferation,
angiogenesis, invasion and finally to metastasis (reviewed in Mantovani, 1992;
Mantovani, 2002). One of many examples of such tumour support is that TAM at
low oxygen tensions found at the centre of a rapidly growing tumour produce
vascular endothelial growth factor (VEGF) that promotes angiogenesis (Talks, 2000).
The "starry sky" macrophages in Burkitt's lymphoma (BL) produce the B cell
survival factor BAFF (B-cell activating factor of the TNF family) (Ogden, 2005).
TAMs also aid tumour expansion and invasion by producing matrix-
metalloproteinases that digest away elements of the extracellular matrix. Such TAM
expression of MMP9 contributed to the growth of a skin cancer (Coussens, 2000).
There is often a symbiotic relationship between the tumour cells and their associated-
macrophage neighbours. For example, some tumour cells produce macrophage
growth factors like M-CSF (macrophage-colony stimulating factor) that promote
malignant behaviour as well as prolonging macrophage survival (Fin, 2001).
There is also evidence that some tumours secrete chemokines that specifically
trigger macrophage infiltration. Tumour chemokines do more than just attract
leukocytes: some CXC and CC chemokines can also stimulate angiogenesis and
metastasis (Keane, 1999; Zlotnik, 2003). The chemokine CCF2 (MCP-1) is
frequently found in solid tumours, but its effect depends upon its local concentration
(Sica, 2005). Fow levels of CCF2 recruited macrophages into a melanoma and
promoted tumour growth. However, much higher levels of CCF2 caused a huge
infiltration of macrophages that destroyed the tumour (Nesbit, 2001). Therefore, the
chemokine balance within a tumour is critical in determining its pathogenicity
(Mantovani, 1992)
"Classical" and "alternative" activation of macrophages
In addition to directly supporting tumour growth, TAMs help tumours to
avoid the attention of the immune system. Most evidence shows that the tumour
microenvironment is rich in the TH2 cytokines IF-4 and IF-6 and these skew TAM
toward the "alternatively-activated" or M2 phenotype as opposed to "classically
activated" or Ml type of macrophage (Mantovani, 2004; Gordon, 2003). A
macrophage's response to infection by intracellular pathogenic mycobacteria, is an
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example of the classical activation of Ml macrophages. TH1 helper T cells secrete
interferon gamma (IFNy) that classically arms macrophages to destroy infected cells.
Ml macrophages also have the potential to kill tumour cells, however, most TAMs
seem to express an M2-like phenotype (Mantovani, 2004).
The "alternatively activated" M2 macrophages have a different role from Ml,
consistent with humoral immunity against extracellular pathogens and also in
angiogenesis, tissue modelling and repair. What is more, apoptotic cells appear to
polarise macrophages towards an M2 phenotype leading them to secrete "type-2"
cytokines like TGFP and IL-10. In the presence of these cytokines, TAMs fail to
instigate an inflammatory reaction to tumour antigens. In this way TAMs help
tumour cells to avoid immune-surveillance and promote tolerance. For example, the
IL-10—rich tumour environment of ovarian cancer induces TAM to produce CCL18.
CCL18 is chemotactic to naive T cells, and in conjunction with M2 macrophages
lacking a co-stimulation (signal 2) this results in anergy and a failure of the adaptive
immune system to detect tumour antigens (Schutyser, 2002). The characteristic
Reed-Sternberg cells are diagnostic in Hodgkin's lymphoma and secrete CCL22 and
CCL17 that account for the T cell infiltration and yet doesn't lead to an immune
response (van de Berg, 1999).
TAMs originate from circulating blood monocytes and there is not much
evidence to suggest that in situ proliferation sustains the population. In the face of
recruitment of fresh potentially inflammatory monocytes the tumour
microenvironment is especially important in driving the recruited monocytes toward
an M2 phenotype (Mantovani, 1992). One tumour where the tissue
microenvironment is rich in IL-10 is Burkitf s lymphoma (BL) (Levens, 2000).
1.8 Macrophage infiltration of Burkitt's lymphoma
Burkitf s lymphoma (BL) is a high grade, B-cell non-Hodgkin's lymphoma.
In its endemic form, BL often affects the jaw of children living in the malaria-
affected countries of West Africa and Papua New Guinea. Tumours from this
geographical location are often associated with Epstein Barr Virus (EBV) infection
(Burkitt, 1958; Berard, 1969). The sporadic form of BL if found more globally,
outside of the endemic areas and is not usually associated with EBV. BL is a
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neoplasm originating from germinal centres B-cells (Gregory, 1988; Chapman,
1998). BL contains frequent apoptotic cells and infiltrating macrophages, which
endow the tumour with its classical 'starry sky' histological appearance (Wright,
1970). The numerous pyknotic nuclei that are found in the tumour are testament to
the high rate of apoptosis that accompanies cell proliferation. In figure 4.1a, tumour-
associated macrophages are found actively engulfing the numerous apoptotic cells
they encounter and consequently, their phagosomes are engorged with apoptotic
bodies.
c-Myc
Apoptotic cells are a consistent feature of BL. The high rate of tumour
growth may limit the availability of nutrients and growth factors causing high rates
of spontaneous apoptosis (Harrington, 1994). In addition, the presence of apoptotic
cells is due to complex interactions between c Myc and EBV (Fujita, 2004). The c-
myc gene product Myc, is a gene-regulatory protein that stimulates cell division. In
BL, chromosomal translocations, most commonly, t8:14 and t2:8, result in the
juxtaposition of c-myc next to powerful genes controlling immunoglobulin
expression. Thus, Myc regulation becomes defective in B-lymphocytes, the cells that
normally produce antibody. As well as stimulating cell division, Myc also drives the
constitutively high rates of apoptosis (Juin, 2002). c-Myc causes mitochondrial
triggering of apoptosis mediated through the pro-apoptotic cytochrome C and
antagonises the anti-apoptotic members of the Bcl-2 family (Moreau, 2003). Anti-
sense oligonucleotides that blocked expression of Myc could also enhance the
survival of BL group-1 cells in a similar way to interferon-alpha (Milner, 1993).
p53
One of the most important checks against tumour proliferation is provided by
p53, a gene regulatory protein that can be mutated in approximately 60% of BL
derived cell-lines (Banthia, 2003; Wiman, 1991). p53 is mutated in the BL-cell line
"Mutu" used in this work. "Mutu" BL-cells are heterozygous for p53 and expresses
one mutant copy and one wild-type copy of the p53 gene (Milner, 1997). DNA
damage, say from UV-light, leads to the activation protein kinases that stabilise the
p53 gene product and prevent its breakdown. High concentrations of p53 can
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stimulate many of the genes important in cell-cycle arrest and apoptosis. The re-
addition of a wild type p53 back into one (of the many BL) lines that had mutated
p53, resulted in apoptosis (Ramqvist, 1993; Wang, 1993). Interestingly, the
chemokine fractalkine has also shown to be a direct target of p53 and potentially
could be up-regulated during apoptosis (Shiraishi, 2000). Production of fractalkine
during apoptosis may attract CX3CRl-expressing cells like macrophages, important
for clearance.
Epstein Barr Virus
Net growth of BL-tumours is a balance between rates of proliferation and
apoptosis. EBV infection is common, and infects approximately 90% of the world's
population. It is one of the causative factors in Burkitt's lymphoma (van den Bosch,
2004). EBV is important for BL-survival because it can prevent apoptosis triggered
by p53 and myc by the up-regulation of bcl-2 (Okan et al, 1995). This work and
work carried out previously in the group showed that the transfection of Bcl-2 into
BL-cell lines could reduce both spontaneous and UVB-triggered apoptosis (Hong
Wang PhD thesis).
When EBV-positive BL cell-lines are cultured up from original tumour
biopsy cells, they can dramatically change their phenotype (Rooney, 1986). They
acquire lymphoblastic characteristics that are similar to EBV immortalised cells that
have escaped T-cell control. Freshly established BL lines have been described as
having a "group I" phenotype close to their in vivo tumour origin and similar to
germinal centre B cells. Interestingly, BL-cell lines that have not been infected with
EBV, retain this more stable, group 1 phenotype. BL-cells in group I do not express
the EBV antigens EBNA-2 (EBV nuclear antigen-2) and LMP (latent membrane
proteins). As BL-cells progress towards a lymphoblastoid like phenotype begin to
express LMP and EBNA-2. Cells displaying these EBV antigens tend to clump
together in culture and become resistant to apoptosis are termed "group III" cells.
The BL-cells with an intermediate phenotype are termed group II (Rooney, 1986;
Rowe, 1987). EBV infected cells must gain access to the B memory pool in order to
survive. Normal B cells, which have not encountered cognate antigen will not
become memory cells and will die by apoptosis. The expression of EBV latent
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proteins protects B cells from apoptosis and smoothes their path into the memory
pool (Gregory, 1991; Milner, 1997; Okan, 1995).
Apoptosis in Burkitt's lymphoma
Interactions between EBV infection, p53 and Myc predispose to apoptosis in
BL (Harrington, 1994). The accumulation of apoptotic cells in BL and also in the
CD 14-/- mouse is striking. This thesis will investigate whether apoptotic cells in BL
are more than just the natural waste products of a successful tumour and if apoptotic
cells can themselves confer any survival advantage. The apoptotic cells may support
the tumour indirectly through interactions with tumour-associated macrophages. The
"starry sky" macrophages provide survival factors such as BAFF/BLyS (B cell
activating factor of the TNF family/B lymphocyte stimulator) that ensure that tumour
cell growth exceeds apoptosis (Ogden, 2005). EBV-positive tumours produce viral
homologs of IL-10 and in turn, this cytokine increases the efficiency of macrophage
engulfment of apoptotic cells (Alcami, 2003). TAM in both BL and a fibrosarcoma
down-regulated the production of IL-12 and NF-kB in response to IL-10 (Ogden,
2005; Sica, 1997). Macrophage phagocytosis of apoptotic cells is often accompanied
by the release of anti-inflammatory mediators like TGF-p, PGE2 and PAF that could
also suppress anti-tumour immunity (Voll, 1997; Fadok, 2001; Fadok, 1998;
Kurosaka, 2003).
Despite their large numbers, apoptotic cells do not appear to result in
inflammation in BL. This thesis will examine whether apoptotic cells are
instrumental in attracting macrophages into BL-tumours.
Summary
The study of Burkitt's lymphoma cells has provided us with much
information about apoptosis (Milner, 1993; Gregory, 1987; Gregory, 1994). The
close association of macrophages and apoptotic cells within this tumour make it an
ideal model for the study of the interactions between phagocytes and dying cells. In
the presence of IL-10, the "starry sky" TAMs are transformed into professional
phagocytes "par-excellence". This enhanced ability to engulf dying cells is a process
dependent on the tethering molecule CD 14 (Devitt, 2004). The observation that
many of the apoptotic cells in the lymphoid organs of the CD 14-/- mouse were found
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to be "free", that is, unattached to a macrophage is very interesting. It suggests that
CD 14 may have a role in the "come-get-me" stage of engulfment, i.e. in macrophage
chemotaxis to apoptotic cells.
This work explores the role of apoptotic cells in the recruitment of tumour-
associated macrophages into Burkitt's lymphoma. This may have some relevance to
macrophage chemotaxis within the physiological setting of the germinal centre and
could shed light on generic mechanisms of macrophage recruitment to tumours.
1.9 Aims
To determine if CD 14 is involved in the attraction to, and uptake of, apoptotic
BL-cells. In order to do this:
(A) This work will enumerate the apoptotic cells in the thymus of the CD14-/-
mouse compared to the wild type on both the BALB/c and C57BL/6
strain backgrounds.
(B) Measure interaction of CD 14-/- macrophages with apoptotic BL-cells in
vivo, compared to wild type macrophages.
(C) Characterise CD14low human macrophages' interaction with apoptotic
BL-cells compared to CD14hlgh macrophages.
(D) Measure macrophage migration to apoptotic BL-cells in a transmigration
assay
(E) To assess the importance of CD 14 and CD36 in this process using bone
marrow-derived macrophages from the CD 14 and CD36 knockout mice
compared to wild type.
Finally the identity of the macrophage chemoattractant molecules released by




2.1 Preparation of human primary cells
The Lothian regional ethics committee approved the use of buffy coats and
donated blood in this work. All procedures involving humans were carried out
according to the strict health and safety-guidelines of the University of Edinburgh.
Human peripheral blood was obtained from normal volunteers and buffy coats were
obtained from the Scottish National Blood Transfusion Service.
PBMC from buffy coats
The whole volume of a single donor buffy coat (approximately 80-120ml)
was made up to 200ml by dilution with PBS. 25ml of diluted blood was carefully
laid over I5ml of Histopaque 1077 (Sigma) in a 50ml sterile tube (Falcon) and
centrifuged for 30 min at 2220 RPM/600g(brake off). The second layer, containing
the white blood cells (wbc) was carefully pipetted off and washed in 200ml PBS and
re-spun at 1200 RPM/400g for 10 min. If the supernatant appeared cloudy, the cells
were washed again to remove contaminating platelets. PBMC were purified by
adherence to plastic. 5x 106 PBMC in IMDMsupp for 1 hour at 37C (without serum)
and were plated onto 6 well plates (Costar, UK). Afterwards, the non-adherent
lymphocytes were removed and the media replaced with lMDMsupp containing 10%
human AB serum (Sigma).
PBMC from peripheral blood
40ml of whole blood was placed into a 5oml centrifuge tube containing 4.4ml
of 3.8% sodium citrate and spun at 1200 RPM/400g for 20 minutes with the break
off. After spinning the upper layer that contained plasma and platelets was removed
and spun art high speed (3000 RPM/800g) to separate the platelets from the plasma.
Plasma proteins were allowed to clot around a sterile paper clip in the presence of a
final concentration of 40mM CaCL2 at 37C.The resulting platelet poor plasma (PPP)
was saved for later use. The erythrocytes remaining in the blood were allowed to
sediment for 30 minutes in the presence of approximately 5ml (10% of blood
volume) of 6%dextran in 0.9% (normal) saline. The wbc in the upper layer were
removed using a pipette and centrifuged for 6 minutes at 960 RPM/300g. The
resulting pellet of wbc, that was contaminated with some erythrocytes, was
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resuspended in the PPP already prepared. 2ml of PPP was added for every 80ml of
wbc. A Percoll gradient (Amersham Pharmacia Biotech, UK) was prepared as
follows: A sterile, 90% Percoll solution was made up in normal saline and kept at
4C. A 42% Percoll solution was made up by adding 0.84mlof 90% Percoll to 1.16ul
of PPP and was vortexed. A 51% Percoll solution was made up by adding 1.02mlof
90% Percoll to 0.98 of PPP and was vortexed. The resuspended wbc were placed in a
15ml conical tube and first the 41%, followed by the 51% Percoll solutions were
under-layed beneath the wbc. The gradient was spun for 10 minutes at 1000
RPM/300g (brake off). Peripheral blood mononuclear cells (PBMC) were removed
from the upper layer and neutrophils from the middle layer, and any remaining
erythrocytes were discarded. Neutrophils were washed in PBC and used immediately
in chemotaxis assays. PMBC were washed in PBS and further purified by either
magnetic cell sorting (Miltenyi Biotech, Germany) or by adherence to plastic. 5x 106
PBMC in IMDMsupp without serum were plated onto 6 well plates (Costar, UK) at
37C for lhr and the non-adherent lymphocytes were removed and the media replaced
with IMDMsupp and 10% heat-inactivated autologous serum or alternatively, human
AB serum (Sigma). The sorting of CD14-positive and negative monocyte fractions
from PBMC was done exactly according to the manufacture's instructions (Miltenyi
Biotech).
Preparation of neutrophils from peripheral blood
Peripheral blood mononuclear cells (PBMC) and neutrophils were isolated
from the blood of normal donors by separation over a Percoll (Amersham Pharmacia
Biotech, UK) gradient as previously described. Neutrophils were washed in PBS and
used immediately. Mononuclear cells were plated at 5x 106 cells/ml in 6 well tissue
culture plates (Costar). Adherent monocytes were either used immediately or
matured into macrophages by culture for a further 8 days in DMEM supp. and heat
inactivated 10% autologous serum or human AB serum (Sigma).
Separation of CD14lowand CD14h'9h human monocytes.
A combination of magnetic cell sorting (MACS) and adherence was used to
isolate CD 14 hlgh and CD14low monocytes from PBMC. PBMC were isolated from the
blood of normal donors by separation over a Percoll gradient as previously described.
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Anti-CD14MACS beads (Miltenyi Biotec, Germany) were used to select CD14
positive monocytes from PBMC (Milteny Biotech) exactly according to
manufacturer's instructions. CD14 positive and negative cells were automatically
separated over magnetic columns (Automax, Miltenyi Biotec, Germany). The CD14-
positive fraction was washed and resuspended to a concentration of 106
monocytes/ml in IDDMsupp without serum for 1 hour. The CD14-negative fraction
(that had not bound the anti-CD 14 labelled magnetic bead) was washed and
resuspended to a concentration of 5x106 cells/ml in DMEM without serum for 1 hr.
Cells were plated into 6-well plates for FACS analysis, 48-well plates for
phagocytosis assays (Costar, UK) and into 0.5 ml chamber glass slides for
immunohistochemistry. After a 1 hour incubation, media and non-adherent cells
were removed and the media was replaced with IDDMsupp with 10% serum. Cells
were harvested at Days 0, 1, 3, 5 and 7 for FACS and immunohistochemical analysis.
Macrophage interaction with apoptotic cells was assayed using 10 day-old
macrophages in 48-well plates.
Burkitt's lymphoma
The Burkitt's lymphoma tumour biopsy specimen was a gift from Katrina
Wood, Department of Pathology, Royal Victoria Infirmary, Newcastle upon Tyne
and The University Newcastle upon Tyne.
2.2 Maintenance of human cell lines
Burkitt's lymphoma cell lines, Mutu and BL2
The BL-cells, Mutu and BL2 were cultured in suspension in RPM1 1640
supplemented with 2mM L-glutamine, lOOU/ml penicillin, 100pg/ml streptomycin
(RPMI supp.) and 10% serum supreme (Biowhittaker, MA) (Gregory, 1990).
Mono Mac 6
MM6 cells were cultured in DMEM supplemented with 2mM L-glutamine,
lOOU/ml penicillin, lOOpg/ml streptomycin (RPMI supp) and 10% serum supreme
(Biowhittaker, MA) (Ziegler-Heitbrock, 1988).
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Transfection of Mutu and BL2 with bcl-2
Mutu were transfected with the plasmid pEFZ>c/-2MClneopA by
Hong Wang using a method described in his thesis "Regulation of death and survival
in Burkitt's lymphoma cells" Nottingham University 1996 (Visvader, 1992). BL2
were also transfected with the plasmid pEF6c/-2MClneopA by Carol Anne Ogden.
BL-cells that had been transfected with bcl-2 (Mutu bci-2 BL2 bcl.2) were cultured with
RPMI supp containing 2.5mg/ml neomycin (Gibco Invitrogen, UK). Cells were
passaged every 2-3 days and were maintained at an average concentration of 106
cells/ml.
Cryopreservation of cell lines
Cell lines required for future use were washed and resuspended in 1ml FCS
and then mixed with 1ml of 90% FCS/10% dimethyl sulfoxide (DMSO). Cells were
aliquoted into cryotubes and frozen slowly first in the -70C freezer for 48hr and then
transferred into liquid nitrogen for longer-term storage. To thaw cells, cryo tubes
were wrapped in aluminium foil and left at room temperature. Once defrosted, cells
were washed several times in medium to remove residual DMSO.
2.3 Preparation of mouse primary cells
All animal work was performed under licence from the UK Government
Home Office and with the approval of the review boards of the Universities of
Nottingham and Edinburgh.
Mice
Balb/c wild type and the C57BL/6 wild type mice were purchased from B&K
Universal (Hull,UK). Balb/c CD 14-/- were produced as described by (Haziot, 1996)
and were provided by Sanna Goyert, Northshore New York. The Balb/c mice were
held in conventional housing at the University of Edinburgh.
C57BL/6 CD14-/- mice were obtained from Jackson laboratories (Jackson,
Maine USA) and were certified as being specific pathogen free and were housed in
individual ventilator cages. C57BL/6 CD36-/- animals were a kind gift from
Professor John Savill, University of Edinburgh, and were held in conventional
housing at the University of Edinburgh.
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Mouse bone-marrow-derived macrophages (BMDM)
Mouse macrophages were cultured from bone marrow using previously
described methods (Ren, 2001; Savill, 1992; Johnson, 1983). Entire femurs were
removed from mice using a sterile scalpel, by disarticulation at the hip and
osteotomy through the proximal tibia and fibula. Bones were placed in 100% alcohol
for 5 minutes. Muscle was cleaned away from bone and the shaft of the femur was
cut at each end. Marrow flushed out of the femur using a small gauge (orange)
needle connected to 5ml syringe containing with DMEM supplemented with 2mM L-
glutamine, lOOU/ml penicillin, 100p.g/ml streptomycin, (DMEMsupp)(Gibco, Paisley,
UK). The cells were dispersed by drawing them up and down through a medium
gauge (green) needle. Bone marrow cells were washed in 10ml DMEMsupp and
centrifuged at 1200 RPM/400g for 5 minutes. Cells were stained with trypan blue
and counted using a glass haemocytometer; they were resuspended at a concentration
of 10 6 cells/ml in DMEMsupp containing 10% heat inactivated FBS and 10%
conditioned supernatant from L929 cells as a source of M-CSF (Labtech
International, UK) (Hume, 1983).
Bone marrow cells were plated out into sterile tissue culture plastic plates
(Costar UK). Macrophages to be used for chemotaxis assays were seeded in 6-well
plates and those to be used for phagocytosis assays were seeded into 48-well plates.
Cells were maintained in an incubator kept at 37Cand 5% CO 2 After 24 hours in
culture, supernatants containing non-adherent cells were removed and adherent
macrophages were washed in PBS and then fresh media was added. Bone marrow-
derived macrophages (BMDM) were cultured for up to two weeks and fresh media
was supplied after every three days in culture.
Mouse thymus for transmission electron microscopy (TEM)
Wild type and mice and CD14-knockout mice were used between 6- 8 weeks
of age. One wild type mouse and one CD 14-/- mouse were injected with 200pg of
dexamethasone ip (Organon,UK) 24 hours prior to sacrifice, and a second pair of
mice were injected with PBS vehicle control. Each thymus was briefly examined
before processing for TEM. 4 x 2mm3 pieces of thymus were cut from the remaining
lobe. Both the cortex and medulla regions of the thymus were sampled. Tissue was
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immediately fixed in freshly glutaraldhyde. Mr Stuart McKenzie from the
Department of Pathology of the University of Edinburgh and the Lothian University
Hospitals Trust kindly prepared the specimens for TEM. Briefly, specimens were
dehydrated, and embedded in resin and sections were cut and mounted on copper
grid. Specimens were viewed using the electron microscope at the Western General
Hospital, Edinburgh and photographs were taken of representative material. Black
and white photographs were scanned and saved as JPEG files.
Mouse thymocytes for FACS
After sacrifice, the thymus was removed. Thymus tissue was squashed
between two glass slides. The liberated cells were suspended in PBS in a 15ml tissue
culture plastic tube. Dense thymus tissue fell to the bottom of the tube and the single
cell-suspension above was aspirated, spun down at 1200 RPM/400g and resuspended
in Annexin V binding buffer ready for staining with Annexin V FITC (AxV) and
propidium iodide (PI). Cells were analysed by FACS, 10 000 events were counted
and the total percentage of AxV- PI- (viable cells) versus the AxV+ PI+ (apoptotic
cells) was compared for each mouse.
2.4 Immunohistochemistry
Haematoxylin and eosin immunostaining of cytospins
Cells were washed and resuspended in RPMI or PBS with 10% serum
supreme (Biowhittaker, MA) at a concentration of 2.5 xlO5 cells/ml. 200ul of the cell
suspension was added to each sample chamber. Poly-L-lysine coated or BDH
superfrost-plus glass slides were used. The cells were spun on a Shandon Cytospin3
(Shandon Inc. USA) at 75g for 3 min. Cells were left to air-dry and were fixed in
methanol for 2 min, eosin stained in Diff-Quikl for 2 min followed by haematoxylin
staining in Diff-Quik 2 (Dade UK) for one minute and then immediately rinsed in
water. After drying for lOmin cytospins were wetted in xylene and mounted in pertex
mountant (Cellpath, UK).
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Deoxynucleotide transferase-mediated dUTP nick end labelling (TUNEL)
staining of fixed tissue
A TdT-FragEL ™ DNA fragmentation kit (Oncogene research products) was
used for TUNEL staining which labels the brakes in the DNA found in apoptotic
cells. The manufacturers instructions for the kit were followed exactly, except that
one drop of reagent A was added per ml of reagent B of DAB liquid (Dako) and was
used in place of the kit's DAB 0.7mg tablet.
lOmM Tris pH 8 was made up as follows. 1.21 lg of Tris was dissolved into
one litre of dH20, and HCL was then added to reduce the pH to 8.0. The pH was
measured using a pH meter. ImM MgS04 was made up as follows. 247mg MgSCL
was dissolved into one litre of lx TBS. The kit's proteinase K was diluted 1:100
from concentrate, lug/ul DNAse-1 was made up as follows: lOmg/ml of DNAse-1
(Sigma) was diluted 1:10 in ImM MgSCL in lxTBS. Hydrogen peroxide was made
up as follows. 1ml of 30% H2O2 was diluted 1:10 in 100% methanol to a final
concentration of 3% H2O2.
After mounting a glass cover slip over the samples, the number of positive
cells that stained brown in the cortex and the medulla were counted. Three
representative sections each 5pm thick were taken 50pm apart through the whole
thickness of the thymus from each mouse. For each section, four randomly selected,
non-overlapping high power fields were selected. Each field was 100pm x 100pm. A
HOME ™ computer with Axio-home software (Zeiss) was used to keep a tally of
positive cells and to ensure that positive cells were counted only once. The mean
number of cells in each high-power field was counted and all data was graphed using
Graph Pad Prism software version 3.02.
CD68 immunohistochemisty
The human Burkitt's lymphoma tumour biopsy specimen was a gift from
Katrina Wood, Department of Pathology, Royal Victoria Infirmary, Newcastle upon
Tyne and The University Newcastle upon Tyne. The formalin-fixed, paraffin-
embedded Burkitt's lymphoma tumours were cut into 4 pm-thick sections using a
microtome and mounted onto Vectabond-coated glass slides (Vecta, CA
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Paraffin-embedded slides were dewaxed in xylene, for 10 minutes at room
temperature, then rehydrated to water by 2 minute sequential washes in absolute
alcohol, 74% alcohol, then 64% and finally deionised water. If antigen retrieval was
required, slides were placed in a plastic dish (with a lid) containing Vector antigen
unmasking solution (Vector, USA) that had been diluted 1:100 in deionised water.
Slides were microwaved for 3x 5 minutes at 1000 watts. The slide rack was turned to
disperse air bubbles after each 5-minute cycle. Slides were then cooled in running tap
water for 20 minutes. Non-specific staining was blocked using 0.15% H2O2 diluted
in tap water for 15 minutes. Slides were washed twice for 5 minutes in PBS and
loaded onto a Shandon Sequenza staining rack that prevented tissue drying
(Shandon,USA). The Sequenza reservoir had a capacity of 125ul and all antibodies
and solutions were made up to a volume of 125ml. Sections were blocked with
Vector Avidin D blocking solution for 15 minutes, washes twice in PBS for 5
minutes and then further blocked with Vector Biotin solution for 15minutes followed
by 2 5-minute PBS washes. A 1:50 dilution of a mouse anti-human CD68
monoclonal antibody clone PG-M1 was made into a 5% goat serum (Harlan Sera-
Lab) in PBS containing 4 drops of biotin block per/ml. Slides were incubated for 1
hour at room temperature, washed in PBS and then incubated with a secondary
antibody. A biotinylated goat anti-mouse Ig monoclonal antibody (Dako) diluted
1:300 in PBS containing 5% normal goat serum and biotin block was incubated for
30 min.
After staining with specific antibodies, slides were washed with PBS
followed by a 30-minute treatment with R.T.U Vectastain Elite ABC reagent, that
contains a preparation of streptavidin-horse radish peroxidase (HRP). After three 5-
minute washes in PBS, antibody labelling was visualised using a
diaminobenzidinetetrahydrochloride (DAB) substrate solution for 5 minutes. DAB
was freshly prepared immediately prior to use by adding one drop of liquid (20juJ)
DAB to 1ml of substrate chromogen solution (Dako Liquid DAB kit, Dako,
Denmark). Slides were removed from the Sequenza rack and washed in PBS. Tissues
were counterstained blue in haematoxylin (Shandon) for 30 seconds and then dipped
in Scott's tap water for 30 seconds. Slides were then dehydrated in ascending
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concentrations of alcohol (same% as before). Slides were cleared in xylene and
mounted with a Pertex mountant and protected with glass coverslips.
Confocal fluorescent microscopy of CX3CL1-labelled cells
A confocal microscope can focus on ultra-thin sections of a cell. Only when
the laser is focused to a high resolution is the light sufficient to excite fluorescence.
Thus the sections viewed are thinner than the cell width. A confocal microscope has
an advantage over light microscopy because it can differentiate between surface and
intracellular molecules.
Mutu BL-cells were incubated with a mouse anti-fractalkine antibody clone
81513 (R&D systems) and bound antibodies were revealed by incubation with a
secondary, goat anti-mouse Igalexa-fluor green 488-labeIled antibody. Cells were
fixed in 1% paraformaldehyde at 4C overnight and suspended in a 50:50
PBS/glycerol mix containing 1% vector shield (Vector) and finally, mounted with
Movoil for confocal microscopy. Cells were viewed using a TCS-NT confocal laser
scanning microscope (Leica Microsystems) coupled with TiiSapphire lasers. Images
were obtained with the kind assistance of Linda Wilson at the University of
Edinburgh.
2.5 Fluorescence-activated cell sorting
Fluorescence-activated cell sorter (FACS) analysis of cells is used to
characterise single cells within a suspension. When cells are labelled with fluorescent
antibodies, the machine is able to measure the size, granularity and fluorescence of
an individual cell as it passes in a stream across photodetectors. FACS analysis of
cells was carried out using either a Coulter EPICS XL (Coulter) or a Becton
Dickinson FACS Calibur (BD Immunocytometry systems).
For fluorescent antibody labelling, approximately 2x103 cells were added to
96 well round-bottom tissue culture plates (Costar) for each test, and washed in
200pl of FACS buffer, and spun down at 1200 RPM for 5 minutes at 4C. Cells were
then resuspended in lOOpl of cold FACS buffer and placed on ice. For single step,
direct labelling of cells, FITC, RPE or RPE-Cy5 conjugated antibodies or isotype
control antibodies were added to cells and incubated on ice in the dark for 20
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minutes. The concentration of antibody added varied depending on the manufacturers
recommendations and the optimum antibody concentration was titrated for each cell
type used. Two-step, indirect labelling of cells was done when the primary antibody
was not conjugated to a fluorochrome. After the first incubation, cells were washed
and incubated with a secondary antibody conjugated with FITC, RPE or RPE-Cy5.
Secondary antibodies were either full length or Fab fragments of antibodies raised
against the primary immunoglobulin.
Cells were washed twice in cold FACS buffer and then resuspended in 400pl
cold FACS buffer and used immediately. Propidium iodide (PI) and (ToPR03) are
two intracellular dyes that are taken up by dead and fixed cells, lpl of PI or ToPR03
was added immediately to cells before running on the FACS machine in order to
discriminate dead from viable cells. If cells were not be analysed immediately, they
were fixed in a 50:50 mixture of200pl FACS buffer and 200pl of FACS fix buffer to
a final concentration of 1% formalin. Cells were then stored at 4C in the dark until
further use. Cells were analysed by a Coulter EPICS XL FACS machine and data
files were analysed using Flow-Jo software.
2.6 Molecular Biology
Preparation of total RNA
An RNeasy Mini Kit (Quiagen) was used to extract total RNA from Mutu
BL-cells, macrophages and monocytes according to the manufacturer's instructions.
A maximum of 107 cells were suspended in an appropriate volume of the supplied
RLT lysis buffer. Cells were then homogenised by passing through QIAshredder
coloums (Quiagen). One volume of 70% ethanol was added to the homogenised
lysate prior to being added to a Rneasy spin column. The lysate was centrifuged at
13,000 RPM/16060g for 15 sec and the column washed with the supplied RW1
buffer. Contaminating DNA was removed using RNAse-free DNAse (Quiagen). The
column was washed twice in supplied RPE buffer. Total RNA was eluted in 20-30pl
of RNAse/DNAase-free water (Promega Corporation).
The total amount of RNA was measured using a spectrophotometer,
Ultrospec 200 (Pharmacia Biotech). The absorbency of known dilutions of extracted
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RNA were measured at 260 and 280nm. These readings were converted to
concentrations using the following formula (Sambrook, 1989):
1 A260 unit of RNA = 40pg/ml
To determine the purity of the RNA solutions, the ration of absorbance at 260nm and
280nm (OD260.280) was measured. Ideally this value should be 2.0 for RNA. Running
2ul of the diluted RNA sample on a 1% agarose gel for 25 minutes checked the
quality of the RNA sample. The resulting gel showed good 28s and 18s bands.
Additionally, any contamination of the RNA sample with DNA was checked by
running a PCR in the absence of reverse transcriptase (RT). These controls were
necessary as many chemokine receptors are encoded by single exons, meaning that
any contamination with genomic DNA may lead to a false positive result.
RT-PCR
CDNA was prepared using an access RT-PCR system kit A1250 (Promega).
The reverse transcriptase enzyme used was RT superscript™ (InVitrogen) because it
had no endonuclease activity and gave higher cDNA yields. 0.5pl of RNAse
inhibitors were added to 5pg of RNA to a final volume of 7pl in RNAse/DNAase-
free water (Promega Corporation). This was placed in a sterile, RNAse/DNAase-free,
thin-walled tube and denatured for 5 minutes at 94C. The denatured sample was
placed on ice and the following added:
4pl 25mM MgCh






to a final volume of 20pl. Tubes were placed in a thermocycler (Perkin Elmer) at
42C for 1 hour followed by 95C for 5min and 4C for eternity. After diluting the
cDNA sample to lOOpl volume by adding 80pl of RNAse/DNAse-free water,
samples were stored at -20C until further use.
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PCR
Fractalkine, fractalkine receptor and (3-Actin primers were a kind gift from Dr
Robert Nibbs, University of Glasgow. All PCR was performed in the Beatson
laboratory in Glasgow.
Primers
All primers were designed by Dr Robert Nibbs and manufactured by TAGN
Ltd and MWG-Biotech, Glasgow.
CX3CL1 forward: 5'-CCA CGG TGT GAC GAA ATG-3'
CX3CL1 reverse: 5'-CCA TTT CGA GTT AGG GCA-3'
CX3CR1 forward: 5'-GAA ATC TGG CCC GTG CTC-3'
CX3CR1 reverse: 5'-CGG TTG CAT TTA GCC ATT G-3'
p-Actin forward: 5'-TCC ATC ATG AAG TGT GAC GT-3'
p-Actin reverse: 5'-TAC TCC TGC TTG CTG ATC CAC -3'
Primers were diluted in RNAse/DNAse-free water to a final concentration of
10pM. Pre-aliquoted Reddy mix Master Mix 0.2ml tubes (AM337-415 Abgene)
containing loading dye, were used for PCR. 1.25pl of forward primer, 1.25pl of the
reverse primer and 2.5pl of cDNA were added to the master mix. Water only and
genomic DNA were added in place of cDNA as controls. Tubes were vortexed gently
and placed on ice. cDNA was amplified in a thermocycler (Perkin Elmer) under the
following conditions: Hot start 94C for 5 minutes




And afterwards 4C for eternity
Products from this reaction were kept at 4C for approximately 48 hours until
further use. Amplified products were separated out on a 1.5% agarose (Flogen) gel
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containing 1 Of-il ethidium bromide. 20jlx1 of amplified product was run per well and
fragment size was read using a coloured marker (Bioline Hyperladder-1). After
approximately 45 minutes, gels were removed from the tank and viewed under UV
light and photographed.
2.7 Western Blotting
Preparation of cell lysates
All steps were carried out at 4C using ice-cold solutions. Live and apoptotic
Mutu BL-cells were washed twice in PBS and spun down. The 0.5ml of extraction
buffer was added per 0.5x 106cells in the pellet. %). 50x Extraction Buffer was made
up as follows: 20mM Tris-HCl (0.242g for 100ml) 2mM EGTA (0.076g for 100ml)
and 2mM EDTA. The pH was adjusted to 7.5 with HC1 This mixture was aliquoted
and stored at -20C. lOul of Triton x-100 was added to 10ml of a 1:50 dilution of the
extraction buffer to a final concentration of 0.1% v/v. One tablet of protease
inhibitors was added to 10ml of the buffer. The lysed cells were centrifuged at 3000
RPM for 10 minutes at 4C. 2pl of protein extract was added to 798pl of dH20. The
total protein concentration in the samples was compared to a BSA standard
concentration curve measured using a Bradford protein assay. A BSA standard curve
of 2,4,8,12,and 20 pg/fJ.1 was prepared by adding 1,2,4,6 and lOjxl of a standard stock
solution (2pg/ul BSA) to 799,798,796,794,and 790 p.1 (respectively) of dH20. A
blank reference sample was prepared by adding 2pl of buffer to 798pl of dH20.
Whilst stirring on a vortex, 200pl Bradford reagent (Biorad) was added to each tube
and the colour reaction proceeded for 10 minutes. 200j.il of each sample was next
placed in a 96 well flat-bottomed plate and read at 540nm in a plate reader (Anthos
Labtec Instruments). A standard curve was plotted and the protein concentration of
the samples read off. All protein samples were diluted to 5 jig/ pi in sample buffer.
8ml of 4x sample buffer was prepared by adding 1ml of 0.5M tris-HCL
pH6.8 to 3.8ml of dH20, 0.8ml of glycerol, 1.6ml of 10% (w/v) SDS, 0.4ml beta-
mercaptoethanol and 0.4ml of 1% (w/v) bromophenol blue. Samples were denatured
by boiling in a xl concentration of sample buffer for 5 minutes.
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SDS-polyacrylamide gel electrophoresis
Gels were prepared as follows: A 12% separating gel was made up using
3.35ml dH20 plus 2.5ml Tris-HCL pH 8.8, lOOpl of 10% SDS, 4ml of
30%Acrylamide/bisAcrylamide, 150pl of 10% Ammonium Persulphate and 5pl
TEMED. A 4% stacking gel was prepared as follows: 6.1ml dH20 plus 2.5ml Tris-
EICL pH 6.8, lOOpl of 10% SDS, 1.3ml of 30%Acrylamide/bisAcrylamide, 150pl of
10% APS and lOpl TEMED. The separating gel was poured between two sheets of
the Bio-rad mini gel apparatus. Once firm, the stacking gel was poured over a comb
ensuring that no air bubbles became trapped.
A running buffer was prepared as follows: To make a lOx PAGE buffer 144g
of glycine and 30g of Tris Base were added to 1 litre of dH20. The running buffer
was prepared by taking 80ml of the PAGE buffer and 8ml of a 10% SDS solution
and adding 912mlof dH20. The reservoir of the Bio-rad apparatus was filled with
running buffer and the samples were loaded alongside a broad range molecular
weight marker ranging from 10 to 250. The 8kDA chemokine domain fragment of
fractalkine was added to one lane as a positive control. Two samples were run on a
separate gel and tested for p-actin as a positive control of sample loading and protein
content. Gels were run at 50mAmps for approximately 45 minutes.
Transfer of proteins from SDS-polyacrylamide gels to a solid support
Once the proteins had separated, gels were immobilised onto nitrocellulose
paper (Amersham Biosciences) soaked in blotting buffer and sandwiched between
layers of filter paper (Whatman) and sponge in the Bio-rad mini-Protean apparatus.
The blotting buffer was prepared by adding 100ml of the xlO PAGE buffer to 200ml
of methanol and adding 700ml dH20. Proteins were transferred from the gel to the
membrane at 400mAmp for 30 minutes. Once transferred, the nitrocellulose papers
were placed in a petri dish and stained.
Antibody labelling of protein bands
Proteins were blocked for 2 hours at room temperature using a 5% solution of
non-fat skimmed milk powder (Tesco) made up in TBS. Membranes were labelled
with a mouse anti-fractalkine monoclonal antibody clone 815 13 at a concentration
2pg/ml 1:250 (R&D Systems) or with a 1:500 mouse anti p-actin antibody (Sigma)
70
and incubated for either 2 hours at room temperature or overnight at 4C. The
secondary antibody, biotinylated goat anti-mouse IgG antibody was diluted in TBS
containing 5% milk to a ratio of 1:10 000. The secondary antibody was incubated for
either, 1 hour at room temperature or overnight at 4C. Membranes were washed in
TBS and bands revealed using enhanced chemiluminescence (ECL) (Upstate
Biotech). The ECL solution was prepared by adding 1ml of solution A to 1ml of
solution B per membrane for 1 minute. Membranes were wiped, wrapped in cling
fdm and exposed to film. Size of the revealed protein bands was compared to the
molecular weight ladder, p-actin was seen at its expected size of 42kDa and the
chemokine domain of fractalkine was seen at its expected size of 8.5kDa.
2.8 Measurement of apoptosis
Induction of apoptosis in BL-cells
Irradiation with Ultraviolet Light UVB was routinely used to induce
apoptosis in BL-cells. BL-cells in suspension were washed in fresh media RPMIsupp
and placed in flat-bottomed flasks and exposed to 200mJ/cm2 of UVB in a
transilluminator (UV products limited, UK). 16 hours after this treatment, routinely
more than 90% of cells were apoptotic and trypan blue-positive. Alternatively,
apoptosis was induced chemically by incubation with lpM ionomycin for up to 16
hours, with lplml staurosporine for 8 hours, or lpM actinomycin D for 8 hours.
After chemical treatment cells were washed in fresh media and routinely, over 90%
of cells were apoptotic and trypan blue-positive.
FACS-based measurement of apoptosis
The light scatter properties of viable and apoptotic BL-cells differ when
analysed by FACS (Dive et al, 1992). Figure 2.8a(i) shows the forward versus side
scatter plot of a mixture of viable and apoptotic BL-cells. The smaller and more-
dense apoptotic cells fall close to the y-axis whereas the viable cells fall closer to the
x-axis. For every experiment, the flow cytometric data was confirmed by analysis of
nuclear morphology by staining of cytospins with H&E or checking nuclear
morphology with 4,6-diamidino-2-phenylindole (DAPI) detailed below.
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Annexin V and propidium iodide staining of BL-cells
All fluorescence labelling was carried out in the dark on ice. To measure
apoptosis, 106 cells were washed and maintained in calcium containing buffer and
labelled with annexin V (AxV) and propidium iodide (PI) (Bender Med Systems,
USA). The AxV-binding buffer was made up as follows: 2ml of lOmM HEPES
pH7.4, 9.3ml of a 0.1M stock of NaCl (140mM), 2.5ml of a 0.1M stock of CaCl2
(25mM) made up to 100ml with distilled water. For each sample of cells, 10pl of PI
(50ju.g/ml) lp.1 FITC AxV (25pg/ml) and 89pl of buffer were added. After a 15
minutes incubation on ice in the dark, 400pl of binding buffer was added and run on
the Coulter XL FACS machine.
4', 6-diamine-2'-phenylindole dihydrochloride (DAPI) nuclear staining
Cells were checked by light microscopy for phenotypic changes of apoptosis
such as membrane blebing, pyknosis and cell shrinkage. Condensed chromatin was
visualised by 4', 6-diamine-2'-phenylindole dihydrochloride (DAPI). Cells were first
fixed in 1% formaldehyde for a minimum of 12 hours at 4C. DAPI was added to a
final concentration of 0.25(ig/ml. A drop of the cell suspension was placed on a glass
slide (under a glass coverslip) and analysed by fluorescence microscopy (Axioskop2,
Zeiss Switzerland). Two hundred cells per sample were scored as having viable or
apoptotic morphology and the percentage of apoptotic cells was recorded for each
experiment. Figure 2.8a(ii) shows that viable Mutu BL-cells have large round nuclei
whereas, apoptotic cells have condensed and blebed nuclei with a typical "popcorn"
appearance.
Transfection of BL-cells with bcl-2
Once BL-cells had been transfected with bcl-2, they were resistant to the
UVB-induction of apoptosis. 16 hours after induction of apoptosis 83% of Mutu BL-
cells were in the apoptotic zone, but only 15% of the transfected cells were apoptotic
(figure 2.8b). What is more, UVB-treated BL-cells transfected with bcl-2 did not
stimulate macrophage transmigration in the transwell assay. Therefore, UVB-treated-
BL-cells (transfected with bcl-2) were not routinely used in experiments.
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Preparation of necrotic cells
Mutu BL-cells were placed in fresh RPMIsupp in the absence of serum at a
concentration of 106/ml. Cells were then placed in a water bath at 100C and boiled
for 20 min. All cells were trypan blue-positive after this treatment.
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(i) FACS light scatter plots of BL-cells showing 'viable' and
apoptotic' zones, (ii) DAPI nuclear labelling of viable cells with
large round nuclei and apoptotic BL-cells that have condensed
nuclei and a "popcom-like" appearance.
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Figure 2.8b
FACS analysis of light-scatter properties of Mutu. Forward scatter (FS)
versus side scatter (SS) is plotted. Mutu with and without bcl-2 were
examined 16 hours after UV-induction of apoptosis. Mutu are shown falling
into the viable zone. Only 3.16% of Mutu BL fall in the viable zone after UV-
treatment. Mutu bcl-2 are relatively resistant to apoptosis and have more
viable cells after UV-treatment (58.5%).
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2.9 Macrophage-apoptotic cell interaction assay
Human monocyte-derived macrophages and murine bone marrow-derived
macrophages (BMDM) were seeded into 48 well plates. Ten-day old macrophages
were used for all phagocytosis studies. Mutu were induced to become apoptotic by
100mJ/cm2 UVB-light.16 hours after UV treatment over 90% of the Mutu were
apoptotic. Apoptosis was confirmed by the ability of cells to bind annexin-V FITC
and by DAPI staining of alterations in the nuclear morphology of the apoptotic cells.
Apoptotic cells were twice washed in sterile PBS and resuspended in serum-free
RPMIsupp at a concentration of 5xl06 cell/ml.
Macrophages were washed and placed in serum-free media DMEMSUpp for
thirty minutes. Media was aspirated and the wells were washed with PBS. The
suspension of apoptotic cells was added to the wells at a ratio of five apoptotic Mutu
to one macrophage. The cells were co-incubated for 0-75 minutes at 37C and 5%
CO2 Each condition was set up in triplicate. Control wells containing only
macrophages without apoptotic cells, measured the baseline level of macrophage
phagocytosis. At the end of the experiment, wells were vigorously washed with PBS
to remove any non-adherent cells. The plate was viewed under the light microscope
to ensure that apoptotic cells had been thoroughly removed before fixing in 1%
formalin overnight at 4C. Plates were washed with PBS and stained with
haematoxylin (DiffQuik II Dade) for five minutes and then washed once more in
PBS. The nuclei of the macrophages and the shrunken pyknotic nuclei of the
apoptotic cells inside the macrophages was seen clearly at x400 magnification using
an inverted microscope. Two hundred macrophages were counted in each well and
the percentage of macrophages that had interacted with apoptotic cells was
calculated. The mean and standard deviation of the mean was calculated for three
wells.
2.10 Macrophage transmigration assay
Introduction
This thesis examines macrophage migration to human and murine apoptotic
cells. Primary macrophages are large, adherent and terminally differentiated cells
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that are not often studied in chemotaxis assays in vitro. Instead, monocyte cell lines
are usually substituted for primary macrophages. More mobile monocyte cell lines
can be transfected with chemotactic receptors and used as surrogate macrophages.
There are many ways of measuring chemotaxis: Sophisticated time-lapse digital
imaging can be used to measure macrophage directional movement both in vitro and
in vivo. Monocyte and macrophage migration can be monitored under agarose but
this requires very accurate measuring of the "front" of migrating cells because they
might only move l-2mm in the space of 4 hours (Heit, 2003). An alternative is to
wound a macrophage monolayer by the scraping off of a line of adherent
macrophages from the bottom of a tissue culture dish; this allows the movement of
neighbouring cells, as they move into the wound site, to be monitored.
The transwell assay is a simple device for measuring cell chemotaxis. Cells
are placed in an upper chamber and are allowed to transmigrate through a porous
membrane towards chemotactic molecules. The setting up of a robust transwell
system to measure macrophage chemotaxis to apoptotic cells is described in this
chapter.
Preparation of cells to be placed in the lower chamber
BL were passaged 48 hours prior to use in the assay. 10-30ml of BL were
placed under a UVB transilluminator (UV products limited, UK) and exposed to
200mJ/cm2 of UVB light (approximately 20 minutes) at RT. 12 hours after UV-
induction of apoptosis BL, were washed in RPMI supp without serum, centrifuged at
1000 RPM and resuspended serum-free RPMIsupp at a concentration of 2xl06
cells/ml. BLbd-2 or untreated BL-cells were washed and resuspended to a
concentration of 2xl06 cells/ml in the same way. 600pl of each cell suspension or
control solution was pipetted into a separate well of a 24-well tissue culture plate
(Costar, UK) and kept at 37C and 5%C02. In addition, 600ul of serum-free RPMIsupp
was used as a negative control. Either 10"8M fMLP (V-formylated-Methionine-
Leucine-Phenylalanine) (Sigma, UK) or recombinant CCL5 (Peprotech, UK) was
diluted in 600ul of serum-free RPMIsuppto a final concentration of lOOng/ml and was
used for positive controls. All conditions were set up in duplicate. A separate well of
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assay. Instead, cells in these wells were used to assess the number of apoptotic cells
present in each well at the end of the experiment. FACS was used to assess apoptosis
using Annexin V and PI labelling, and nuclear morphology was assessed by
microscopy of DAPI stained cells. Once all conditions had been set up, the plate was
returned to the 37C incubator whilst the macrophages (or other migrating cells) were
prepared for use.
Preparation of cells to be placed in the upper chamber
Primary eight day-old macrophages were grown in 6-well tissue culture
plates (Costar, UK). Non-adherent cells were removed by washing with cold, sterile
PBS (4C). 1ml of cold PBS was pipetted over the macrophages and plates were
placed on ice for 5 minutes. Macrophages were harvested using a cell lifter (Costar,
UK), washed in RPMIsupp without serum, centrifuged at 1 OOOrpm and resuspended at
a concentration of 106 macrophages/ml. The number of cells was counted on a
haemocytometer and viability was assessed using trypan blue exclusion. Further
manipulations such as the incubation with antibody for 30 minutes, or the addition of
chemokines and inhibitors were done at this point.
Chemotaxis experiments were performed in 6.5mm diameter transwells
(Costar,UK) with an uncoated polycarbonate membrane containing 5pm-diameter
pores, using a modification of Boyden's technique (Barleon, 1996). 105
macrophages/monocytes or neutrophils were placed in lOOpl of RPMI supp in the top
of a transwell and allowed to transmigrate to the bottom well at 37°C, 5% CO2 for
either 1 hour (neutrophils) or 4 hours (monocytes and macrophages). Transwell
inserts were removed and non-migrated cells were removed from the upper well by
pipette. The upper membrane was wiped using a clean cotton bud. The lower side of
the filter was not disturbed as the migrated cells were adherent to the underside.
Filters were fixed in 100% methanol for ten minutes and allowed to dry and each
transwell was labelled with a permanent marker pen for identification. Cells on the
filter were stained by emersion into a well containing Dif-Quik II (Dade, Germany)
for ten minutes. Transwells were tapped dry and placed into a clean 24-well plate.
The number of cells that had migrated was counted in 10 random high-power fields
(x400 magnification) using an inverted microscope (Zeiss Axiovert 25). The mean
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number of cells counted in ten high power fields was calculated and significance was
measured using the Student's t-test. Experiments were repeated a minimum of three
times. All data was graphed and analysed using Graph Pad Prism software version
3.02.
In one experiment, the macrophages that had passed through the filter
membrane, towards apoptotic BL-cells were studied. At the end of the transmigration
assay, the non-migrated cells were removed from the upper well in the usual way and
immunolabelled with anti-CD 14 antibodies and analysed by FACS. Placing the
filters in ice-cold 2mM EDTA isolated the macrophages that had migrated to the
lower surface of the filter. These adherent macrophages were freed by gently tapping
the inserts. A minimum of ten filters was required to harvest enough macrophages
for analysis. After washing in PBS, the CD 14 expression of the macrophages that
had migrated to apoptotic BL-cells was compared to non-migrating cells in the upper
well.
Preparation of supernatants
BL-cells were washed and placed in serum-free media and treated with UVB-
light to induce apoptosis and kept in an incubator at 37C. 16 hours later over 90% of
cells were apoptotic. Cells were gently spun down at 1200 RPM supernatants were
aspirated off and passed through a 0.2pm-pore filter. Likewise, supernatants were
collected from live BL-cells and BL-cells transfected with bcl-2 that had not been
exposed to UVB. After boiling at 100C for 20 minutes, necrotic-cell supernatants
were prepared also passed through a 0.2pm-pore filter.
Controls
Each transwell experiment included a negative control (media only in the
lower chamber and a positive control (either CCL5 or fMLP in the lower chamber.
In addition every experiment included wells containing 2x i06/ml BL-cells for the
purpose of monitoring the rate of cell apoptosis that varied between experiments.
Chemotaxis is directional cell motion along a concentration gradient. Chemokinesis
is the increased activity (including movement) of a cell stimulated by a chemical.
Chemokinesis itself may increase the number of cells passing through the filter. To
test whether apoptotic BL-cells were truly chemotactic to macrophages, the same
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concentration of cells was placed above and below the filter. There was no
concentration gradient across the filter in these chemokinesis-control wells. The
number of macrophages stimulated to move by chemokinesis was subtracted from
the number responding to the chemotactic gradient. A checkerboard analysis was
done to establish whether apoptotic BL-cells and their supernatants were true
chemokines. Increasing concentrations of the BL-cells and their supernatants were
placed in the upper chamber to abolish the chemotactic gradient. Apoptotic BL-cells
and their supernatants were judged to contain true chemokines because increasing the
concentration in the upper chamber reduced macrophage migration through the filter.
If apoptotic BL-cells had simply caused chemokinesis, macrophage migration would
have been simulated by the overall increase in BL-cell concentration.
Inhibition of transmigration by vMIPII, CX3CL1 and pertussis toxin
The anti-fractalkine monoclonal antibody clone 51637.11 (R&D systems)
was titrated for its ability to block macrophage migration to the 8kDa chemokine
domain of fractalkine (Peprotech) in a transmigration assay. The ND5o dose for this
antibody quoted in the data sheet was 15-30pg/ml. The number of macrophages that
transmigrated to the chemokine domain of fractalkine was much lower than
responded to apoptotic BL-cells. However, a significant reduction in macrophage
chemotaxis of more than 50% was observed when 50p.g/ml of antibody was placed in
the lower chamber with the apoptotic BL-cells.
The viral peptide vMIPII (macrophage inflammatory protein II) was also
titrated for its ability to block macrophage migration to the 8.5kDa chemokine
domain of fractalkine (Peprotech) in a transmigration assay (Boshoff, 1997). Again,
macrophage transmigration to CX3CL1 was of a lower magnitude than to apoptotic
BL-cells. A concentration of 300ng/ml vMIPII was able to significantly block
macrophage transmigration and was used to block macrophage transmigration to
apoptotic BL-cells.
Pertussis toxin (PTX) inactivates the Gj subunit of the trimeric G-proteins that
are activated by chemokine receptors, including CX3CR1. Macrophages were pre-
treated with lOOng/ml of PTX (Alexis) overnight at 37C. Cells were washed well
before use in transmigration assays. There was no difference in macrophage viability
as judged by trypan blue exclusion between the PTX-treated and untreated cells.
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Adaptation of the transmigration assay for Mono mac 6 cells
Mono mac cells (MM6) are a monocyte cell line. When MM6 were
substituted for macrophages in the transmigration assay, they did not adhere to the
underside of the filter membrane but passed directly into the lower chamber.
Counting the number of transmigrated MM6 was performed most reliably and
reproducibly done by FACS. BL-cells were first stained with a Calcein AM
fluorescent dye (Molecular probes) in order discriminate between the migrated
MM6 cells and apoptotic BL-cells. Mutu BL-cells were labelled fluorescent green
using Calcein AM using the following protocol. Mutu BL-cells were washed and
resuspended in RPMI at a concentration of 2xl07cells/ml. lul of Calcein AM green
(from a ImM stock) was added per ml of cells to a final concentration of lpM and
incubated at 37C for 15 minutes. Cells were then thoroughly washed in RPMI and
resuspended at 106cells/ml for induction of apoptosis to be used in the transmigration
assay. After the assay the transwell inserts were removed and 400pl of RPMI
containing 2Mm EDTA was added to the lower chamber. Cells were pipetted from
wells and vortexed before counting on the FACS machine. BL-cells were gated out
by both size and fluorescence. The reproducibility of counts was measured by the
addition of a known number of flow-calibration beads (Coulter). Three, 30-second
counts were made from each well. Each experiment was performed in duplicate wells
and the average number of MM6 cells that migrated was calculated from six counts.
Adaptation of the transmigration assay for mouse BMDM
Bone marrow derived murine macrophages were used after 10-14 days in
culture. The protocol for measuring mouse macrophage transmigration to human BL-
cells was changed so that 10"8M fMLP was used as a positive control in place of
human CCL5. BMDM were washed in 0.01% BSA to prevent clumping of cells and
adherence to tissue culture plastic. In addition, Both the BL-cells and BMDM were
suspended in media containing 0.01% BSA for the transmigration assay.
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Chemicals and reagents






















Sodium phosphate dibasic anhydrous
































DMEM Dulbeco's modified eagle medium
FBS foetal bovine serum
G418 sulphate
IMDM Iscoves modified Dulbecco's medium
L-glutamine
Macs beads

















lOmM dNTP solution Invitrogen
DNA lOObp ladder Invitrogen
DNA 1Kb ladder Invitrogen















BS7 48 neubauer haemocytometer
Conical polypropylene tubes 15 and 50 ml
Incubator











Fluorescence microscope Axioskop 2
Leica inverted TCS-NT microscope
Leica upright TCS-NT microscope
Olympus CK2 light microscope








Anthos It-2 plate reader
Cecil-200 spectrophotometer
Coulter EPICS XL-MCL FACS machine
Waterbath
Horizon gel tanks












NAME CLONE SPECIES CLASS LABEL MANUFACTURER
CX3CR1 polyclonal Rabbit IgG MBL
CX3CL1 polyclonal Goat IgG R&D systems
CX3CL1 81506 Mouse IgGl R&D systems
CX3CL1 polyclonal Goat IgG Biotin R&D systems
CX3CL1 51637 Mouse IgGl R&D systems
CX3CL1 81513 Mouse IgGl R&D systems
CD 14 TuK4 Mouse IgG2a RPE Serotec
CD 14 UCHM1 Mouse IgG2a RPE Serotec
CD 14 TuK4 Mouse IgG2a RPE Dako
CD 14 61D3 Mouse IgGl Birmingham University
CD14 63D3 Mouse IgGl Birmingham University
CD68 PG-M1 Mouse IgG3 Dako
Isotype control Mouse IgGl Sigma
Isotype control Mouse IgG2a Sigma
Isotype control Mouse IgG3 Sigma
Isotype control MCA 929 Mouse IgG2a RPE Serotec
Isotype control MCA928 Mouse IgGl RPE Serotec
Anti-mouse Fab polyclonal Goat Ig Fab RPE Dako
Anti-mouse Ig polyclonal Goat HRP Dako
Alexa Flour 488 A-11001 Goat Ig Fab 488 Molecular probes
Anti-mouse Ig polyclonal Goat FITC
Anti -mouse Ig polyclonal Goat HRP
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CHAPTER 3
The role of CD14 in the clearance of apoptotic cells
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Introduction
This laboratory established an important role for CD 14 in the clearance of
dying cells, by showing that antibodies against CD 14 could reduce macrophage
phagocytosis of apoptotic cells in vitro (Devitt, 1998). When the CD 14 knockout
mouse (CD 14-/-) was produced some years ago using a gene targeting approach, it
became possible to investigate the role CD 14 in vivo (Haziot, 1996). Detailed
histological studies showed that a number of organs in the Balb/c CD 14-/- contained
persistent apoptotic cells compared to wild type mice (Devitt, 2004). These apoptotic
cells were described as "free" because they were not associated with macrophages,
suggesting that the accumulation of apoptotic cells might be due to a defect in
macrophage clearance, especially since both the knockout and the wild type mice had
equivalent numbers of tissue macrophages. Since the rates of apoptosis were also
comparable between the knockout and wild type mice, this raised the possibility that
there was a defect in macrophage clearance of apoptotic cells in the Balb/C CD14-/-
that resulted in the persistence of cell corpses observed in vivo. Apoptotic cells that
were injected directly into the peritoneum of wild type mice were swiftly
phagocytosed (in about 15 minutes) but this was significantly delayed in mice
without CD 14 (Devitt, 2004). Again this suggested that CD 14 was important for the
process of clearing away dying c ells in vivo (Devitt, 2004).
The experiments presented in this chapter sought to confirm published work
and to extend these observations to the C57BL/6 mouse strain. The thymus of CD14
knockout (CD 14-/-) mouse was studied and the number of apoptotic cells in the
organ was compared to the wild type. Because the CD 14-/- macrophages have a
defect in the tethering of apoptotic cells to macrophages, it was hypothesised that the
CD 14-/- would have increased numbers of apoptotic cells in vivo.
The persistence of apoptotic cells in the CD 14-/- thymus was examined on
both the Balb/c and the C57BL/6 backgrounds, so as to reveal any specific
differences in between the two mouse strains. The Balb/c mouse has a polarised T-
helper cell type-2 response (TH2) resulting in secretion of IL-4 and TGFJ3 in
response to overwhelming Leishmania infection. In contrast, C57BL/6 strains clear
this pathogen through aTHl response by secreting IFN-y (Heinzel, 1989). Generally,
macrophages have more flexibility in their function compared to lymphocytes, and
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similarly, they can be skewed to either a Ml or a M2 phenotype (Gordon, 2003). In
the presence of TGFp, an "alternatively activated" or M2, macrophage may have
reduced nitric oxide production and killing but improved phagocytosis (Mills, 2000).
Considering the polarisation of these two strains, a different ability to clear away of
apoptotic cells between the Balb/c and the C57BL/6 mice might be predicted.
Finally, a population of CD14|0W macrophages were isolated from human
blood and their ability to phagocytose apoptotic cells was compared to the CD14hlgh
subset of monocyte-derived macrophages (Ziegler-Heitbrock, 1996).
3.1 The Balb/c CD14-/-mouse-thymus contained an
increased number of apoptotic cells compared to the
wild type
The thymus of a young adult mouse is the site of T cell selection and
normally contains large numbers of apoptotic thymocytes. Treatment with a steroid
like dexamethasone, 24 hours prior to sacrifice, can be used to induce a synchronous
and dramatic apoptosis of thymocytes (Wyllie, 1982; Devitt, 2004). Transmission
Electron Microscopy (TEM) was used to visualise thymus tissues from the CD 14-/-
mouse ex vivo and the number of apoptotic cells was qualitatively examined.
Balb/c CD14-/- thymus observed by Transmission Electron Microscopy
(TEM)
(Figures 3.1a)
Each thymus was briefly examined before processing for TEM. There was no
gross evidence of infection or tumour present in the thymi examined from either the
Balb/C CD 14-/- or from the wild type, and the wet weight of the thymi was similar.
The thymi from the mice that had been treated with 200pg of dexamethasone were
smaller than the mock-treated (PBS) control organs.
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The thymi from CD14-/- and wild type were examined under the electron
microscope and there were more apoptotic cells in the thymi from the knockout
mice. It was common to see more than two apoptotic cells per visual field (at 2000x
magnification) in the CD 14 knockout, and the tissue macrophages were observed to
contain apoptotic bodies.
The thymi from CD 14-/- and wild type mice that were treated with
dexamethasone, or a mock PBS injection, were next examined under the electron
microscope {figure 3.1a). Mice that lacked CD 14 had more apoptotic cells than the
wild types. Dexamethasone induced a massive amount of apoptosis in both mice, and
again, the CD 14-/- thymus contained more apoptotic cells than the wild type. In
sections of the dexamethasone-treated CD 14-/- thymus, it was usual to observe at
least three apoptotic cells per visual field (at 2000x magnification).
Overall, there was a qualitative increase in the number of apoptotic cells in
the CD 14-/- compared to the wild type thymus. Objective measurement of the
number of apoptotic cells in each thymus was not possible because of the small
numbers of animals used in each group and the limited access to the TEM.
Nevertheless, the effect of dexamethasone was apparent in both the wild type and
knockout animals both macro and microscopically.
Increased numbers of Annexin V-positive thymocytes in Balb/c CD14-/-
ex vivo
(Figure 3.1b)
Annexin V (AxV), which binds to exposed phosphatidylserine on apoptotic
cells was used to label dying cells. FACS analysis of AxV-positive cells can be used
to quantify the number apoptotic cells within an organ ex-vivo (Dive, 1992;
Koopman, 1994). The FACS data from this experiment is shown in Figure 3.1c.
Injection with dexamethasone increased the number of Annexin V-positive cells in
both the CD 14-/- and the wild type thymus, but overall, the level of apoptotic cells
was always higher in the CD 14-/-.
91
Increased numbers of Annexin-V positive
apoptotic cells in the Balb/c CD14-/- thymus
Control Dexamethasone
Wild type
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FL1 LOG: AxV
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Figure 3.1b
Flow cytometry of thymocytes from CD 14-/- and wild type mice
treated with PBS (control) or 200pg dexamethasone. The log-
fluorescence intensity of FITC-labelled AxV in CD 14+/+ wild type
(black) and CD 14-/- (grey) thymocytes. The percentage of cells
falling into the apoptotic gate are labelled.
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Increased numbers of TUNEL-
positive cells in the Balb/c
CD14-/- thymus
iii) CD14-/- negative control iv) CD14-/-TUNEL
Figure 3.1c
TUNEL-staining of apoptotic cells (brown) in the thymus of Balb/c
CD 14-/- (iv) and wild type cells (ii) compared to a negative controls.
Methyl green counter-stain.
cis
CD14-/- thymus shows increased numbers of TUNEL-positive apoptotic
thymocytes
(Figure 3. lc)
During apoptosis, a cell cleaves its DNA into small fragments. It is these
different-sized lengths of DNA that give rise to the characteristic "ladder"
appearance when DNA is run out on a gel. TUNEL (TdT-dependant dUTP-biotin
nick end labelling) is a biochemical method of identifying apoptotic cells in tissue. A
Biotin-tagged dUTP is added to the free 3' ends of the DNA fragments by a TdT
enzyme. Subsequently the fragmented DNA can be visualised by streptavidin linked
to a peroxidase. Finally a (brown) colour substrate is added in order to visualise the
free "nicked ends" of fragmented DNA in apoptotic cells.
TUNEL staining confirmed the earlier TEM and FACS findings by showing
increased numbers of apoptotic cells in the thymus of the Balb/c CD 14-/- mice
compared to wild type. Figure 3.Id is a representative image showing both cortex
and medullary regions of the thymus at 200x magnification. Apoptotic cells were
stained brown and all nuclei were counterstained green. The majority of apoptotic
cells were found in the cortex, close to the cortico-medullary junction.
Three different methods, TEM, FACS and TUNEL-labelling, were three
methods used to show that the Balb/c CD 14-/- had persistent apoptotic cells in its
thymus. The qualitative results from this small preliminary experiment are in
agreement with previous work (Devitt, 2004).
It was conceivable that CD 14-/- cells might be more sensitive to
dexamethasone than wild type thymocytes and the high numbers of apoptotic cells in
the CD 14 knockout mouse were due to an increase in the cell death rate. However,
earlier work had shown that thymocytes from the CD 14-/- die at exactly the same
rate as the wild type thymocytes after ex vivo steroid treatment (Devitt, 2004).
3.2 Quantitative analysis of the numbers of
apoptotic cells in the thymus of the CD14-/- mouse
(Figures 3.2a and 3.2b)
TUNEL staining was used to quantify the number of apoptotic cells in thymi
of Balb/c CD 14-/- mice compared to wild type animals. Thymus tissues were
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examined from six mice in each group. Organs were fixed in formalin, embedded in
wax and sectioned. Representative sections from the full thickness of the thymus
were mounted onto glass slides. After TUNEL-labelling, the number of apoptotic
cells in the cortex and medulla was enumerated.
The CD14-/- BALB/c thymic cortex has increased numbers of TUNEL-
positive cells compared to that of the wild type animals
(Figure 3.2a)
There was a significant increase in the number of TUNEL positive cells in the
cortex of the BALB/c CD 14-/- mice compared to wild type (Student's t-test
**p<0.005). This result was in accordance with previous observations from this
laboratory (Devitt, 2004). There was a small increase in the number of TUNEL
positive cells in the medulla of the BALB/c CD 14-/- mouse compared to wild type
controls. However, it did not reach statistical significance.
Balb/c CD14-/- bone-marrow derived macrophages have impaired
interaction with apoptotic cells in vitro
(Figure3.2b)
Having shown that CD 14-/- Balb/c mice had increased numbers of apoptotic
cells in their thymi, bone marrow derived macrophages (BMDM) were studied in
vitro. It was hypothesised that apoptotic cells accumulated in Balb/c CD 14-/-
because CD 14-/- macrophages were defective in their ability to clear away apoptotic
cells. The ability of macrophages that lacked CD 14 to clear away apoptotic
lymphocytes was investigated using a standard interaction assay.
Cells from the Burkitf s lymphoma cell line "Mutu" were treated with UV-
light to induce apoptosis (Gregory, 1990). These cells were then "fed" to a
monolayer of BMDM in culture and the number of phagocytosed cells was counted.
BMDM from CD14 knockout mice was compared to wild type macrophages. The
phagocytosis assay was performed in serum-free conditions and apoptotic cells were
incubated with macrophages, for 15, 30, 45, 60 or 75 minutes.
Balb/c CD 14-/- macrophages phagocytosed fewer apoptotic Mutu BL-cells
compared to wild type macrophages. After a 1-hour incubation, fewer CD 14-/-
macrophages interacted with apoptotic cells compared to the wild type (*p<0.05)
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Balb/c CD14-/- mice have
increased numbers of
TUNEL-positive apoptotic cells







The number TUNEL-positive cells in the medulla and cortex of
thymus from Balb/c CD 14-/- (black) mice (n=6) compared to wild
type (grey) ( n=6).CD14-/- have significantly higher numbers of




have reduced interaction with
apoptotic BL-cells
15 30 45 60 75
Time (minutes)
CD14 +/+ * p< o.05







CD 14-/- bone marrow-derived macrophages (BMDM) (white
squares have reduced interaction with apoptotic Mutu BL-cells
compared to wild type macrophages ( black squares). The
reduction in phagocytosis was significant after 60 minutes.
(*p<0.05, Student's t-test).
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(figure 3.2b). The lack of CD14 did not have a significant effect on the clearance of
apoptotic cells at earlier time points.
The CD14-/- C57BL/6 thymic cortex contained equivalent numbers of
apoptotic cells as the wild type
(Figure 3.2c)
The importance of CD14 in the clearance of apoptotic cells was next
examined in a different mouse strain. The C57BL/6 mouse differs from Balb/c in its
susceptibility to leishmania, and it is used in mouse models of autoimmune diseases
like EAE (experimental autoimmune encephalitis). This was an important
experiment to do because the persistence of apoptotic cells in the PSR knockout
animals depended on the particular strain of mouse. Isogeneic C57BL/6 mice did not
have a clearance defect whereas the mixed 129/C57BL/6 had a persistence of
apoptotic cells (Bose, 2004; Li, 2003).
The number of apoptotic cells in the thymi from six CD 14-/- mice on the
C57BL/6 background was compared to wild type. In contrast to the results from the
BALB/c strain, there was no significant difference between the numbers of TUNEL
positive cells in the cortex or medulla of the C57BL/6 CD 14-/- mice compared to
wild type controls (ns p> 0.1).
This may indicate a strain difference in the use of CD 14 for the clearance of
apoptotic cells. C57BL/6 may not rely on CD 14 for clearance to the same degree as
the BALB/c strain. It will be interesting to see whether a CD14-defect is exposed in
the C57BL/6 strain after a dexamethasone challenge and whether the C57BL/6
macrophages have a clearance defect in vitro. There is also a difficulty comparing the
BALB/c and C57BL/6 animals directly because both were housed in different
conditions. The C57BL/6 mice were obtained from Jackson laboratories and were
certified as being specific pathogen free and were kept in IVC cages whereas the
BALB/c lived in conventional housing.
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C57BL6 CD14-/- mice have the
same frequency of apoptotic
cells in the thymus compared





The number TUNEL-positive cells in the medulla and cortex of
thymus from CD 14-/-(black, n=6) mice compared to wild type
(grey, n=6).There was no significant difference between the number
of apoptotic cells in the thymus of the CD 14-/- and the wild type
mice.
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CD14-low monocytes do not up-
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Figure 3.3a
Flow cytometry of CD 14 expression on CD14-high and CD14-low
monocytes as they matured into macrophages. Forward versus side scatter
profile of CD14-high (i) versus CD14-low (ii) monocytes. Both monocytes
were of equivalent size. Log-fluorescence intensity of PE-labelled CD 14
expression on developing monocytes compared to isotype control (dashed
line), in CD14-high (iii) compared to CD14-low (iv) monocytes.
3.3 CD14low monocytes from human peripheral blood
mature into CD14low macrophages that have a defect
in interactions with apoptotic cells
Next, the CD 14 observations were extended to human macrophages. A
population of human monocytes with low levels of CD 14 that also express CD 16
have been well characterised in the literature. However, the ability of these CD14low
CD16+monocyte-derived macrophages to phagocytose apoptotic cells had not been
examined previously (Ziegler-Heitbrock, 1996). CD14low monocyte-derived
macrophages were isolated from peripheral blood monocytes and their ability to bind
to apoptotic cells was examined.
Both the CD14high and the CD14low human monocytes matured into
macrophages that expressed CD68
(Figures 3.3a and 3.3b)
Monocytes were isolated from peripheral blood over a density gradient and
then CD 14 h,gh monocytes were separated from CD 14 low monocytes using magnetic
bead separation. The CD14hlgh and the CD14low fractions were seeded into culture
dishes (for FACS) or onto glass slides (for immunohistochemistry) for one hour
before the non-adherent cells were washed away.
After separation from peripheral blood, the CD14hlgh and CD14low monocytes
were analysed by FACS. Both the CD14hlgh and the CD14|0W monocytes were of
similar size and granularity as assessed by their forward and side scatter profiles on
FACS (figure 3.3a). However, previous publications had shown that the CD14low
monocytes were smaller than the CD14hlgh monocytes (Ziegler-Heitbrock, 199).
The expression of surface CD 14 on CD14hlgh and the CD14low monocytes was
analysed as they matured into macrophages in vitro. Figure 3.3a shows the log-
fluorescence intensity of PE-labelled CD 14 staining of monocytes as they matured
compared to IgG2a isotype control. The CD14hlgh monocytes maintained high levels
of CD 14 expression as they matured into macrophages. After one week in culture,
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Macrophages derived from both
CD14-high and CD14-low human
monocytes expressed CD68
(i) CD14-high (ii) CD14-low
Figure 3.3b
Immunohistochemistry of 7-day-old human macrophages
derived from CD14-high and CD14-low monocytes . Cells
positive for the macrophage scavenger receptor CD68 were
stained brown and nuclei were counter-stained blue with
haematoxylin.
only a minority of the CD 14low macrophages expressed CD14. This suggested that
CD 14low monocytes maintained their phenotype as they matured into macrophages.
Both the CD14hlgh and the CD14low monocytes were able to adhere to glass
slides and both stained equally well with the macrophage marker CD68 (figure 3.4b).
Using this method of isolation, less than 5% of all the monocytes were CD14low; this
figure was in-line with published data (Ziegler-Heitbrock, 1996). The small number
of CD14low macrophages obtained by this method was adequate to perform
reproducible interaction assays. However a higher yield might have been obtained by
using FACS sorting of immunolabelled cells.
CD14|0W human macrophages interact poorly with apoptotic cells
compared to CD14h'9h macrophages
(Figure 3.3c)
The phagocytic function of macrophages that had been matured from
CD14low monocytes was compared to that of CDl4hlgh macrophages. Although
CDl4low macrophages appeared to have a similar phenotype to CD14hlgh
macrophages they bound significantly fewer apoptotic cells (**p<0.00l) (figure
3.3c). Low levels of CD 14 impaired macrophage phagocytosis of apoptotic cells.
The result from human CD14low macrophages was in agreement with the findings of
the Balb/c CD 14 -/- mouse macrophages.
Figure 3.3c shows the average result of two macrophage and apoptotic cell
interaction experiments. 27.67% of the macrophages that had matured from CD14hlgl1
monocytes interacted with apoptotic cells. Significantly fewer of the CD14low
macrophages bound apoptotic cells (12.98% **p<0.001). This preliminery data
would be in line with previous data showing a possible role for CD 14 in macrophage
binding to apoptotic cells. (Devitt, 1998).
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CD 14|0W human macrophages
have reduced interaction with






Phagocytosis of apoptotic Burkitt's lymphoma cells (Mutu) by
macrophages matured from CD14-high (black) and CD14-low (grey)
monocytes. Significantly fewer CD14-low macrophages phagocytosed
apoptotic Mutu compared to CD14-high macrophages (**p< 0.001,
student's t-test) Mean data + SEM from four experiments was plotted.
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Chapter 3 summary
• The CD 14-/- BALB/c mouse has more "free" apoptotic cells in the thymic
cortex than the wild type in vivo.
Quantitative analysis of apoptotic cells by TUNEL labelling shows that the
BALB/c CD 14-/- mouse has increased numbers of apoptotic cells in the
thymic cortex but the C57BL/6 does not.
In vitro interaction assays showed that BALB/c CD 14-/- macrophages had a
partial defect in the clearance of apoptotic BL-cells
Approximately 5% of human monocytes isolated from peripheral blood were
CD14|0W and, like murine CD 14 -/- BMDM, the CD 14low human macrophages
also had a defect in the phagocytosis of apoptotic cells
The results of this chapter confirmed published work indicating that CD 14-/-
macrophages on the Balb/c background had a clearance defect leading to an
accumulation of apoptotic cells seen both in vivo and in vitro. Interaction assays
confirmed that Balb/c CD 14-/- macrophages had a defect in the phagocytosis of
apoptotic cells. However, this defect was not observed in the C57/BL6 mouse. This
may be due to the Ml-like macrophages in the C57BL/6 strain or due to differences
in the housing of the mice.
The first step in the clearance of apoptotic cells involves a macrophage
"sensing" and then "moving towards" the dying cell, before finally phagocytosing it.
Balb/c CD 14-/- macrophage-phagocytosis of apoptotic cells was reduced, but not
completely blocked. The CD 14-/- on the Balb/c background had many "free"
apoptotic cells that were not associated with macrophages. Therefore, it was
hypothesised that, in addition to tethering defect, CD 14-/- macrophages may also
have a fault in the come-get-me stage of apoptotic-cell clearance. The next chapter
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Introduction
The previous chapter showed that the Balb/c CD 14-/- mouse had increased
numbers of apoptotic cells in the thymus in vivo, which may have been due in part, to
a defect in the tethering of apoptotic cells to macrophages. The large number of
"free" apoptotic cells, those not associated with macrophages in the CD 14-/-
suggested there might also be a defect in these animals' "sensing" and "moving"
towards apoptotic cells (Devitt, 2004). Experiments presented in this chapter have
investigated the role of macrophage chemotaxis to apoptotic cells that might account
for the accumulation of cell bodies seen in the CD14-/-.
While much has been learned in recent years of the mechanisms by which
apoptotic cells are recognised and engulfed by macrophages, little is known of the
processes underlying the 'sensing' of apoptotic cells by phagocytes. Recent studies
have highlighted the importance of chemoattractant molecules that are released
during normal cell death and of how macrophages respond to these come-get-me
signals, in readiness to engulf the apoptotic corpse (Kao, 1994; Audran, 1996;
Horino, 1998; Segundo, 1999; Cocca et al., 2002 and Lauber et al., 2003). Apoptotic-
cell clearance might be delayed by faulty macrophage chemotaxis resulting in
unwanted inflammation and a predisposition to autoimmune diseases like systemic
lupus erythematosus, (Herrmann, 1998). An alternative view is that the persistence of
apoptotic cells may prolong the anti-inflammatory responses that accompany their
engulfment by macrophages (Devitt, 2004; Gregory, 2004).
Chemotaxis is the directional movement of a cell up a chemokine gradient
and is important in a number of biological processes including leukocyte recruitment
to the sites of inflammation, and wound healing (Zlotnik, 2000). This chapter
examines the migration of macrophages to chemoattractant molecules released from
apoptotic Burkitt's lymphoma (BL) cells. Migration and phagocytosis involve
common membrane and cell-shape changes, and both these processes are regulated
by shared signalling pathways that involve integrins and small G proteins (Hogg,
2001). Apoptotic-cell engulfment and cell migration in the nematode worm
(Caenorhabditis elegans) has been shown to be governed by the same highly-
conserved genes (Wu, 1998). Given the mechanistic similarities between
phagocytosis and chemotaxis, it was reasoned that macrophage receptors involved in
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the recognition and engulfment of apoptotic cells might also function in the
chemotactic response of macrophages to such cells.
This chapter focuses on two receptors that have important roles in the
clearance of apoptotic cells: the lipolysaccharide receptor, CD 14 and the class B
scavenger receptor, CD36. The work published by Lauber et al, (whilst the present
work was in progress) demonstrated that the lipid, lysophosphatidylcholine (LPC)
was a chemoattractant released by apoptotic cells (Lauber, 2003). It is significant that
both CD 14 and CD36 can bind lipids and so may be able to "sense" chemotactic
molecules (like LPC) released by apoptotic cells.
Using cells established from Burkitt's lymphoma (BL) as a source of
apoptotic cells, the transmigration assay described in Chapter 2, was used to measure
macrophage chemotaxis to apoptotic BL-cells. Finally, experiments to characterise
the chemoattractive molecule released by dying Burkitt's lymphoma cells will be
described.
4.1 Macrophages are actively phagocytosing
apoptotic-cells in Burkitt's lymphoma
(Figure 4.1)
Burkitt's lymphoma (BL) is a small non-cleaved B cell tumour that contains
many macrophages diffusely distributed amongst the "monotonous sea" of tumour
cells. Sections prepared from human tumours and stained with H&E (figure 4.1 (i))
showed many apoptotic cells with typical shrunken, pyknotic nuclei (marked by an
asterisk). Apoptotic cells were more intensely stained blue compared to neighbouring
live cells. Pale-staining macrophages stood out from the surrounding dense nuclei of
the tumour cells that created the characteristic "starry sky" appearance of the tumour
seen at low power. The cytoplasm of the macrophages was engorged with apoptotic
bodies (marked with an arrow), indicating that macrophages had actively
phagocytosed apoptotic cells in situ. The high numbers of macrophages distributed
throughout the tumour was striking when the cells were labelled with anti-CD68, a
macrophage marker (figure 4.1(h)).
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4.2 Macrophage chemotaxis to Mutu BL-cells
(Figure 4.2a)
Macrophage transmigration to Mutu BL-cells, containing varying amounts of
apoptosis was measured using the transwell system. Mutu transfected with the anti-
apoptotic gene bcl-2 (Mutu bci-2) had the lowest numbers of apoptotic cells (15%),
Mutu BL-cells (Mutu BL-cells) had intermediate levels of spontaneous apoptosis
(23%), and 89% of UVB-treated Mutu BL-cells (Mutu uvb) were apoptotic.
lOOng/ml CCL5 in RPMI was used as a positive control and media alone as the
negative control in all experiments.
Figure 4.2a is a representative example of 7 separate experiments and shows
that week-old macrophages preferentially migrated to apoptotic rather than to live
Mutu BL-cells. Macrophage chemotaxis to UVB-treated Mutu BL-cells was
significantly higher than to Mutu BL-cells bci-2 (***p<0.0001, student's t-test).
Transfection of Mutu BL-cells with bcl-2 prevented Mutu BL-cell apoptosis and
virtually abolished macrophage chemotaxis. Macrophage migration to untreated
Mutu BL-cells depended on the number of (spontaneously) apoptotic cells present
and was always higher than Mutu bci-2-and lower than Mutu uvb-
Macrophage chemotaxis increases with apoptosis
(Figure 4.2b)
The number of apoptotic cells was carefully measured for every individual
experiment because the percentage of apoptotic cells varied slightly each time.
Apoptosis was measured by binding of FITC-labelled AxV and PI uptake by FACS
and was confirmed by DAPI staining and fluorescence microscopy. This data
collection allowed the rate of macrophage chemotaxis to be compared to the amount
of apoptosis. Macrophage chemotaxis data from 7 experiments was collected
together and was plotted against the percentage of Annexin V-positive Mutu BL-
cells (figure 4.3b). The chemotactic index refers to the fold increase in the number of
transmigrated macrophages above the negative (media) control. It can be seen that
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Macrophages were allowed to transmigrate to media alone (negative
control), or Mutu BL-cells with various levels of apoptosis, Mutu bcl-
2, Mutu, UV-treated Mutu, or to lOOng/ml CCL5 (positive control) for
4 hours. The mean number (+SD) of macrophages transmigrating was
counted for each condition. One representative experiment of 7 is
shown. Macrophage chemotaxis to UV-treated Mutu BL-cells
containing 89% apoptotic cells was significantly higher than to Mutu
bcl-2 containing 15% of apoptotic cells (***p<0.0001, student's t-
test). % apoptosis is shown.
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Macrophage chemotaxis to Mutu bcl-2, Mutu BL cells, and UV-treated
Mutu BL cells was compared to the number of apoptotic cells. Apoptosis
was measured as the percentage of Mutu BL cell-binding FITC-labelled
Annexin V analysed by flow cytometry. The chemotaxis index was the fold
increase in the number of transmigrated macrophages compared to media
alone (negative control).
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This result showed that dying Mutu BL-cells released one or more
chemoattractant molecules that attracted macrophages. The higher the number of
AxV+ apoptotic cells, the greater was the number of macrophages that transmigrated.
4.3 Macrophage chemotaxis to apoptotic Mutu BL-
cells in relation to the kinetics of apoptosis
(Figure 4.3)
A 24-hour time-course experiment was performed to determine at
what time during programmed-cell-death apoptotic Mutu BL-cells released
chemotactic molecules that recruited macrophages. Macrophages were allowed to
migrate to Mutu BL-cells at different times after induction of apoptosis. Aliquots of
2x 106 cells/ml of Mutu BL-cells were treated with 100mJ/cm2 UVB light at various
times. Mutu BL-cells were washed, and placed in a 24 well plate. Macrophages were
allowed to transmigrate for four hours and then the filters where counted as has been
previously described. Figure 4.3 shows macrophage chemotaxis to apoptotic Mutu
BL-cells at different time-points after the induction of apoptosis. Open circles show
the baseline transmigration of macrophages to the media only (negative control) and
the filled circles plot macrophage migration to UVB-treated Mutu BL-cells. There is
an increase in macrophage transmigration as early as 4 hours after UVB-treatment.
When macrophage migration is compared to the kinetics of Mutu BL-cell apoptosis
it can be seen that macrophage migration to Mutu BL-cells occurred early after the
induction of apoptosis, at about 4 hours, when the majority of cells were still in the
viable zone (as shown by FACS). At this time-point, the majority of BL-cells had
intact cell membranes and did not take up Propidium iodide. These results suggest
that apoptotic cells actively released the chemotactic molecule, early on, whilst their
membranes were still intact. Macrophage migration was sustained over the 24-hour
period and did not tail off despite all Mutu BL-cells falling into the dead zone at
these latter time points. This might suggest that apoptotic Mutu BL-cells first
released an early burst of chemotactic molecules followed by a passive leak of
chemotactic molecules at the later time points.
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Kinetics of macrophage
chemotaxis to apoptotic Mutu
BL-cells
Apoptosis 14% 15% 20% 28% 29% 42% 74% 80%
Figure 4.3
Mutu were treated with 100mJ/cm2 UVB to induce apoptosis and
were harvested at various time points over 24 hours. Macrophages
were allowed to migrate to to Mutu (filled circles) for 4 hours or to
media alone (empty circles). The mean (+SD) of macrophages
transmigrated of ten high-power fields at x400 magnification is
shown. A representative result from two experiments is plotted. The
percentage of apoptotic cells shown.
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4.4 Macrophage chemotaxis to "leaky" or necrotic
BL-cells
(Figure 4.4)
The next objective was to determine if macrophage transmigration was
specific to apoptotic cells in particular, or to dying cells in general. The "danger
hypothesis" stated that, in the absence of infection, endogenous cell products can
cause inflammation and DC maturation (Gallucci, 1999). Spilled cell contents from
dying cells may contain many danger signals, not least uric acid, an endogenous
adjuvant in its own right (Shi, 2003). These spilled intracellular contents can be
chemoattractive to leukocytes. Intracellular components like ATP and heat shock
protein gp96 can induce chemotaxis (Honda, 2001; Binder, 2000). The previous
experiments suggested that Mutu BL-cells released chemotactic molecules about 4
hours after the induction of apoptosis and this release continued when the cells
became leaky Therefore, macrophage transmigration to leaky, necrotic cells was
compared to apoptotic cells.
Mutu BL-cells were boiled for 20 minutes, and after this treatment, 100% of
the cells were necrotic and trypan blue positive. Macrophages were allowed to
migrate to Mutu BL-cells, apoptotic Mutu BL-cells and necrotic Mutu BL-cells. As
shown previously, macrophages preferentially migrated to apoptotic Mutu BL-cells
compared to live Mutu BL-cells (Figure 4.4). Macrophages migrated significantly
more to the necrotic Mutu BL-cells, compared to apoptotic Mutu BL-cells that had
intact cell membranes (***p < 0.0001, student's t-test). This suggested that, after an
initial release, chemoattractant molecule continued to passively leak out of necrotic
cells. This mechanism might maintain the concentration gradient allowing a
sustained macrophage migration to cells that have begun to disintegrate. Indeed, in

















media Mutu Mutu uv Mutu Nec CCL5






Macrophages migrated to Mutu BL-cells, UV-treated BL-cells, necrotic Mutu
BL-cells, media only (negative control) and lOOng/ml CCL5 (positive control).
The mean (+SEM) number of transmigrated macrophages for each condition is
plotted. One representative experiment of two is shown. Macrophages
preferentially migrated to apoptotic Mutu BL-cells compared to viable Mutu
(***p<0 0001, student's t-test). There was a significant increase in the number
of macrophages that migrated to necrotic Mutu compared to apoptotic (UV-
treated) Mutu, (***p<0.0001, student's t-test). % number of apoptotic cells is
shown for each treatment.
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4.5 Chemotaxis of monocytes and neutrophils to
apoptotic BL-cells
The previous sections dealt only with macrophage chemotaxis to apoptotic
cells. Macrophages are commonly seen infiltrating Burkitt's lymphoma, but
neutrophils are seen very rarely in the tumour (Wilkins, 2005). With this in mind, the
transmigration of other leukocytes to apoptotic Burkitf s lymphoma was investigated.
Examination of monocytes and neutrophils would show whether or not the receptors
employed in chemotaxis to apoptotic cells were specific to macrophages.
Monocyte chemotaxis to apoptotic Mutu BL-cells
(Figure 4.5a)
Experiments were performed to see if primary monocytes could also
transmigrate to apoptotic Mutu BL-cells. Primary human monocytes were isolated
from human blood, separated on a Ficoll gradient and allowed to adhere to plastic for
1 hour. Non-adherent cells were washed off and adherent monocytes were used
immediately in a transmigration assay. Figure 4.5a is a representative example of
three experiments showing transmigration of monocytes to Mutu BL-cells. lOOng/ml
of CCL5 was used as a positive control and media alone served as a negative control.
Monocytes, like macrophages, preferentially migrated to apoptotic Mutu BL-cells,
rather than Mutu BL-cells that had been transfected with bcl-2 (***p<0.0001,
student's t-test).
Overall, monocytes transmigrated less well to apoptotic Mutu BL-cells
compared to macrophages. Monocytes may express lower levels of chemokine
receptors than macrophages, or perhaps cells were damaged whilst being lifted out of
plates before use in the transmigration assay. An alternative strategy would have
been to use antibody-coated magnetic beads to purify monocytes and store them in
teflon-coated tubes until use. Lauber et al, had already shown chemotaxis of primary
monocytes to apoptotic cell supernatants using this approach and also observed that
primary monocyte transmigration to apoptotic cell-lines was less efficient than that
of macrophages (S.Wesselborg, personal communication, (Lauber, 2003).
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Monocyte, MM6 and neutrophil
chemotaxis to apoptotic BL-cells
media Mutu bd_2 Mutu Mutuuv fmlp
Figure 4.5
Monocyte (A), MM6 (B) and neutrophil (C) chemotaxis to Mutu bcl-2, Mutu
and UV-treated Mutu BL-cells. Apoptosis was induced by UV-light.
Chemotaxis in monocytes and neutrophils was measured as the mean number of
transmigrated cells counted per high power field. Chemotaxis in MM6 was
measured by counting the number of transmigrated cells by FACS. The mean
number (+SEM)of migrated cells was plotted for each condition. One
representative result from at least three separate experiments is shown. There
was no neutrophil chemotaxis to apoptotic Mutu. students t-test ***p<0.0001,
**p< 0.005, * p< 0.02.
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A monocyte cell line, THP-1 was used in lieu of primary monocytes in many of the
experiments to overcome the problem of the low mobility of primary monocytes
(Lauber, 2003). Likewise, in the next experiment, the transmigration of another
monocytic cell-line MonoMac 6 (MM6) was measured.
Mono Mac 6 (MM6) chemotaxis to apoptotic Mutu BL-cells
(Figure 4.5b)
MM6 is a human monocyte cell line established from a myeloid leukaemia
(Medzhitov, 1997; Ziegler-Heitbrock, 1988). MM6 are non-adherent in culture and
can be matured into macrophages using PMA and vitamin D3. MM6 were used to
examine monocyte chemotaxis to apoptotic cells.
MM6 were placed in the top chamber of a transwell experiment and allowed
to transmigrate towards apoptotic Mutu BL-cells in the lower chamber. MM6 were
non-adherent and passed through the filter into the lower chamber and so were
counted by FACS. Figure 4.5b shows the results from three experiments. Chemotaxis
index refers to the fold increase in the number of MM6 that migrated to Mutu BL-
cells compared to the media (negative control). MM6 preferentially moved towards
apoptotic Mutu BL-cells compared to Mutu BL-cells bci-2- The numbers of MM6 that
transmigrated to Mutu BL-cells and UVB-treated Mutu BL-cells was significantly
higher than to Mutu bci-2 (***p<0.0001, student's t-test) Increased numbers of MM6
cells moved towards apoptotic cells BL-cells, similar to the pattern that had been
observed in macrophages and primary monocytes.
Polymorphonuclear leukocyte chemotaxis to apoptotic Mutu BL-cells
(Figure 4.5c)
In stark contrast to monocytes and macrophages, neutrophils failed to migrate
to Mutu BL-cells, despite migrating effectively towards 10"8M fMLP (Figure 4.5c).
At the end of the experiment, over 90% of the neutrophils were viable (as determined
by tryphan blue exclusion) at the end of the short (1 hour) migration period. Cytospin
preparations of neutrophils also showed no evidence of degranulation. Mutu BL-cells
were not chemoattractive to neutrophils and appeared to be capable of actively
preventing neutrophil transmigration, presumably through the release of soluble
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inhibitory-factors. Failure of neutrophil chemotaxis to Mutu BL-cells appeared to be
independent of apoptosis, since, Mutu bci-2, (with low levels of apoptosis) and Mutu
uvb, containing large numbers of apoptotic cells, both inhibited chemotaxis.
These in vitro findings reflected the number of neutrophils seen in Burkitf s
tumours in vivo. The histological picture of Burkitf s lymphoma, shown in figure 4.1,
shows a paucity of infiltrating polymorphonuclear cells. The observation that
neutrophils failed to migrate to apoptotic Mutu BL-cells requires further work. One
prediction might be that Mutu BL-cells failed to secrete CXCL chemokines. This
chemokine group express the ELR (Glutamate-Leucine Arginine) tripeptide, a
sequence that specifically attracts neutrophils. The role of two phagocyte receptors
both expressed by macrophages, but not by neutrophils, in the chemotaxis to
apoptotic BL-cells was investigated next.
4.6 The role of CD14 and CD36 in macrophage
chemotaxis to apoptotic BL-cells in vitro
Having shown that apoptotic cells, but not neutrophils attracted macrophages
the role of CD 14 and CD36 was investigated. There are many mechanistic
similarities between phagocytosis and chemotaxis and it is possible that macrophage
receptors involved in the recognition and engulfment of apoptotic cells might also
function in the chemotactic response to dying cells. Recently, the lipid
lysophosphatidylcholine (LPC), released by apoptotic cells was shown to function as
a chemoattractant for macrophages (Lauber et al. 2003). As CD 14 can bind
phospholipid its role in macrophage chemotaxis to apoptotic cells was investigated.
The lipid receptor, CD 14 has an important role in macrophage phagocytosis
of apoptotic cells in vivo. Chapter 3 described how Balb/c CD 14-/- mice had
increased numbers of "free" apoptotic cells in the thymus and how this might be
explained because the CD 14-/- macrophages had failed to migrate towards apoptotic
cells. To determine whether the CD 14 was important in "sensing" the presence of a
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Transmigrated macrophages expressed high levels of CD 14. Macrophages
were harvested from the underside of the transwell filter, after
transmigration to apoptotic Mutu. Transmigrated macrophages were
compared to input macrophages (pale blue). Macrophages were labelled
with the anti-CD 14 monoclonal antibody (TuK2). A mixture of input and
transmigrated macrophages was labelled with the IgG2a isotype control
antibody. Log fluorescence RPE-Cy5 intensity is plotted against relative
cell number. One representative experiment of two is shown.
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Human macrophages that have transmigrated to apoptotic BL-cells
express high levels of CD14
(Figure 4.6a)
The level of CD 14 expression was measured on transmigrating human
macrophages as an initial indicator of a possible role for CD 14 in chemoattraction of
human macrophages. Mutu BL-cells were labelled with a fluorescent green marker at
the start of the experiment so that they could easily be differentiated from
macrophages during subsequent FACS analysis. The CD 14 expression of
macrophages that had transmigrated in response to apoptotic cells was compared to
that of macrophages at the start of the experiment (input macrophages). After
removing macrophages from the top chamber, macrophages that had transmigrated in
response to apoptotic Mutu BL-cells were lifted off the underside of the filter by
soaking in 5mM EDTA, spun down, collected and labelled with mouse anti-human-
CD14 antibody. Fluorescent green, Mutu BL-cells were easily discriminated from
macrophages by both fluorescence (log CM-green-FLl) and light scatter properties,
and were gated out by FACS.
Figure 4.6a shows surface expression of CD 14 on macrophages (log-CD 14-
Cy5-FL4 immunofluorescence). Macrophages that had transmigrated to apoptotic
Mutu BL-cells expressed higher mean levels of CD 14 than the input macrophages. It
is possible that a CD14hlgh population of macrophages had been specifically recruited
to apoptotic Mutu BL-cells. Alternatively, the subset of macrophages that initially
expressed low levels of CD 14 at the beginning of the experiment (CD14low), up-
regulated CD 14 during transmigration. It can be seen that CD 14 was not globally up
regulated on all macrophages, because the histogram for the transmigrated
macrophages did not shift to the right. Therefore, it is most likely that it was the
CD14lllgh cells within the input population that had responded to the apoptotic cells.
However this experiment did not demonstrate a role for CD14 in this chemotactic
process.
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CD14-/- and CD36-/- mouse bone marrow-derived macrophages (BMDM)
have no defect in chemotaxis to apoptotic Mutu BL-cells
(Figure 4.6b)
If CD 14 were important in the "sensing" and "moving towards" apoptotic
cells, anti-CD 14 antibodies would be expected to inhibit human macrophage
chemotaxis. Preliminary studies using whole antibodies against human CD 14
showed that anti-CD14 did prevent macrophage transmigration to apoptotic Mutu
BL-cells whereas an isotype control antibody had no effect. However, Fab fragments
would be required to test the specificity of the anti-CD 14. It is possible that antibody
complexes binding to macrophages may have caused a steric hindrance to
movement. To avoid this difficulty macrophages from mice deficient in CD14 were
used in transmigration assays.
The assay used for human cells was adapted in order to use mouse bone
marrow-derived macrophages (BMDM). 10"8M fMLP was used as positive control
instead of human CCL5. In a similar way to human monocyte-derived macrophages,
mouse BMDM migrated to apoptotic Mutu BL-cells. Mouse Balb/C BMDM
migrated to UVB-treated Mutu BL-cells significantly more than to Mutu BL-cells
that had been transfected with bcl-2 (* p<0.05, student's t-test).
CD36 can bind lipids and like CD 14, might also be a candidate for a
macrophage chemotactic receptor. Since the CD36-/- mouse is on the C57BL/6
background, the transmigration assay was adapted once more to investigate C57BL/6
mouse. There was no strain difference between mice the chemotaxis to apoptotic
cells using this assay. This species crossover showed that chemotaxis to apoptotic
cells was a conserved phenomenon between the humans and mice. Therefore, CD14-
/- macrophages could be used to test the hypothesis that CD 14 had a role in
macrophage chemotaxis to apoptotic cells.
Figure 4.6b shows that BALB/c mouse macrophages, that were deficient in
the phagocytic receptor CD 14, had no defect in chemotaxis to apoptotic Mutu BL-
cells. Although important for the phagocytosis of apoptotic cells, this result indicated
that CD 14 was not necessary for macrophage chemotaxis to apoptotic cells. And
likewise, CD36-/-have normal chemotaxis to apoptotic BL-cells.
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Apoptosis 99% 99%
Figure 4.6b
BMDM from the CD 14-/- (A) and the CD36-/- (B) and respective wild type
controls (+/+) were allowed to transmigrate to Media alone (negative control),
UV-induced apoptotic Mutu and 10-8M fMLP (positive control). Transmigration
of both -/- and +/+ BMDM to fMLP is plotted. One representative experiment of
four is shown and the mean (+SD) for each condition is plotted. There was no
significant difference between CD 14-/- and wild type macrophage transmigration
(p=0.26). And there was no significant difference between CD36-/- and wild type
macrophage (ns p=0.56, student's t-test). % number of apoptotic cells shown.
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4.7 Macrophage chemotaxis to apoptotic BL-cells
was not due to Epstein Barr Virus
(Figure 4.7)
The last section of this chapter will seek to characterise the chemotactic
molecules that are released by apoptotic Mutu BL-cells. Although all experiments
were performed in sterile conditions, each Mutu BL-cells carried a potential danger
signal because of the presence of a latent infection with the Epstein-Barr virus
(EBV). EBV can have profound immunomodulatory effects on cells both in vitro and
in vivo that might additionally affect the secretion of chemotactic molecules. For
example, EBV positive Hodgkin's lymphomas have increased secretion of
chemokines (CCL5 (RANTES) and CXCL10 (IP-10)), whereas mononuclear cells
from EBV-infected individuals are unable to produce CCL3 (MlPl-a) even after
stimulation with LPS (Teruya-Feldstein, 2000 and Jabs, 2002).
In order to assess whether EBV infection influenced macrophage chemotaxis
to apoptotic cells, an EBV negative Burkitt's lymphoma cell line, BL2 was compared
to Mutu BL-cells. Figure 4.7 shows a typical result of macrophage chemotaxis to
Mutu bd.2 Mutu BL-cells and apoptotic Mutu BL-cells compared to the EBV negative
cells. Additionally, BL2 were transfected with the same bcl-2 construct that had been
transfected into Mutu BL-cells (by Carol-Anne Ogden). Like the Mutu bci-2, BL2 bci-2
also had low levels of spontaneous apoptosis. Figure 4.7(ii) is a representative
example of five experiments and shows that macrophages also transmigrated to the
EBV-negative cell line, BL2. Macrophages preferentially migrated to apoptotic BL2
compared to BL2 bci-2, similar to Mutu BL-cells.
These results demonstrated that macrophages migrated preferentially to
apoptotic cells from two different BL-cell lines. This means that EBV is not needed
for macrophage chemotaxis in this model but it remains possible that EBV stimulates
the production of chemotactic molecules in the EBV positive Mutu BL-cells.
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Apoptosis of cell lines was induced by UV-light. Macrophages were allowed to
transmigrate to bcl-2 transfected, untransfected live, UV-treated BL-cells, media
only (negative control) and lOOng/ml CCL5 (positive control). The mean number
(+SEM) of transmigrated cells counted per high power field, for each condition
was plotted.One representative result from at least three separate experiments is
shown. Macrophage chemotaxis to apoptotic, UV-treated BL-cells was
significantly higher than to untreated BL-cells. Macrophage chemotaxis to
apoptotic BL occurred in both EBV positive and EBV negative cells. % of
apoptotic cells is shown.
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4.8 The method of induction of apoptosis does not
affect macrophage chemotaxis to apoptotic BL-
cells
(Figure 4.8)
It could be argued that the mode of induction of apoptosis gave a shock to the
cell that itself affected the release of chemotactic molecules. For this reason,
spontaneously apoptotic Mutu BL-cells were compared to cells induced by other
apoptotic stimuli for their ability to attract macrophages. Macrophages were able to
transmigrate to spontaneously apoptotic cells, suggesting that chemotaxis was to
common products released during programmed cell death and was not dependent on
the stimulus that induced cell apoptosis. In order to further assess whether the
method of induction of apoptosis affected the rate of macrophage chemotaxis to
apoptotic cells, different chemical methods of inducing apoptosis were compared to
treatment with UVB-light (figure 4.8). UVB-light treatment was compared to
chemical induction of apoptosis using ionomycin, actinomycin D and staurosporine.
Actinomycin D is a drug that can bind to DNA and block the movement of RNA
polymerase and so prevents RNA synthesis. Ionomycin is a calcium ionophore that
raises intracellular calcium levels and triggers apoptosis and staurosporine is an
antibiotic from streptomyces that can inhibit protein kinase C.
Mutu BL-cells became apoptotic after an 8-hour incubation with lpg/ml
actinomycin D, 16-hours after incubation with lpg/ml ionomycin and 8 hours after
incubation with lpg/ml Staurosporine. Mutu BL-cells were thoroughly washed in
PBS and then used in a transmigration assay. All four methods effectively induced
apoptosis. Mutu BL-cells induced by UVB-light were 89% apoptotic by FACS (i),
when treated with actinomycin D were 85% apoptotic by FACS (ii), by ionomycin
were 60% apoptotic by FACS (iii) and by staurosporine were 93% apoptotic by
FACS (Figure 4.8 (iv)). Macrophages migrated preferentially to apoptotic cells
compared to live cells, irrespective of the method used to induce cell death.
Actinomycin D did not inhibit macrophage chemotaxis and so it is likely that Mutu
BL-cells regulated the production of the "apoptotic chemokine" post-translationally,
and did not transcribe it de novo.
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Macrophage chemotaxis to apoptotic
Mutu BL-cells is independent of the



















Mutu Mutu c nCCL5
Apoptosis 79% 85% Apoptosis 79% 93%
Figure 4.8
Apoptosis of Mutu was induced by 100mJ/cm2 UV-light, lpg/ml
ionomycin, lpg/ml actinomycin D or lpg/ml staurosporine. Macrophages
were allowed to transmigrate to Mutu BL-cells, Mutu BL-cells induced into
apoptosis, media only (negative control) and lOOng/ml CCL5 (positive
control). The mean number (+SEM) of transmigrated cells counted per high
power field for each condition was plotted.One representative result from
two is shown. Macrophage chemotaxis to apoptotic Mutu was significantly
higher than to live Mutu (** p< 0.005 and **p< 0.0001, student's t-test).
Macrophage chemotaxis to apoptotic Mutu occurred independently of the
stimulus used to induce apoptosis. % apoptosis is shown
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4.9 Macrophage chemotaxis to conditioned media
from apoptotic BL-cells
(Figure 4.9)
In 1999 Segundo et al published that supernatants from apoptotic germinal
centre B-cells from tonsil were chemotactic for monocytes. The active
chemoattractant was found in the blebs that had budded off from the apoptotic cell
surface (Segundo, 1999). To determine whether chemotactic molecules from
apoptotic Mutu BL-cells could be demonstrated in cell free preparations, conditioned
media was prepared from 2xl06/ml Mutu BL-cells in serum-free media 12 hours
after induction of apoptosis.
A cell-free supernatant was prepared by passing suspended cells through a
sterile 0.2pm diameter filter. The ability of macrophages to transmigrate to the
conditioned supernatants was compared to the original batch of 2xl06/ml Mutu BL-
cells in suspension. Figure 9 is a representative example of three experiments and
shows macrophage chemotaxis to conditioned media from apoptotic Mutu BL-cells
was equal to macrophage chemotaxis to whole cells in suspension. This confirmed
that the bioactive moieties were released from the apoptotic cell into the
supernatants.
Subsequently, it was found that the chemoattractant activity of conditioned
media began to deteriorate after storage at -20°C. Therefore, the supernatants were
placed in a water bath at 95°C for half an hour to further test the stability of
conditioned media. Raising the temperature to 95°C significantly inhibited
macrophage chemotaxis to conditioned supernatants from apoptotic BL-cells.
It seemed likely that the heat-labile chemotactic moiety present in the
conditioned supernatant was a protein because it was heat labile. This result was
different to the result published by (Lauber, 2003) who had shown that conditioned
supernatants from different apoptotic cell lines contained a lipid chemotactic











Mutu BL-cells were treated with 100mJ/cm2 UV-light to induce
apoptosis.Macrophages were allowed to transmigrate to UV-treated Mutu
BL-cells, the conditioned supernatant from the same cells (hatched), media
only (negative control) and lOOng/ml CCL5 (positive control). The mean
number (+SEM) of transmigrated macrophages per high power field for each
condition was plotted.One representative result of three experiments is
shown. Macrophage chemotaxis to apoptotic Mutu was significantly higher
than to the negative control (p= 0.20, student's t-test). There was no
significant difference between macrophage chemotaxis to apoptotic Mutu
BL-cells, and to their cell-free conditioned supernatants. % apoptosis is
shown.
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4.10 Inhibitors of chemotaxis prevent macrophage
transmigration to apoptotic BL-cells
(Figures 4.10a and 4.10b)
Chemokines are small protein cytokines that direct cell movement. They
share common structural motifs that can be copied by certain viruses. These viral
homologs can be used experimentally to inhibit cell movement. In addition, all
chemokines that signal through G-protein linked receptors can have their activity
altered using inhibitors of this signalling pathway.
Pertussis toxin inhibits macrophage chemotaxis to apoptotic Mutu BL-
cells
(Figure 4.10a)
Pertussis toxin (PTX) was used to inhibit macrophage chemotaxis in the
transwell assay. PTX blocks calcium dependent G protein-linked chemokine
receptors, and could also affect macrophage chemotaxis to apoptotic Mutu BL-cells.
The chemokine receptors are serpentine receptors that signal through trimeric GTP-
binding proteins and so they are called G-protein-coupled receptors (GPCR)
(Zlotnik, 2000). PTX catalyses the ADP-ribosylation of the alpha subunit of Gb
which in turn inhibits cAMP production by adenylyl cyclase. In such a way, PTX can
have profound inhibitory effects on many GPCR including the chemokine receptors.
Overnight pre-treatment of macrophages with lOOng/ml PTX abolished
macrophage chemotaxis to both apoptotic cells and CCL5 (figure 4.10a).
Importantly, PTX-treated macrophages were still viable at the end of the
transmigration assay: 91% of PTX-treated macrophages excluded trypan blue
compared to 90% of control macrophages. However, other functions of the PTX-
treated macrophages were not assessed for. With this caveat in mind, PTX inhibition
of macrophage chemotaxis indicated that macrophages might be using one of 18
known chemokine receptor to move towards one of the 44 known chemokines
(Zlotnik, 2000). Although chemokine receptors are notoriously promiscuous in their
choice of ligand, this result helped to narrow down the search for an "apoptotic
chemokine" released by apoptotic BL-cells.
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Viral Macrophage Inflammatory protein II (vMIPII) inhibits macrophage
chemotaxis to apoptotic BL-cells.
(Figure 4.10b)
Experiments using a viral inhibitor of chemotaxis was used to confirm that
macrophages used a known chemokine receptor when transmigrating to apoptotic
BL-cells. Many viruses encode homologues of chemokines and their receptors,
presumably to evade immune detection (Alcami, 2003). The herpes virus that is
associated with Kaposi's sarcoma (KSHV), human herpes virus 8, produces a broad-
spectrum chemokine antagonist called vMIPII. Chemokine receptors from all three
of the family groups (CC, CXC and CX3C) can be blocked in vivo by vMIPII
(Kledal, 1997), although, in some situations it can be an agonist. vMIPII is
chemoattractive to TH2-Iymphocytes and eosinophils and can direct the type of
immune response away from TH1 towards aTH2 (Weber K, S et al). Work by Chen
et al, had already shown that vMIPII was able to inhibit CX3CL1 -induced leukocyte
migration in the rat (Chen, 1998).
Next, the inhibitory action of vMIPII on fractalkine-induced chemotaxis was
examined in the human macrophage transmigration system. Macrophages were
tested for their ability to transmigrate to recombinant human fractalkine in the
presence of 60, 300 and 600ng/ml of vMIPII. At the lowest concentration of
60ng/ml, vMIPII was able to significantly inhibit macrophage chemotaxis to soluble
fractalkine (data not shown). vMIPII had no toxic effect as to macrophages as over
90% were viable after exposure, as measured by trypan blue exclusion. Therefore, a
concentration of 60ng/ml of vMIPII was used to inhibit macrophage chemotaxis to
apoptotic cells.
The effect of 60ng/ml vMIPII on macrophage chemotaxis to Mutu BL-cells is
shown in figure 4.10b. vMIPII was not toxic to macrophages and had no effect on
chemotaxis of macrophages to Mutu BL-cellSfiC/_2. vMIPII significantly blocked
macrophage chemotaxis to apoptotic Mutu BL-cells (***p<0.0001 student's t-test).
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Macrophage chemotaxis to
apoptotic Mutu is blocked by
pertussis toxin
100n
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Macrophages were treated with 1 OOng/ml pertussis toxin (PTX) (black
bars) for 12 hours or left untreated. PTX treatment was not detrimental
to macrophage viability. Macrophages were allowed to transmigrate to
media alone (negative control) Mutu bcl-2, Mutu BL-cells, UV-treated
Mutu BL-cells, or to 1 OOng/ml CCL5 (positive control). The mean
(+SD) of macrophages transmigrating was counted for each condition.
Macrophage chemotaxis to Mutu BL-cells and CCL5 was significantly
inhibited by PTX treatment. (***p< 0.0001, student's t-test).% of
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Macrophages were allowed to transmigrate to Mutu BL-cells, Mutu
BL-cells induced into apoptosis, media only (negative control) and
lOOng/ml CCL5 (positive control) with (hatched bars) or without
vMIPII. The mean number (+SEM) of transmigrated cells counted per
high power field for each condition was plotted.One representative
result of three is shown. Macrophage chemotaxis to apoptotic Mutu
BL-cells was significantly inhibited in the presence of vMIPII (***p<
0.0001, student's t-test). % apoptosis is shown.
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Chapter 4 summary
Mononuclear phagocytes but not neutrophils transmigrated to apoptotic
Burkitt's lymphoma cells in vitro. Potentially, this is a novel mechanism for
apoptotic cell recruitment of tumour-associated macrophages into Burkitt's
lymphoma in vivo.
The lipid receptors CD14 and CD36 are not required for macrophage
chemotaxis to apoptotic cells.
Neither EBV infection nor the method used to induce Mutu BL-cells to
undergo apoptosis affected macrophage chemotaxis to apoptotic cells.
Conditioned supernatant from apoptotic Mutu BL-cells was chemotactic to
macrophages and the chemotactic activity was abolished by heat treatment.
Pertussis toxin and vMIPII blocked macrophage chemotaxis to apoptotic
cells. Therefore, it is likely macrophages are using a known G-protein linked
chemokine receptor.
The chemokine superfamily is now almost complete. The genome contains a
complement of 42 known human ligands, all between 70-90 amino acids long and
each containing two conserved-cysteine residues. Therefore it is unlikely that there
are many chemokines left to be discovered (Zlotnik, 2003). Results in this chapter
have suggested that apoptotic Burkitt's lymphoma cells were releasing one or more
of these 42 known chemokines.
The next chapter will describe why CX3CL1 (fractalkine) was chosen as a
candidate molecule for further investigation out of the 42 possible chemokines and








The previous chapter showed that the viral chemokine antagonist, vMIPII,
was able to block macrophage chemotaxis to apoptotic cells. vMIPII is a broad-
spectrum chemokine-antagonist that blocks the actions of CXC chemokines and
fractalkine (Chen, 1998). Inhibition of macrophage chemotaxis to apoptotic cells by
vMIPII suggested these cells were releasing one of the 42 known chemokines that
had been already characterised.
In 2003, Geissmann published work from mice describing a subset of "non¬
inflammatory" monocytes. These cells had high expression of the fractalkine
receptor (CX3CRlhlgh) and constitutively homed into the lung but did not enter sites
of inflammation in the gut (Geissmann, 2003). It is possible that these fractalkine-
receptorhlgh monocytes might also be attracted into a non-inflammatory tumour
environment. In chapter 4, monocytes and macrophages, but not neutrophils,
transmigrated to apoptotic BL-cells. This cell-specificity of chemotaxis to apoptotic
BL-cells matched the pattern of fractalkine receptor expression (CX3CR1). I.e.
Monocytes and macrophages both express CX3CR1 and move towards apoptotic
BL-cells, but neutrophils do not (Imai, 1997). This suggested that the role of
fractalkine in the recruitment of macrophages into Burkitt's tumours warranted
further investigation.
Fractalkine had already been shown to be a direct target of p53 and as such
was likely to be expressed in apoptotic cells (Shiraishi, 2000). When p53 becomes
mutated, its protective effect is lost and tumours can then emerge. Mutu BL-cells
have one normal p53 allele and one mutant p53 allele (Wiman, 1991). Taken
together, these observations led to the hypothesis that Burkitt's lymphoma cells
release fractalkine during the quiet process of apoptosis. The fractalkine produced by
apoptotic cells might recruit a "non-inflammatory, CX3CRlhlgh" subset of
macrophages into BL-tumours.
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5.1 Macrophages express a functional fractalkine
receptor (CX3CR1)
The original paper describing the fractalkine receptor showed that both
macrophages and monocytes expressed CX3CR1 (Imai, 1997). The aim of this
section was to confirm the published data and to see whether macrophages derived
from peripheral blood monocytes used the fractalkine receptor in the transmigration
assay in vitro.
Monocyte and macrophage expression of CX3CR1 mRNA
(Figure 5. la)
RNA was isolated from the monocytic cell-lines THP-1, MM6 and primary
human macrophages. RNA was reverse-transcribed and cDNA was amplified by
PCR using CX3CR1-specific and actin-specific primers. Products from the PCR
reaction were electrophoresed and bands of the predicted size were detected in all
cell types (figure 5.1a). The products that were amplified between actin primers are
shown as a positive control. Primers were designed to span intron boundaries and all
samples were checked to ensure that there was no contamination of the RNA with
DNA.
The results in figure 5.1a are qualitative and the bands shown can only
represent the presence or absence of RNA. CX3CR1 was detected in both the THP-1
and the MM6 monocyte cell lines and in three macrophage donors. Interestingly, one
of four human donor macrophages did not contain RNA for the fractalkine receptor.
Next, CX3CR1 protein was quantified by specific antibody labelling, because the
amount of mRNA does not necessarily reflect amounts of active protein.
Monocyte and macrophage expression of CX3CR1 protein
(Figure 5.1b)
The monocytic cell lines THP-1 and MM6, and primary human monocytes
and macrophages were all immunolabelled with a rabbit-polyclonal antibody against
amino acids 2-21 from human CX3CR1. A second PE-labelled goat anti-rabbit
immunoglobulin antibody was used to detect bound primary antibody. A rabbit
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Fractalkine receptor (CX3CR1)
expression in macrophages and
monocytes




A gel picture showing amplified products of the correct length from
a RT-PCR reaction for fractalkine receptor compared to an actin
control. Fractalkine receptor RNA was present in three out of four
macrophage donors (MO) and in the monocyte cell lines THP1 and
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Figure 5.1b
FACS showing expression of fractalkine receptor (CX3CR1) on
monocytes (i), macrophages (ii), THP-I (iii) and MM6 (iv)
monocytic cell lines. Log FL2 fluorescence intensity of CX3CR1
is compared to secondary only PE labelled goat-anti rabbit Ig
only or negative control CD 19.
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polyclonal anti-CD 19 was used as a negative control because CD 19 is a B-cell
marker that is not expressed by monocytes.
Figure 5.1b shows log-fluorescence intensity of PE-labelled antibody staining
of fractalkine receptor on THP-1 and MM6 cell lines, and monocytes and
macrophages. Both monocytes and macrophages expressed the fractalkine receptor.
Primary monocytes had two peaks which may represent the CX3CRhlgh versus
CX3CRlow populations that have been previously described (Ancuta, 2003). Next, the
functional activity of CX3CR1 was tested in the transmigration assay in vitro.
Macrophages were initially tested for their ability to migrate to the 8.5kDa
chemokine domain of recombinant human fractalkine. Overall, macrophage
transmigration to recombinant fractalkine was much less than to apoptotic BL-cells.
Macrophage transmigration to 50ng/ml and lOOng/ml of fractalkine was significantly
greater than to media alone (data not shown), demonstrating that macrophage
CX3CR1 was able to function as a chemotaxis receptor in the transmigration in vitro
assay.
These experiments showed that primary human macrophages, derived from
peripheral blood monocytes, expressed a functional fractalkine receptor. Whether
Mutu BL-cells released fractalkine during apoptosis was investigated next.
5.2 Apoptotic Mutu BL-cells express fractalkine
(CX3CL1)
Mutu BL-cells express fractalkine messenger RNA
(Figure 5.2a)
mRNA was isolated from Mutu BL-cells containing a range of
apoptotic cells. Mutu BL-cells, which had been transfected bcl-2 to prevent
apoptosis, contained only a few apoptotic cells, whereas UVB-treated BL-cells had a
higher percentage of apoptotic cells. In addition, UVB-treated Mutu BL-cells were
harvested at various time-points after induction of apoptosis and mRNA was reverse
transcribed. The resulting products from the PCR reaction were electrophoresed and
bands of the predicted size were detected as shown in figure 5.2a. Products amplified
between actin primers are shown as a positive control. The results in figure 5.2a are
I4l
only qualitative and therefore can only represent either the presence or absence of
mRNA.
Live Mutu BL-cells and Mutu bci-2 cells with low levels of apoptosis, both
expressed mRNA for fractalkine. However as soon as 2 hours after the UV-induction
of apoptosis, the level of fractalkine mRNA was barely detectable and no mRNA
was present at the later time points. This was not due to a general degradation of
mRNA in the UV-treated cells, because the actin transcripts were still present 24-
hours after the induction of apoptosis.
Actinomycin D was used to induce BL-cell apoptosis as it triggers death by
preventing de novo mRNA transcription. The use of actinomycin D to induce
apoptosis did not inhibit macrophage chemotaxis to apoptotic cells. This suggested
that fractalkine mRNA may not be produced de novo during apoptosis but might be
released pre-formed. Supporting this idea, experiments on damaged neurones had
shown that membrane-associated fractalkine was released early, many hours before
cell death eventually occurred (Chapman, 2000).
Mutu BL-cells express fractalkine (CX3CL1) protein
(Figures 5.2 b and 5.2c)
B cells and other leukocytes were described as having "scant" levels of
fractalkine mRNA in the original paper detailing the discovery of fractalkine,
(Bazan, 1997). Although subsequently, it was reported that fractalkine mRNA was
expressed on activated B cells (Schaniel, 1998), fractalkine expression by apoptotic
B-lymphocytes had not been investigated.
Mutu BL-cells were harvested 12 hours after UV-induction of apoptosis and
the expression of fractalkine in the apoptotic cells was compared to untreated control
Mutu BL-cells. It was seen that Mutu BL-cells had low levels of fractalkine staining
that increased dramatically after the induction of apoptosis. When cells were back-
gated onto the light-scatter plots, it was found that cells expressing the highest level
of fractalkine were the leaky cells that fell into the apoptotic zone. Three different
antibodies, (two mouse monoclonals (81513 and 51637.1 1) and one goat polyclonal)
all labelled the apoptotic Mutu BL-cells in a similar pattern. Since all three
antibodies labelled Mutu BL-cells in the same way, it was unlikely that they were
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Fractalkine (CX3CL1) mRNA
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Figure 5.2a
A gel picture showing amplified products of the correct length
from a RT-PCR reaction for the chemokine fractalkine
(CX3CL1) compared to an actin control. Fractalkine was
present in Mutu BL cells and Mutu bcl-2 that were transfected
with the anti-apoptotic bcl-2. RNA for fractalkine became
undetectable less than 4 hours after UV-treatment to induce
apoptosis. Results were not quantitative.
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cross-reacting with CD84 as had been seen in previous experiments using the goat
polyclonal antibody (Lucas, 2001).
To further investigate at what stage of apoptosis cells expressed fractalkine,
Mutu BL-cells were harvested from a high-density culture containing a mixture of
viable, early and late apoptotic cells and were triple-stained with Annexin V-FITC,
Fractalkine-PE and ToPR03. Like propidium iodide, ToPr03 binds to DNA in leaky
cells only after they have lost membrane integrity. Early apoptotic Mutu BL-cells
were impermeable and were AxV+/ToPR03-, whereas the late apoptotic cells were
leaky and took up ToPR03 (AxV+/ToPR03+). FACS analysis revealed that early
apoptotic cells expressed very low levels of surface fractalkine but once cells became
leaky, fractalkine staining greatly increased. This suggested that fractalkine within
the cells was accessible to the antibody once membrane integrity was lost during the
course of apoptosis. It will be important to confirm that viable cells lose surface
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Figure 5.2b FACS dot plot of of fractalkine-PE
expression by Mutu BL-cells plotted against AxV-FITC.
Viable cells (AxV-/ Topr03+) express fractalkine
CX3CL1. Early apoptotic cells (AxV+/ Topr03-) express
less fractalkine than both viable and late apoptotic cells
that are (AxV+/Topr03+).
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Confocal microscopy showing antibody staining of fractalkine in Mutu
BL-cells
(Figure 5.2c)
Viable and apoptotic Mutu BL-cells and were stained with either a
monoclonal antibody against fractalkine or an IgGl isotype control antibody. A
secondary antibody labelled with Alexafiuor-green™ was used for confocal
microscopy because it was more stabile than FITC. Cells were fixed in 1% formalin
prior to the addition of ToPR03, to enable the viable cells to be discriminated from
the dead cells using nuclear morphology. Under the confocal microscope, viable cells
had a large nucleus surrounded by a thin rim of cytoplasm whereas apoptotic Mutu
BL-cells had the characteristic "pop corn"-like nuclei.
Figure 5.2c shows a mixture of live and apoptotic Mutu BL-cells viewed
under the confocal microscope. Fractalkine was labelled green and nuclei were
stained blue with ToPR03. Fractalkine was found clustered at the plasma membrane
of viable Mutu BL-cells and there was no intracellular labelling. Once leaky,
intracellular fractalkine was stained bright green in the apoptotic cells and also in the
blebs of cell debris. These results are consistent with the notion that, following the
induction of apoptosis, cells became leaky and the intra-cellular stores of fractalkine
became accessible to antibody.
Western blotting of fractalkine in Mutu BL-cells
(Figure 5.2d)
Western blotting was used to further identify fractalkine in apoptotic Mutu
BL-cells and to confirm the specificity of the monoclonal antibody (clone 51637.11).
Cell-lysates from viable Mutu BL-cells and UVB-treated Mutu BL-cells were
compared. Protein extracts were denatured and run on an acrylamide gel under
reducing conditions, and the 8.5kDa chemokine domain of recombinant fractalkine
was used as a positive control. The products were transferred onto nitrocellulose
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paper and probed with two different anti-fractalkine antibodies. Transferred proteins
were labelled with either an antibody against the N-terminal (chemokine) domain
(R&D systems clone 51637.11), or a chicken polyclonal antibody, (a kind gift from
David Greaves, Oxford) which was raised against the C-terminal peptide of the
intracellular domain of fractalkine (Lucas, 2001).
As expected, the N-terminal antibody labelled the 8.5kDa chemokine domain
but the C-terminal antibody did not. The predicted size of full-length fractalkine is
95kDa. Figure 5.2f showed that the N-terminal antibody recognised two bands, one
of approximately 95kDa and a second smaller band of about 60kDa. The larger band
may represent glycosylation of the full-length protein. Interestingly, the larger
95kDa-band was absent in the lysates from the apoptotic Mutu BL-cells. This
suggested that fractalkine was cleaved during apoptosis.
The polyclonal antibody raised against the intracellular C-terminus picked up
many bands that could represent cleaved products of the full-length protein. In
addition, the C-terminal antibody also picked up the same two (95kDa and 60 kDa)
bands that were also labelled by the N-terminal antibody. The apoptotic cells
contained different sized small lengths of fractalkine, and a dense band at 25kDa.
The smaller fragments in found in the apoptotic cell lysate may be due to increased
proteolysis.
Antibody-staining experiments concluded that viable Mutu BL-cells
expressed full-length fractalkine on their surface that was either cleaved prior to
release, or was degraded at some point during apoptosis. Further studies must be
designed to measure the time-course of the release of fractalkine from the surface of
cells during apoptosis. Furthermore, the detection of the secreted chemokine by
ELISA of the conditioned media of apoptotic cells should be done to confirm that
Mutu BL-cells release fractalkine during apoptotic cell death.
5.3 The functional activity of fractalkine in
macrophage chemotaxis to apoptotic Mutu BL-
cells
Having shown that Mutu BL-cells produce fractalkine, and that macrophages
expressed its receptor, the ability of fractalkine to inhibit macrophage chemotaxis to
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apoptotic BL-cells was tested. Fractalkine was added to the top well of the
transmigration chamber in direct competition with any chemotactic molecule
produced by apoptotic Mutu BL-cells in the chamber below. The anti-fractalkine
neutralising antibody (clone 51637.11) was used to specifically mop up any
fractalkine produced by apoptotic Mutu BL-cells in the lower well.
Fractalkine inhibited macrophage chemotaxis to apoptotic Mutu BL-
cells in a competitive assay
(Figure 5.3a)
The effect of fractalkine on macrophage chemotaxis to apoptotic Mutu BL-
cells was tested in a competition assay in which lOOng/ml of the recombinant
chemokine domain of fractalkine was added to the top chamber (that contained the
macrophages), for the duration of the transmigration assay. This approach was taken
to determine whether chemotaxis towards fractalkine produced by Mutu BL-cells
could be prevented by effectively abolishing the chemotactic gradient. Figure 5.3a
shows that fractalkine significantly inhibited macrophage chemotaxis to media, to
Mutu BL-cells and to apoptotic Mutu BL-cells (*p<0.05 and ***p<0.0001
respectively, student's t-test). However, the addition of fractalkine to the upper well
did not affect macrophage chemotaxis to lOOng/ml CCL5, which was the positive
control.
The fact that fractalkine blocked chemotaxis to Mutu BL-cells but not to
CCL5 suggested that soluble recombinant fractalkine was specifically competing
with the fractalkine released by the apoptotic cells below. However, results showed
that there was also an element of non-specific inhibition of macrophage chemotaxis
to the media. It was possible that when fractalkine was placed in the upper well with
macrophages, it was able to de-sensitise its own receptor, perhaps by down-
regulating its surface expression.
It was probable that there was an element of non-specific inhibition that
caused fractalkine to inhibit macrophage chemotaxis to the media (negative control).
Therefore, to overcome this problem, a monoclonal antibody that could neutralise
fractalkine was used to examine the specific contribution of fractalkine to
macrophage chemotaxis to apoptotic Mutu BL-cells.
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Fractalkine (CX3CL1) inhibition












Macrophages were placed in a transwell with or without lOOng/ml of
fractalkine and were allowed to transmigrate to media alone (negative
control), Mutu, UV-treated (apoptotic) Mutu and lOOng/ml CCL5
(positive control). One representative experiment of six is plotted, the
mean + SEM number of macrophages that transmigrated was counted
for each condition. % of apoptotic cells is shown. Macrophage
chemotaxis to media, Mutu and apoptotic Mutu was significantly
inhibited by fractalkine in the upper well (*p<0.05 (media),***p<0.001
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(*** p< 0.0001)
Figure 5.3b
Macrophages were allowed to transmigrate to media alone (negative
control), Mutu, UV-treated (apoptotic) Mutu and lOOng/ml of CCL5 in the
presence or absence of a blocking monoclonal antibody against the
chemokine domain of fractalkine (clone 51637.11). One representative of
four experiments is plotted and the mean (+SEM) number of macrophages
that transmigrated is shown for each condition. Macrophage chemotaxis to
Mutu and apoptotic Mutu was significantly inhibited by 50pg/ml of the
antibody when placed in the lower well (***p<0.0001, student's t-test).
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Anti-fractalkine antibody (clone 51637.11) blocks macrophage
chemotaxis to apoptotic Mutu BL-cells
(Figure 5.3b)
A monoclonal antibody was used o determine how important the contribution
of fractalkine was to macrophage chemotaxis to apoptotic Mutu BL-cells. The mouse
monoclonal anti-fractalkine antibody (clone 51637.1 1) binds to the chemokine
domain of fractalkine and blocks its action. First, the antibody was tested to
determine its ability to inhibit macrophage migration to recombinant fractalkine.
50pg/ml of 51637.11 was added to the lower well of a transmigration assay in
order to block the chemokine activity of any fractalkine released by Mutu BL-cells.
Figure 5.3b shows that 51637.11 was able to block macrophage chemotaxis to Mutu
BL-cells. The inhibitory effect of 50pg/ml of the 51637.11 antibody was compared to
an IgGl isotype control antibody at the same concentration. Again, the anti-
fractalkine antibody reduced macrophage chemotaxis to apoptotic Mutu BL-cells,
whereas the isotype control antibody had no effect. In all of these experiments, the
anti-fractalkine antibody only partially blocked macrophage migration. This may
have been because other chemotactic molecules, besides fractalkine, were being
released from apoptotic Mutu BL-cells or that the concentration of the antibody was
not saturating. It is unlikely that fractalkine is the sole chemokine responsible for
macrophage migration, because other chemotactic molecules like the phospholipid
LPC are also released by cells during apoptosis (Lauber, 2003).
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Chapter 5 summary
This chapter has shown:
Macrophages express a functional receptor for fractalkine (CX3CR1)
Live and apoptotic Burkitt's lymphoma cells express fractalkine
An anti-fractalkine neutralising antibody was able to inhibit macrophage





This thesis has investigated the role of macrophage receptors in the
chemotaxis to, and engulfment of apoptotic cells. The work presented here sprung
from the observation that the CD 14 knockout mouse had accumulated large numbers
of apoptotic cells in its organs. Antibodies against CD 14 blocked human
macrophages from phagocytosing apoptotic cells, and revealed for the first time,
CDM's function in the clearance of apoptotic cells (Devitt, 1998). It followed from
this observation, that mice deficient for the CD 14 receptor might also have a defect
in the phagocytosis of apoptotic cells.
Further work presented in Chapter 3 of this thesis, identified a strain-specific
defect in the phagocytosis of apoptotic lymphocytes in vitro by the BALB/c CD 14-/-
macrophages. CD 14 is used by macrophages to grasp apoptotic cells before
phagocytosing them. It is not known if the tethering defect reduced the efficiency of
apoptotic cell-clearance and was responsible for the accumulation of apoptotic cells
seen in the BALB/c CD14-/- mouse in vivo (Devitt, 2004). Previous work by the
group observed that different tissues in the CD 14-/- had excess numbers of apoptotic
cells that were "free" from contact with surrounding macrophages. This suggested
that the CD 14-/- macrophages might also have a difficulty "sensing" and "moving
towards" dying cells in addition to the observed phagocytosis defect. While much
has been learned of the mechanisms by which apoptotic cells are recognised and
engulfed by macrophages, little is yet known of the processes underlying the
'sensing' of apoptotic cells by phagocytes. Recent studies have highlighted the
importance of chemokine release during normal cell death, and of how macrophages
may sense and then move towards a dying cell in readiness to engulf the apoptotic
corpse (Audran, 1996; Kao, 1994; Lauber, 2003; Cocca, 2002; Horino, 1998;
Vegundo, 1999).
The fact that the CD 14-/- mouse macrophages had failed to tether apoptotic
cells might be one explanation for the accumulation of apoptotic cells seen in the
thymus. So, the importance of CD 14 in human macrophage clearance was
investigated next in a subset of monocytes that expressed low levels of CD 14. This
minority subset of circulating human monocytes was originally isolated from
peripheral blood mononuclear cells and expressed low levels of both surface CD 14
(CD14low) and CD 16 (Ziegler-Heitbrock, 1991). Experiments described in Chapter 3
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showed that CD14|0W monocytes maintained low levels of surface CD 14 over 7 days
in culture during which they matured into macrophages. Similar to mouse CD14-/-
macrophages, the human CD14low macrophages were also found to be inefficient at
interacting with apoptotic cells.
Earlier studies on the CD14low monocytes had shown that they expressed a
different set of chemokine receptors compared to the CD14hlgh cells (Weber, 2000).
The CD14low monocytes expressed high levels of CX3CR1 and responded to its
chemokine, fractalkine (Ancuta, 2000). It was also possible that CD 14 might be
important for reading the "come-get me" signals put out by apoptotic cells. The
CD14lovv monocytes are a subset of cells with distinct migrating characteristics.
Human CD14low monocytes display a specific set of chemokine receptors, as well as
the fractalkine receptor (CX3CR1) they also express CCR5 (Ancuta, 2003;
Geissmann, 2003; Weber, 2000). Study of human CD14hlgh monocytes showed that
they expressed CCR2 and moved towards CCL1 (MCP-1) (Weber, 2000). Whereas
the CD14|0W monocytes failed to respond to CCL1, but moved preferentially to
CX3CL1 (fractalkine) instead (Ancuta, 2003). The CD14low CX3CRlhlgh monocytes
are expanded in HIV and may promote infection because CX3CR1 itself is a co-
receptor for the virus (Thieblemont, 1995). The migratory patterns of these CD14low,
CX3CRlhlgh monocytes seem to be quite distinct from the CD14hlgh monocytes.
Expression of the fractalkine receptor was able to direct mouse monocytes away
from the site of peritoneal inflammation and into the lungs (Geissmann et al., 2003).
This seemed to mark out a different, kind of role for these CD14|0W, CX3CRlhlgh
monocytes.
Every day, about 340 million monocytes leave the circulation in the
absence of any inflammation at all. However, the steady-state mechanism that
controls this enormous exodus of cells is largely unknown (Muller, 2001). It remains
to be seen whether the same chemokines that are released during inflammation, can
also recruit monocytes into unperturbed tissues. One or two, so-called "constitutive"
or "homeostatic" chemokines, like CCL20 (SLC) and CXCL14 (BRAK), have been
described, but none of these are widely or consistently expressed throughout the
body (Kurth, 2001). Fractalkine receptor (CX3CL1) may be a candidate for a
"constitutive" chemokine that directs monocyte traffic (Lucas, 2003; Geissmann,
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2003; Kremlev, 2005). Fractalkine is widely expressed in the body for e.g. by
epithelial cells and neurons, and its receptor is found on both monocytes and
macrophages (Jung, 2000; Bazan, 1997; Lucas, 2001). To maintain the number of
resident tissue macrophages there must be a constant recruitment of monocytes.
Therefore a constitutive chemotactic molecule might be released during normal cell
turnover. Since apoptosis occurs in all tissues, a dying cell may be one source of such
a chemotactic molecule that could recruit monocytes destined to become the next
tissue macrophages. Once in situ, these tissue macrophages could themselves release
growth factors to stimulate stromal cell division (Chazaud, 2004).
Supposing that apoptosis was an engine driving the constitutive migration of
monocytes out of the circulation and into tissues, it might also direct macrophages
into tumours that contain frequent apoptotic cells. The work presented in this thesis
shows that fractalkine (CX3CL1), a chemokine that is known to direct the
homeostatic flow of CX3CRlhlgh monocyte traffic into tissues like the lung, may
indeed be important in recruiting macrophages to a non-inflammatory tumour
environment. Results presented here show that apoptotic Burkitf s lymphoma cells
expressed fractalkine that could attract monocytes and macrophages towards tumours
cells in vitro. These observations increase our understanding of macrophage
chemotaxis to apoptotic cells and may shed light on the recruitment of tumour-
associated macrophages into Burkitf s lymphoma.
6.1 The persistence of apoptotic cells may
sometimes be anti-inflammatory
Although CD 14 is important for tethering apoptotic cells prior to
phagocytosis (Devitt, 1998; Devitt, 2004), the results presented here demonstrate that
it is not required for macrophage chemotaxis. Experiments with BMDM showed that
CD 14-/- Balb/C mouse-macrophages had no defect in migration to apoptotic cells.
However, when human macrophages were used in the transmigration assay, the cells
that had migrated expressed high levels of CD 14. Perhaps this CD 14 was
upregulated in readiness to tether and engulf an apoptotic target. Unexpectedly, the
apoptotic cells so prominent in the CD 14 knockout mice persisted in the absence of
inflammation or autoimmune disease, even into ripe old age (Devitt, 2004). Put
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together, this suggests that rather than being pro-inflammatory, persistent apoptotic
cells may well sustain an anti-inflammatory environment, at least in the CD 14
knockout mouse and perhaps also in a tumour situation (Ogden, 2005).This work
supports a role for apoptotic cells in tumour survival. Furthermore, the persistence of
apoptotic cells may even aid wound healing, neovascularisation and promote tissue
repair (Sun, 2005; Volin, 2001). Experiments from the CD 14 -/- mouse support a
rather controversial view that challenges the dogma that necrotic cells are necessarily
pro-inflammatory (Gregory, 2004).
Interactions between phagocytes and apoptotic cells can be neutral but they
can also dramatically suppress inflammation. This is usually achieved by secretion of
cytokines like TGF-p, PGE2, and PAF (Voll, 1997; Fadok, 1998; Fadok, 1998;
Kurosaka, 2003). The view that necrotic cells and persisting apoptotic cells are
inflammatory is challenged by the apparently harmless accumulation of apoptotic
cells seen in the CD 14 knockout mouse and also described in this work (Devitt, 2004
; Gregory, 2004; Bryne, 2002). Although macrophage interactions with apoptotic
cells are often non-inflammatory or even anti-inflammatory, there are some
exceptions to this. Indeed, apoptotic cells can be inflammatory. Repeated injection of
apoptotic cells leads to auto-antibody production, leading to the production of auto¬
antibodies and immune diseases like SLE (Botto, 1998; Scott, 2001; Cohen, 2002;
Szondy, 2003; Hanayama, 2004; Casciola-Rosen, 1994; Mevorach, 1998). Impaired
phagocytosis of apoptotic cells leads to autoantigens being cross-presented by DCs to
CD8 T cells causing diseases like SLE (Albert, 1998; Albert, 1998a). Dying cells
also release uric acid that is a potent adjuvant that can stimulate lymphocyte
responses (Gallucci, 1999; Shi, 2003). Therefore, the dogma that apoptotic cells are
"good" and necrotic cells are "bad," appears to be simplistic (Gregory and Devitt,
2004).
The observation that CD 14-/- mice had persistent apoptotic cells in the
absence of inflammation is striking, and needs to be further examined using different
background strains. This work described an accumulation of apoptotic cells in the
thymus in the BALB/c strain that was not apparent in the C57BL/6. In light of recent,
strain-specific differences seen in the phenotypes of the PSR-/- mice, the CD 14
knockout needs careful examination on the C57BL/6 background (Weitzman, 2004;
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Kunisaki, 2004; Bose, 2004). It will be interesting to discover whether the C57BL/6
CD 14-/- also has a phagocytosis defect in vitro. It may be that the C57BL/6 strain
does not rely so heavily on CD 14 for apoptotic cell removal. The C57BL/6 may use
an alternative repertoire of phagocytic receptors to the BALB/c. The clearance
mechanisms in the C57BL/6 might need to be stressed by injury or infection,
mimicked by using steroids in vitro, to induce overwhelming apoptosis that then
exposed a clearance defect.
For this work the different mouse strains were housed in different conditions;
the C57BL/6 were kept in specific pathogen-free cages whereas the BALB/c were in
conventional housing. Arguably, these different environments may lead to
differences in the presence of low-grade infection or in commensal flora. Any
infection (how ever insignificant) might increase cell apoptosis or reduce the
effectiveness of macrophage clearance. The original paper that described the CD 14-/-
knockout showed these mice had a paradoxical rise in the number of bacteria
surviving in the blood (Flaziot, 1996). Additionally, neutrophil infiltration was
delayed into the peritoneum of infected CD14-/-animals (Yang, 2002) suggesting
that an inflammation caused by infection may not be apparent. In these
circumstances it would be possible to culture organisms directly from blood or
perform PCR to completely rule out the presence of such sub-clinical infections.
However, CD 14-/- mice had no defect in the phagocytosis of group B streptococci or
IgG-opsonised cells (Haziot, 1996; Henneke, 2002; Devitt, 2004). It is conceivable
that loss of CD 14 may delay the evolution of the innate response, and it follows that
macrophages deficient in CD14 may not always produce the cardinal signs of
inflammation. However BALB/c CD14-/- animals seemed to show no systemic signs
of ill health, they produced TNFa responses to LPS and had normal auto-antibody
titres; in addition, CD 14-/- macrophages produced TGFp after engulfing apoptotic
cells (Devitt, 2004). The clearance mechanisms available to macrophages are so
varied and efficient that it is rare to observe apoptosis on routine histological slides.
Apoptotic cells are rarely seen in the histological analysis of normal tissues but are
more common in embryonic tissues and in developing thymus, were cell-turnover is
massive. Therefore, an infection needs be massive in order to overcome this
clearance system. The apoptotic cells that are so visible in the CD14-/- mouse
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thymus are more likely to be due to clearance defect to apposed to a sub-clinical
infection.
The increased numbers of apoptotic cells observed in the thymus of the
CD 14-/- mice may reflect a failure of thymocyte selection and that the loss of CD 14
would also affect antigen presentation in the thymus (Esashi, 2003). The fact that
apoptotic cells are found widely distributed in the BALB/c CD 14-/- mouse, and not
just in the thymus again points to a genearalised clearance defect rather than to a
change in the level of T cell survival in these mice. It is interesting to note that the
BALB/c CD 14-/- mouse also had increased numbers of apoptotic cells in non-
lymphoid organs like the lung and colon (Devitt, 2004). This widespread distribution
of apoptotic cells is not seen in all knockout-mice deficient for other phagocytic
receptors. For example, the Clq-/- mouse has an organ-specific accumulation of
apoptotic cells in the kidney but not in the spleen (Botto, 1998). Overall, the
persistence of apoptotic cells in the CD 14-/- appears to have no deleterious effect on
the mouse, and likewise, as will be discussed below, the apoptotic cells in Burkitf s
lymphoma may promote tumour evolution and prolong tumour life
6.2 Are macrophage phagocytic receptors also
important for chemotaxis to apoptotic cells?
Many of the receptors involved in apoptotic cell clearance, including CD14
and scavenger receptors, have been seconded from other duties, like scavenging
lipids and immunological tasks. It is possible that one or more of the many
phagocytic receptors has a second role: that of finding or sensing, an apoptotic cell.
Chemotaxis is the directional movement of a cell up a chemokine gradient and is
important in a number of biological processes including leukocyte recruitment to
sites of inflammation, and wound healing (reviewed in Zlotnik, 2000). The work
presented here reveals an additional role for fractalkine in macrophage chemotaxis to
apoptotic cells. Different groups have earlier described a variety of chemotactic
molecules (such as PAF, LPC, SI9 and EMAP1I) released by apoptotic cells
(Bratton, 1993; Horino et al., 1998; Wakasugi, 2003; Lauber, 2003; Kao, 1994).
Until now however, no one has yet demonstrated the release of a known chemokine
by apoptotic cells
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The migration of macrophages to "come-get-me" signals from apoptotic BL-
cells was examined in Chapter 4. Migration and phagocytosis involve common
membrane and cell shape changes and both processes are known to be regulated by
the same signalling pathways involving integrins and small G proteins (Hogg, 2001;
Aderem, 1999). Indeed, apoptotic-cell engulfment and cell migration in the nematode
worm Caenorhabditis elegans have been shown to be governed by common genes
that are conserved in flies and mammals (Wu, 1998). Recent experiments in C.
elegans show that the intracellular pathways of chemotaxis and engulfment come
together resulting in lamellipodia formation (deBakker, 2005). The upstream
membrane receptor that recognises the "come-get-me" and "eat-me" signals may
well be one of approximately 550 G-protein-coupled chemoreceptors present in the
worm's genome (Robertson, 1998).
Given the mechanistic similarities between phagocytosis and chemotaxis, it
was supposed that macrophage receptors involved in the recognition and engulfment
of apoptotic cells might also have a dual function in the chemotactic response of
macrophages to such cells. Not only would these macrophage receptors recognise
apoptotic cell's "eat-me" ligands but they may also pick up "find-me" clues. The
discovery that apoptotic cells released the lipid lysophosphatidylcholine (LPC)
supported the investigation of the phagocytic lipid-receptors CD 14, and CD36 in
chemotaxis of macrophages to dying cells (Lauber et al. 2003). Although a dying cell
may well release lipids to attract phagocytes towards the end of its life, the results
from this work show that macrophage chemotaxis to an apoptotic cell does not
require the 'phagocytic lipid receptors' CD14 and CD36. The negative results from
this part of the work do not invalidate the general approach. If the search had
continued it may well have proved fruitful and have led to the discovery of the
involvement of a chemokine receptor like fractalkine. Later on during the course of
these studies the similarity in the structure of CD36 and the chemokine CXCL16 was
the clue that fractalkine might be a candidate chemokine that was released by
apoptotic cells (Shimaoka, 2000; Shimaoka, 2004; Wuttge, 2004).
CD36 is a class B scavenger receptor that binds oxidised lipids and is an
important contributor to the pathogenesis of atherosclerosis. In addition to binding
native lipids, CD36 can also recognise the PAMP lipoteichoic acid, produced by
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gram-positive bacteria (Hoebe, 2005). SR-PSOX is a scavenger receptor, expressed
by macrophages that is also found in atherosclerotic lesions (Minami, 2001). The
surprising finding about SR-PSOX was that it was also a chemokine and was given
the name CXCL16 (Wuttge, 2004). Subsequently, quite a number of chemokines
have been identified that also have a scavenger function (Shimaoka, 2004). Although
CXCL16 and fractalkine belong to different chemokine families they both have the
same "chemokine on a stalk" structure. Despite this similarity, no scavenger function
for fractalkine has been identified so far. However, fractalkine may bind to an
unidentified PAMP on red blood cells infected by Plasmodium falciparum. The
sequestration of parasitised erythrocytes in cerebral vessels is a lethal development in
the pathogenesis of malaria and the same antibodies that prevented macrophage
chemotaxis to apoptotic cells blocked this binding (Hatabu, 2003). The fact that
Plasmodium falciparum, an organism that has evolved to live undetected in its host,
interacts with fractalkine is very interesting. The parasite may have used fractalkine
to provide a non-inflammatory conduit into the host cells. It is also possible that the
parasite is camouflaging itself as an effete erythrocyte to take advantage of the quiet
immune response associated with the clearance of apoptotic cells.
Interestingly, the surface of parasitised erythrocytes contains "knobs" that
mediate the adhesion of the parasitised cells under flow conditions. The malaria
parasite-protein PfEMP-1 is concentrated on these knobs and is able to bind to
CD36, and this interaction can be blocked by PS-containing liposomes (Eda, 2002).
The knobs on parasitised cells carrying motifs recognised by both CD36 and
fractalkine look very similar to the blebs seen on apoptotic cells. During apoptosis a
cell pinches off small "blebs" of its plasma membrane. On the blebs are concentrated
autoantigens, and possibly chemoattractant molecules that provide a chemotactic
gradient for macrophages to trace to an apoptotic cell (Casciola-Rosen, 1994;
Segundo, 1999).
6.3 Is fractalkine a non-inflammatory chemokine?
This work describes the release of fractalkine by apoptotic Burkitt's
lymphoma cells and the possibility arises that fractalkine might contribute to the anti¬
inflammatory milieu of the tumour. This may be surprising, given that early work
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grouped fractalkine with inflammatory chemokines. The labelling of fractalkine as
inflammatory must be revisited in light of the work presented here and other recent
publications (Lucas, 2003; Geissmann, 2003; Kremlev, 2005).
Much evidence supports a pro-inflammatory role for fractalkine (Efsen, 2002;
Fraticelli, 2001; Nishimura, 2002; Yoneda, 2000; Yoshida, 2001). The "chemokine
on a stalk" structure of fractalkine allows it to both attract and tether leukocytes to
endothelium (Haskell, 2000; Bazan, 1997). An anti-fractalkine antibody could
prevent monocyte infiltration of the synovium in collagen-induced arthritis, but did
not increase production of IFNy or auto-antibody (Nanki, 2004). TNFa together with
IFNy together raised fractalkine levels in astrocytes and smooth muscle cells
(Yoshida et ah, 2001; Ludwig, 2002). Whereas IL-4 and IL-13, both TH2-type
cytokines have no effect on fractalkine expression. This has lead to a model of
fractalkine being able to polarise T cells towards THl-type responses (Fraticelli et
ah, 2001). Fractalkine is also produced during liver injury and anti-fractalkine
antibodies can prolong the survival of cardiac allografts (Efsen et ah, 2002; Haskell,
2001); the CX3CR1-expressing cells doing the damage to these organs are cytotoxic
lymphocytes and NK cells.
The majority of work to date describe fractalkine's major role as
inflammatory, but some more recent publications reveal a more complex, reparative
and non-inflammatory role for this cytokine (Lucas, 2003; Geissmann, 2003;
Kremlev, 2005). This would fit in with fractalkine's proposed function in the
clearance of apoptotic cells that is also predominantly non-inflammatory. Fractalkine
is important in plaque stability and repair during atherosclerosis (Lucas, 2003). This
paper has shown that the fractalkine released by the smooth muscle cells in
atherosclerotic plaques helps to stabilise plaques and prevents rupture and
subsequent thrombosis. The smooth muscle cells in the plaque secrete fractalkine
that aids repair. Disappointingly, the fractalkine knockout mice and the CX3CR1
knockout mice appeared to have no obvious phenotype or disease (Jung, 2000; Cook,
2001). However, defects emerged when these mice were crossed with other mice.
The Apo3 transgenic mouse has an accelerated process of atherosclerosis, and
dramatic reductions in the size of plaques was seen when this mouse was crossed
with the fractalkine receptor knockout mouse (Combadiere, 2003). The brain's
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macrophages, the microglial cells can up-regulate fractalkine receptor in response to
IL-10 a chemokine that is found in abundance in BL (Ogden, 2005; Kremlev, 2005).
It is possible that the IL-10 environment in BL similarly up-regulates CX3CR1
expression of tumour-associated macrophages. When IL-10 was added to the
microglial-like cell-line "HAPI" it overcame the effect of LPS and increased
expression of CX3CR1. At the same time as promoting fractalkine-receptor
expression, IL-10 reduced TNFa and CCL5 (RANTES) production, but neither IL-10
nor LPS alone affected fractalkine expression (Kremlev, 2005).
Geissmann's group showed that monocytes that expressed high levels of
CX3CR1 trafficked away from a septic peritoneum and migrated into the lung.
Generally, the lung is a non-inflammatory environment (Geissmann, 2003). Alveolar
macrophages can deal with large amounts of inhaled LPS daily, and cope efficiently
with pathogens without provoking damaging inflammation that might prevent gas
exchange. More recently, a specialised, myeloid DC that expresses CX3CR1 has
been described in the lamina propria of the murine intestine (Niess, 2005). This DC
puts out dendrites into the gut lumen where it samples and phagocytoses both
commensal and pathogenic bacteria. In the absence of the fractalkine receptor, these
DCs did not put out dendrites and stopped sampling the intestine. The mice lacking
the fractalkine receptor were susceptible to challenge by an invasive S.typhimurium
and an additional phagocyte was recruited to deal with the infection. Their role in
defence against entero-invasive bacteria seems to be in part, an early warning of
S.typhimurium, and part tolerance to commensal bacteria.
Undoubtedly, fractalkine's role may change in different organs and whether it
has pro or anti-inflammatory actions is influenced by the local tissue
microenvironment. Fractalkine may have an anti-inflammatory role in tissues rich in
IL-10 such as Burkitt's Lymphoma and perhaps in mouse strains such as the BALB/c
(Ogden, 2005; Mills, 2000; Kremlev, 2005). When IL-10 is constitutively expressed
by macrophages, under the control of CD68, they become "alternatively activated,"
however, it remains to be seen whether fractalkine receptor is a marker of the M2-
macrophage (Lang, 2002). There is evidence that in the brain apoptotic cells secrete
fractalkine after treatment with glutamate. The released fractalkine may guide
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microglial (macrophage-like) cells towards the apoptotic cells in the brain
(Maciejewski-Lenoir, 1999; Tong, 2000; Erichsen, 2003).
6.4 Fractalkine in Burkitt's lymphoma
Tumour-associated macrophages (TAM) have been described as "benign" in
standard pathology textbooks (Cotran, 1989). TAM may influence the pathogenesis
of Burkitt's (and related) lymphomas by multiple means, including helping the
tumour to avoid immune detection as has been suggested for other malignancies
(Mantovani, 2002). Results from Chapter 4 showed that apoptotic tumour cells
recruited monocytes and macrophages in vitro. Once arrested in the tumour
microenvironment, these cells may acquire an "alternatively-activated" phenotype
through the engulfment of apoptotic cells. The release of TGF-p and IL-10 after the
phagocytosis of apoptotic cells may aid tumour growth and allow evasion of anti-
tumour immunity (Savill, 2000; Ogden, 2004).
Macrophages are the predominant infiltrating cell in Burkitf s lymphoma and may
represent the tingible body macrophages seen in healthy germinal centres. BL
tumours may trap monocytes and macrophages and subvert them into a non¬
inflammatory role to prevent them presenting tumour antigens. The tumour
microenvironment, full of apoptotic cells and rich in IL-10 and may lead to the
emergence of so-called "alternatively activated" macrophages.
In the transmigration assay, the apoptotic cells were artificially separated
from the macrophages by the semi-porous filter. In a preliminary experiment,
macrophages and BL-cells were reconstituted in an in vivo model of Burkitt's
lymphoma. The BL2 Burkitf s lymphoma cell line was injected subcutaneously into
SCID mice. In the absence of adaptive immunity, these mice developed tumours that
had the characteristic "starry sky" appearance of the Burkitf s tumour seen in
humans. Because F4/80-positive mouse macrophages were recruited into the human
tumours this experiment showed that macrophage migration to BL-cells was
conserved between the mouse and humans in vivo as had been seen in vitro. Next the
SCID model will be used to test whether macrophage recruitment into BL is
apoptosis-dependent. Further experiments using the CX3CR1-/- mouse are planned
to see whether fractalkine is important in macrophage chemotaxis to apoptotic BL-
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cells in the mouse. Immunohistochemistry of human Burkitt's lymphoma has shown
that the macrophages infiltrating the tumours do indeed express the fractalkine
receptor (CX3CR1). This preliminary observation requires further work to assess the
importance of fractalkine in the pathogenesis of Burkitt's lymphoma in vivo.
6.5 Where are the cytotoxic cells in Burkitt's
lymphoma?
Macrophages are the predominant cell infiltrating BL. In stark contrast to
monocytes and macrophages, neutrophils failed to migrate to BL-cells despite
migrating effectively towards 10~8M fMLP in vitro. The negative levels of neutrophil
migration towards both live and apoptotic Mutu BL-cells suggested that Mutu BL-
cells release factor(s) that could inhibit neutrophil migration, independently of
apoptosis. Neutrophils showed no evidence of degranulation in these experiments
and >90% of cells were viable when viewed under the microscope. Apoptotic Mutu
BL-cells seemed capable of actively preventing neutrophil transmigration,
presumably through the release of soluble inhibitory-factors. Failure of neutrophil
chemotaxis to Mutu BL-cells was independent of apoptosis, since Mutu bci-2, (that had
negligible apoptosis) and Mutu uv, (having large numbers of apoptotic cells) both
inhibited chemotaxis. The observation that Mutu BL-cells were not chemoattractive
to neutrophils reflects the histological picture where there is a paucity of
polymorphonuclear cells infdtrating the Burkitt's tumours Figure 4.1a. Neutrophils
do not highly express the fractalkine receptor CX3CR1 and this may be one
explanation for their absence (Beck, 2003). However, neutrophils do express G2A,
the receptor for LPC, another chemoattractant molecule released by apoptotic cells
(Yang, 2005). Neutrophils also have the receptor for another chemoattractive
molecule, SI9. Apoptotic HL-60-cells release SI9 that preferentially attracts
monocytes but not neutrophils, despite the fact that both cells express its receptor,
C5a. The lack of a neutrophil migration to S19 may be due to changes in the
structure of SI9 after contact with neutrophil proteases. This may turn SI9 from a
agonist into an antagonist (Nishiura, 1996).
Fractalkine receptor is expressed on natural killer cells and some CD8+
cytotoxic lymphocytes, both cells with the potential to destroy tumour cells like BL
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(Guo, 2003; Morita, 2004; Yoneda, 2000; Nishimura, 2002; Campbell, 2001). There
are no studies published to date describing NK cells in Burkitt's lymphoma. This is
surprising, because NK-cells express high levels of the fractalkine receptor
(CX3CR1) and have an important role in anti-tumour immunity and graft rejection. It
has been shown that anti-fractalkine antibodies block NK-cell infiltration and
prolong cardiac graft survival in rats (Haskell, 2001). Furthermore, Christophe
Combadiere's group showed that transfection of a mouse embryo-cell line (E20) with
fractalkine induced NK cell-infiltration and reduced tumour size (Lavergne, 2003).
However, CD56+ NK cells are not a characteristic feature of Burkitt's tumours
(Bridget Wilson personal communication). Are NK cells excluded from the tumour
in the same way as neutrophils are repelled? NK cells, like monocytes and
neutrophils, express the receptor G2A and should respond to LPC released by
apoptotic cells (Lauber, 2003). There is evidence to suggest that NK cells become
compartmentalised in the circulation where phospholipids like LPC are abundant.
Resting NK cells may be held up in the circulation unless further inflammation
triggers exudation of serum lipoproteins like LPC (Maghazachi, 2005).
6.6 Lysophosphatidylcholine
The finding that the chemoattractant molecule lysophosphatidylcholine (LPC)
was released by apoptotic cells, was published during the course of these studies
(Lauber, 2003). It is unlikely that fractalkine is the only chemoattractant molecule
released by cells during apoptosis, and other chemoattractant molecules like LPC
will also be important. LPC's major role may turn out to be more than chemotactic
(Fadok, 2003; Ravichandran, 2003). There is some debate about whether LPC is pro
or anti-inflammatory, however, recent evidence points to a non-inflammatory role.
LPC was shown to antagonise its receptor G2A, and, when injected into mice, LPC
prevented septic shock (Murkami, 2004; Wang, 2004). The mechanism might be
caused by LPC compartmentalising monocytes in the circulation in the same way as
it holds onto NK cells (Maghazachi, 2005). In this way, LPC would prevent
monocyte migration into inflammed tissues thus stopping TNFa-release and septic
shock (Beutler, 2001).
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In serum, 99% of LPC is bound to albumin. Critically, all experiments in the
Lauber paper, showing that LPC was chemotactic to macrophages, were done in the
presence of serum (Lauber, 2003). LPC is found at such a high concentration in
blood that it is difficult to imagine how a gradient would be formed between the
circulation and the tissues that would allow for monocyte chemotaxis to an apoptotic
cell. Perhaps there is a role for other chemokines, like fractalkine, in drawing
monocytes out from the circulation towards apoptotic cells. The experiments
presented here were all performed in the absence of serum. However, in common
with the previous work, apoptotic cells were more prominently chemotactic for
macrophages compared to monocytes. This may be because monocytes express less
fractalkine receptor (CX3CR1) than macrophages. It is likely that the release of
fractalkine by apoptotic cells is a local signal that aids the navigation of macrophages
within tissues, rather than the movement of monocytes out of the circulation.
Any chemokine produced by an apoptotic cells should be released early on in
the cell death programme in order to ensure swift clearance. This would allow time
for phagocytes to respond to the chemotactic gradient generated by the dying cell.
Critically, LPC, and fractalkine appear to be released early, when the cell's plasma
membrane is intact. Release of fractalkine from the surface of viable cells is a
complex, dynamic process and is tightly controlled by two metalloproteinase
enzymes ADAM 10 and ADAM 17 (TACE).
ADAM 10 releases fractalkine constitutively and ADAM 17 (TACE) can be
induced by inflammatory cytokines and phorbal esters (Garton, 2001; Hundhausen,
2003; Tsou, 2001). Recently, a novel pathway for recycling membrane-bound
fractalkine has been described where intracellular fractalkine is stored in juxtanuclear
vesicles (Liu, 2005). This represents an additional tier in the tight control of
fractalkine release from cells, and may hint at the importance of the bioavailability of
fractalkine. Like most chemokines, fractalkine's release is controlled at the level of
transcription and translation, but the additional recycling pathway does not rely in de
novo synthesis. Potentially, this means that a burst of preformed fractalkine could be
rapidly mobilised early on during apoptosis. These experiments show that
macrophage migration to apoptotic BL-cells occurs early after the induction of
apoptosis and future experiments that measure the release of fractalkine are planned.
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A powerful argument for the importance of LPC in apoptotic cell engulfment
is the direct link between the release of LPC and the execution of apoptosis. The
release of LPC was not specific for any particular cell type, but required the
apoptotic enzyme, caspase 3 (Lauber, 2003). Similarly, the chemoattractive molecule
SI9, was induced during apoptosis (Nishiura, 1996). Lauber showed that the breast
carcinoma cell-line MCF7 that has no caspase 3 did not attract monocytes but after
transfection with caspase 3, apoptotic cells attracted monocytes. Although MCF7
lack caspase 3, they still pass through many of the morphological phases of
apoptosis, they can flip phosphatidylserine and are efficiently phagocytosed by
macrophages (Turner, 2003). However, in the absence of caspase 3, dying MCF7
cells may not be able to release LPC. Caspases are pivotal enzymes in a protease
cascade that triggers apoptosis. The large number of bands seen by western blotting
of fractalkine from apoptotic BL-cells suggests that proteolytic cleavage occurs
during apoptosis. It will be interesting to discover whether the activity of TACE and
ADAM 10 are influenced by caspases. The depletion of cholesterol from cell
membranes can alter the activity of TACE and ADAM10 (Matthews, 2003). This
suggests that a change in membrane fluidity, as occurs during apoptosis could affect
cleavage of fractalkine as well as the release of membrane LPC.
LPC is linked to mitochondrial triggering of cell apoptosis through the bcl-2
group member, bid; full-length bid binds to LPC and incorporates into the lipid
bilayer of the mitochondria. This destabilises the mitochondria allowing the release
of cytochrome C and the activation of caspase-9 (Goonesinghe, 2004). Redistribution
of the membrane lipids like phosphatidylserine and lysophosphatidylcholine is not
just important for apoptotic-cell phagocytosis but is also relevant to chemotaxis.
Altering the LPC content of cells changes their membrane fluidity. The inverted-
cone shape of LPC makes the membrane more convex and prevents its puncture by
viral particles and conversely, stimulates pinocytosis of the membrane (Stiasny,
2004). Intercalation of LPC into the plasma membrane promotes blebbing and these
blebs may contain MFG-E8 and autoantigens (Casciola-Rosen, 1994; Oshima, 2002)
In addition, membrane blebs freed from the apoptotic cell surface may themselves be
chemoattractive to macrophages. Germinal centre B cells isolated from tonsil
undergo spontaneous apoptosis, releasing chemotactic molecules that are
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concentrated in the blebs that pinch off from the apoptotic cell's membrane
(Segundo, 1999). It may prove to be that fractalkine is concentrated in blebs that
were chemoattractive to macrophages. Certainly, the particulate pattern of fractalkine
surface-expression on apoptotic cells seen by confocal microscopy may represent a
concentration of the chemokine in membrane blebs.
6.7 Fractalkine and MFG-E8
Rather than being recruited from circulating monocytes, it is possible that the
TAMs that infiltrate BL are tissue macrophages that move in from nearby. Local
rather than systemic chemokine networks may orchestrate which kind of cells nest
amongst the tumour cells, allowing macrophage access but denying NK cells and
neutrophils. Lymph node architecture is far from arbitrary and is controlled by
cytokine members of the TNF-family like lymphotoxin and chemokines like BLC
(CXCR5) (Mariathasan, 1995; Forster, 1996). In addition to these known
chemokines, fractalkine and MFG-E8 might also have an influence. A role for MFG-
E8 in germinal centre formation has just been described that may have implications
for the study of BL.
With the identity of a receptor that directly binds to PS in doubt, more
attention must be paid to opsonins such as MFG-E8 and Clq, that can link
macrophages to apoptotic cells (Devitt, 2004; Borisenko, 2004). MFG-E8 binds
oxidised PS on apoptotic cells and links (via its RGD motif) to integrin receptor a3p5
or a3p2- This work has shown that CD 14 is up-regulated on macrophages that have
migrated to apoptotic BL-cells. Might it be possible that MFG-E8 or other clearance
receptors might similarly be up-regulated in readiness to phagocytose the dying
target? This would neatly overcome the theoretical problem of fractalkine receptor
desensitisation. As a macrophage moves up the chemokine concentration gradient
fewer and fewer of its receptors are available and so it eventually stops moving at the
site of highest chemokine concentration. This would prevent the macrophage using
CX3CR1 to tether apoptotic cells displaying fractalkine. Currently, the evidence for
MFG-E8 involvement in macrophage chemotaxis to apoptotic cells is indirect but
very exciting.
171
New evidence has emerged that may link MFG-E8 to fractalkine-induced
chemotaxis to apoptotic cells. MFG-E8 was identified to be significantly up-
regulated in a micro-array of genes from macrophage-like microglia cells that had
been treated with fractalkine (Leonardi-Essmann, 2005). If dying and damaged
neurons release fractalkine that causes local macrophages to produce MFG-E8,
couldn't the same thing be occurring in Burkitf s lymphoma? Early and preliminary
experiments presented here show that TAM in BL express CX3CR1 but the presence
of MFG-E8 has not been demonstrated in BL to date. The fact that tingible body
macrophages express MFG-E8 (Hanayama, 2004), and that BL is a tumour that
resembles a germinal centre B cell, makes the up-regulation of MFG-E8 by
fractalkine more likely.
The MFG-E8 knockout mouse has a very interesting phenotype in that the
MFG-E8-/- macrophages are able to tether apoptotic cells but do not phagocytose
them, indicating that integrin signalling is important for the "tickling" stage of
engulfment. Later on, MFG-E8-/- developed an autoimmune glomerulonephritis.
Another extraordinary feature of this knockout was massive spleenomegaly caused
by increased numbers of germinal centres. Despite being three times bigger than the
wild type, the ration of B cells to T cells did not change in the knockout (Hanayama,
2004). This might suggest that MFG-E8 has a role in the regulation of germinal
centre formation.
Conclusion
The search for a "come-get-me" chemokine began by looking at the
phagocytic "tethering" receptor CD 14, and ended with the discovery that fractalkine,
a "chemokine on a stalk" was released by apoptotic BL-cells. If fractalkine behaves
in BL in the same way as it does in the brain and in vitro, its release from apoptotic
cells will prolong the life of the macrophages, perhaps by stimulating the PI3K/Akt
pathway (Boehme, 2000; Shulby, 2004). Thus stimulated, the long-lived TAM might
use MFG-E8 to efficiently engulf even more apoptotic cells, and secrete factors that
stimulate tumour growth (Ogden, 2005). In this way, the persistence of apoptotic
cells within BL maintains a non-inflammatory environment that allows the tumour to
thrive, safe from immune detection.
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The tumour suppressor gene p53, has been described as the most important
gene in cancer (Greenblatt, 1994). As p53 accumulates in damaged cells, it prevents
the defective DNA from replicating and may even drive the cell to commit suicide by
apoptosis. The finding that fractalkine was a direct target of p53 is intriguing and fits
with the idea that fractalkine release by apoptotic cells may not be limited to
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Abstract
In Burkitt's lymphoma (BL), apoptosis occurs at high frequency alongside uncontrolled proliferation. Macrophages
infiltrate these tumours in large numbers and engage in the phagocytic clearance of apoptotic cells in situ. Here we
tested the hypothesis that apoptosis of BL cells may provide a mechanism for recruitment of macrophages to these
tumours. We show that monocytes and macrophages, but not neutrophils, preferentially migrated to apoptotic BL
cells in vitro. Transfection of BL cells with the anti-apoptotic gene bcl-2 both prevented apoptosis and abolished
macrophage chemotaxis. Macrophage migration to BL populations correlated well with the number of apoptotic BL
cells present (the Pearson correlation r = 0.81, p< 0.0001). Chemoattraction of murine macrophages to apoptotic
human BL cells demonstrated that the mechanism was conserved across these species. In an attempt to identify the
macrophage receptors involved in this process, we investigated whether CD 14 and CD36, two receptors important in
the phagocytic clearance of apoptotic cells, were also involved in the chemotactic macrophage response. We found that
bone marrow-derived macrophages from CD14~/_ and CD36~/_ mice moved as well as wild-type macrophages in
chemotaxis assays towards apoptotic BL cells. Migrating macrophages were found to be up-regulated in their
expression of CD 14, however, suggesting that, although this receptor does not appear to be required for 'sensing'
apoptotic cells, it may be up-regulated on the surface of the migrating macrophage in readiness for apoptotic corpse
clearance.
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Introduction
Burkitt's lymphoma (BL) is a malignancy of germinal
centre B-cell origin that is associated histologically with
frequent apoptotic cells and infiltrating macrophages,
which endow the tumour with its classical 'starry sky'
appearance (Burkitt, 1958). The pyknotic nuclei are
testament to the high rate of apoptosis that accompanies
cell proliferation in the tumour and the macrophages are
actively engulfing the numerous apoptotic cells they
encounter. Apoptotic cells can be phagocytosed in many
different tissues by neighbouring cells, including epithe¬
lial cells and fibroblasts, which act as 'amateur'
phagocytes. However, when cell death occurs at high
rates then macrophages, the 'professional' phagocytes,
come into play and efficiently clear away apoptotic cells.
By isolating the dying and dead cells from their
environment, such clearance is not only a damage
limitation measure, but also appears to actively suppress
inflammatory and immune responses (Savill et al., 2002).
While much has been learned in recent years of the
mechanisms by which apoptotic cells are recognised and
engulfed by macrophages, little is yet known of the
processes underlying the 'sensing' of apoptotic cells by
phagocytes (Fadok, 1992). Recent studies have high¬
lighted the importance of chemokine release during
normal cell death and of how macrophages may sense
and then move towards a dying cell in readiness to
engulf the apoptotic corpse (Audran et al., 1996; Cocca
et al., 2002; Horino et al., 1998; Kao et al., 1994; Lauber
et al., 2003; Segundo et al., 1999). Faulty macrophage
chemotaxis towards apoptotic cells might delay clear¬
ance and result in unwanted inflammation and a
predisposition to autoimmune diseases like systemic
lupus erythematosus (Herrmann, 1998; Taylor, 2000).
Chemotaxis is the directional movement of a cell up a
chemokine gradient and is important in a number of
biological processes including leukocyte recruitment to
sites of inflammation, and wound healing (reviewed in
Zlotnik and Yoshie, 2000). Here, we have examined the
migration of macrophages to chemotactic molecules
released from apoptotic BL cells. Migration and
phagocytosis involve common membrane and cell shape
changes and both processes are known to be regulated
by common signalling pathways involving integrins and
small G proteins (Aderem and Underhill, 1999; Hogg
and Leitinger, 2001). Indeed, apoptotic-cell engulfment
and cell migration in the nematode worm Caenorluibditis
eleqans have been shown to be governed by common
genes that are conserved in flies and mammals (Wu and
Horvitz, 1998). Given the mechanistic similarities
between phagocytosis and chemotaxis, we reasoned that
macrophage receptors involved in the recognition and
engulfment of apoptotic cells might also function in the
chemotactic response of macrophages to such cells. In
this study, we have focussed on two receptors that have
important roles in the clearance of apoptotic cells: the
lipolysaccharide receptor, CD 14 and the class B
scavenger receptor, CD36.
Our previous work has shown that CD 14 is not only
involved in the clearance of apoptotic cells by human
macrophages in vitro (Devitt et al., 1998) but also by
murine macrophages in vivo (Devitt et al., submitted).
Significantly, macrophages in multiple tissues of CD 14-
deficient mice show a defect in apoptotic-cell removal
resulting in the persistence of apoptotic cells that are not
associated with phagocytes in situ. One interpretation of
this observation is that the absence of CD 14 caused a
chemotactic defect leading to a reduced efficiency of
apoptotic-cell clearance. In this context, it is worth
noting that neutrophils of the CD 14"'"" mouse have
been shown to be tardy in migrating into an inflamed
peritoneum (Yang et al., 2002).
Both CD14 and CD36 are known to bind lipids and in
this respect may be appropriate candidate chemotactic
receptors of macrophages that sense lipid moieties
released from apoptotic cells. Of particular significance
to this possibility is the recent observation that the lipid
lysophosphatidylcholine is released from apoptotic cells
and appears to function as a chemoattractant for
macrophages (Lauber et al., 2003). CD36 is a well-
characterised scavenger receptor for oxidised low-
density lipoprotein that also recognises altered lipid on
the surface of apoptotic cells (Ren et al., 1995; Savill
et al., 1992). CD 14, as well as binding glycolipids, also
binds phospholipids, a function shared with CD36
(Sambrano and Steinberg, 1995; Yu and Wright,
1997). Here we use macrophages from CD14~'~ and
CD36~'~ mice to investigate the possible role of these
receptors in chemotaxis of macrophages towards apop¬
totic BL cells in vitro.
Materials and methods
Cells
The BL line, Mutu, and stable 6c/-2-transfectant
(Mutu bci-2) were obtained and cultured as described
(Milner et al., 1992). Human peripheral blood was
obtained from normal volunteers and buffy coats from
the Scottish National Blood Transfusion Service.
Ethical approval was obtained from the Lothian
Research Ethics Committee. Human BL tumour biopsy
was a gift from Katrina Wood, University of Newcastle-
upon-Tyne. BALB/c wild-type mice and CD14_/
animals were purchased from B&K Universal (Hull,
UK) and provided by Sauna Goyert, North Shore, New
York, respectively. C57BL/6 wild type and CDSfi"^
mice were a gift from John Savill, Edinburgh University.
The UK Government Home Office approved all animal
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housing and procedures. Bone marrow derived macro¬
phages (BMDM) and peritoneal macrophages were
prepared from 8 to 12 week-old mice. Cell viability
was assessed by trypan blue dye exclusion and purity by
cytospin preparations of cells and by immunostaining
and flow cytometry.
Macrophage culture
Mouse macrophages were cultured as previously
described (Johnson et al., 1983; Ren et al., 2001; Savill
et al., 1992). Briefly, for mouse BMDM, femurs were
removed, cleaned and the marrow flushed with DM EM
supplemented with 2mM L-glutamine, lOOU/ml peni¬
cillin, 100pg/ml streptomycin, (DMEMsupp)(Gibco,
Paisley, UK) 10% heat inactivated FBS and 10%
conditioned supernatant from L929 cells as a source of
M-CSF (Labtech International, UK) (Hume and
Gordon, 1983).
Peripheral blood mononuclear cells (PBMC) and
neutrophils were isolated from the blood of normal
donors by separation over a Percoll gradient (Amer-
sham Pharmacia Biotech, UK). Neutrophils were
washed in PBS and used immediately. Mononuclear
cells were plated at 5 x 106 cells/ml in 6-well tissue
culture plates (Costar). Lymphocytes were removed by
washing after 1 h and adherent monocytes were either
used immediately or matured into macrophages by
culture for a further 8 days in DMEMsupp and heat
inactivated 10% autologous serum or human AB serum
(Sigma).
Maintenance of cell lines
Mutu BL cells were cultured in suspension in RPMI
supplemented with 2mM L-glutamine, lOOU/ml peni¬
cillin, lOOpg/ml streptomycin (RPMIsupp) and 10%
serum supreme (Biowhittaker, MA). Mutu/,<./_2 were
cultured with RPMIsupp containing 2.5mg/ml neomycin
(Gibco Invitrogen, UK).
Immunohistochemistry
Formalin-fixed, paraffin-embedded tumours were cut
into 4 pm-thick sections and mounted onto Vectabond-
coated glass slides (Vecta, CA). Briefly, slides were
dewaxed in xylene, rehydrated and stained with
haematoxylin and eosin (Shandon, UK). Slides were
microwaved in antigen retrieval solution, blocked with
biotin, avidin (Vecta, CA) and 5% normal goat serum
(Harlan Sera-Lab, UK). For immunohistochemistry,
slides were incubated with a mouse monoclonal anti-
human CD68 (Dako, Denmark) followed by a biotiny-
lated goat anti-mouse antibody (Dako). Positive cells
were visualised using a streptavidin-HRP colour reac¬
tion with DAB (Dako) (Vecta, UK). Sections were
counter-stained with haematoxylin (Shandon UK).
Induction of apoptosis
2 x 106 Cells were exposed to 100mJ/cm"2 of UVB
light and used 12 h later after washing in RPMIsupp
without serum.
Chemotaxis assay
Highly pure (>95%) neutrophils were used immedi¬
ately in chemotaxis assays. Monocytes and macrophages
were placed on ice for 5 min and harvested using a cell
lifter (Costar), and then washed in RPMIsupp without
serum. 2 x 106/ml Mutu bcb2, Mutu or UV-treated Mutu
were placed in 24 well plates. RPMIsupp without serum
was used as a negative control and lOOng/ml human
recombinant CCL5 (Peprotech) or 1(U8M fMLP (N-
formylated-methionine-leucine-phenylalanine) (Sigma)
as a positive control. Chemotaxis experiments were
performed in polyvinyl uncoated transwells (Costar,
5 pm pores) using a modification of Boyden's technique
(Barleon et al., 1996). Macrophages (105) were placed in
100 pi of RPMIsupp in the top of a transwell and allowed
to transmigrate to the bottom well at 37°C, 5% C02 for
either lh (neutrophils) or 4h (monocytes and macro¬
phages). Control wells containing BL that had no
contact with macrophages were set up in parallel to
assess the amount of apoptosis at the end of the assay.
Non migrated cells were removed from the upper well
and the upper membrane was wiped. Filters were fixed
in methanol and stained with Dif-Quik II (Dade,
Germany). The number of cells that had migrated was
counted in ten random high-power fields (x 400
magnification) using an inverted microscope. All sam
pies were prepared in duplicate and experiments were
repeated a minimum of three times. The mean number
of cells counted in ton high power fields was calculated
and significance was measured using the Student's t-test.
All data were graphed and analysed using Graph Pad
Prism software version 3.02.
Fluorescence labelling and flow cytometry
All fluorescence labelling was carried out in the dark
on ice. To measure apoptosis, cells were washed and
maintained in calcium-containing buffer and labelled
with annexin V and propidium iodide (Bender Med
Systems, USA). CD 14 expression was measured on
transmigrated macrophages using a phycoerythrin-
labelled (PE) monoclonal mouse anti-human CD 14
and a PE-IgG2a isotype control (Dako, Denmark). All
cells were analysed on a Coulter EPICS flow cytomctcr.
Light scatter properties were used to identify zones
24 L.A. Truman et al. / lmmunobiology 209 (2004) 21-30
containing viable or apoptotic BL cells as described
(Dive et al., 1992). For every experiment, the flow
cytometric data was confirmed by analysis of nuclear
morphology by staining with 4,6-diamidino-2-phenylin-
dole (DAPI) (Sigma,UK). The percentage of cells with
apoptotic morphology matched the number of cells
falling in the 'apoptotic zone' by flow cytometry (data
not shown).
Results
Macrophages phagocytose apoptotic cells in BL
BL is a small non-cleaved B cell tumour that contains
many macrophages diffusely distributed amongst the
"monotonous sea" of tumour cells. H&E staining (Fig.
1 A) shows apoptotic lymphocytes with typical shrunken
pyknotic nuclei (marked by an asterisk) that are more
intensely stained than neighbouring live cells. The
macrophages have large amounts of pale-staining
cytoplasm that stand out clearly from the surrounding
dark tumour nuclei. This creates the characteristic
"starry sky" appearance of BL seen at low power. The
cytoplasm of the macrophages is engorged with
apoptotic bodies (marked with an arrow), indicating
that macrophages are actively phagocytosing apoptotic
cells in situ. The high numbers of macrophages
distributed throughout the tumour are striking when
the cells are labelled with anti-CD68, a macrophage
marker (Fig. 1B).
Mutu BL cells expressing bcl-2 are resistant to
apoptosis
As cells undergo apoptosis they shrink in size and
become more granular as nuclear chromatin clumps
together forming bleb-like structures. These typical
shape changes mean that dying cells can be clearly
discriminated by flow cytometry (Dive et al., 1992). A
representative plot is shown in Fig. 2. After a four-hour
transmigration assay BL were removed from the lower
chamber of the 24-well plate and the number of
apoptotic cells was assessed using FACS. A typical
forward versus side scatter plot of Mutu cells observed
at the end of a transmigration assay is shown. When
transfected with bcl-2, only 8.6% of Mutu bci-2 cells fell
into the dead zone (Fig. 2A). Even 12 h post UV-
treatment, Mutu transfected with bcl-2 remained resis¬
tant to apoptosis and as little as 15% of cells entered the
dead zone (data not shown). Since untreated Mutu BL
cells undergo spontaneous apoptosis in culture, 27.5%
of cells were apoptotic by the end of the experiment
(Fig. 2B). However, 97% of UV-induced Mutu cells
were apoptotic 12 h post-UV treatment (Fig. 2C).
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Fig. 1. Immunohistochemistry of BL: (A) High numbers of
apoptotic cells (*) with condensed nuclei were seen in the
tumour. Pale-staining tumour-associated macrophages were
distributed in a typical "starry sky" pattern. Macrophages
contained phagocytosed apoptotic bodies in their cytoplasm
(arrow). (B) Positive CD68 staining (shown in black)
distinguished macrophages from surrounding tumour cells.
Chemotaxis of human monocytes and macrophages
to apoptotic Mutu BL cells
In transmigration assays, we saw that monocytes and
8-day old macrophages preferentially migrated to
apoptotic Mutu cells (Fig. 3A and B). lOOng/ml CCL5
(human RANTES) in RPM1 was used as a positive
control and media alone as the negative control in these
experiments. Checkerboard experiments (including che-
moattractant in either the upper or lower wells) revealed
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Fig, Light scattnr flnw cytometry plots of Mutu BL populations showing 'viable' and 'apoptotic' zones according to Dive ct al.,
1 99?„ Percentages refer to the number of apoptotic cells falling in the 'apoptotic' zone: (A) Mutu BL cells transfectcd with bcl-2 were
resistant to apoptosis and only 8.6% were apoptotic. (B) 27.5% of Mutu BL cells underwent spontaneous apoptosis in culture. (C)
97% of Mutu cells were apoptotic 16 h following UV-treatment. FS: forward scatter. SS: side scatter.
that macrophage migration was true chemotaxis and not
simply chemokinesis (data not shown). Monocyte and
macrophage chemotaxis to UV-treated Mutu BL cells
was significantly higher than to Mutu hc/_2 (Student's t-
test ***/;< 0.0001), macrophage chemotaxis towards the
bcl-2-expressing BL cells being virtually abolished.
Macrophage migration to untreated Mutu depended
on the number of (spontaneously) apoptotic cells
present and was always higher than Mutu /,c/.2. Macro¬
phages migrated preferentially to UV-treated Mutu that
were over 90% apoptotic. The monocytic cell line Mono
Mac 6 (MM6) also transmigrated to apoptotic BL cells
(data not shown) in agreement with published results
using this cell line in chemotaxis assays in other systems
(Lauber et al., 2003; Ziegler-Heitbrock et al., 1988).
In stark contrast to monocytes and macrophages,
neutrophils failed to migrate to BL cells despite
migrating effectively towards I0~8M fMLP (Fig. 3C).
In these experiments, >90% of the neutrophils were
viable (as determined by tryphan blue exclusion) at the
end of the short (lh) migration period. Cytospin
preparations of neutrophils also showed no evidence
of degranulation. The extremely low levels of migration
of neutrophils towards all three BL preparations (lower
than to media alone, Fig. 3C) suggested that BL cells
release factor(s) that can inhibit neutrophil migration,
independently of apoptosis.
Macrophage chemotaxis correlates with the number
of apoptotic Mutu BL cells
Because the percentage of apoptotic cells varied
slightly between individual experiments we carefully
measured apoptosis by FACS using FITC-labelled
Annexin V. Annexin V binds exposed phosphatidylser-
ine on the outer leaflet of the plasma membrane of
apoptotic cells. We next compared the percentage of
Annexin V-positive cells with the chemotactic index
taken from 23 experiments altogether. The chemotactic
index refers to the fold increase in the number of
transmigrated macrophages above tho negative (media)
control (Fig. 4). Here, Mutu bc/.2 had low levels of
apoptotic cells, a low number of Anncxin V positive cells
and stimulated very little macrophage transmigration.
Mutuuv had a high percentage of Annexin V positive
cells and also a high number of transmigrated macro
phages. The correlation between the percentage of cells
binding Annexin V and macrophage chemotaxis, was
striking (n = 10, Pearson's r = 0.81, ***/?<0.0001).
These results show that dying Mutu cells release one
or more chcmotactic molecules that specifically attract
monocytes and macrophages.
CD14~'~ and CD36~'~ macrophages have no
chemotaxis defect
When we phenotyped the human macrophages that
had transmigrated in response to apoptotic Mutu BL
cells we noted that they expressed higher levels of the
phagocytic receptor CD 14 compared to input macro¬
phages (Fig. 5A). We adapted our transmigration assay
to use mouse bone marrow-derived macrophages. Using
10~SM fMLP as a positive control, we saw that mouse
BMDM migration to human apoptotic Mutu BL was a
conserved phenomenon between these species. Mouse
BMDM also preferentially migrated to apoptotic Mutu
BL cells in the same way that human macrophages had
(data not shown). We then examined macrophages



















































Fig. 4. Macrophage migration to Mutu BL cells is correlated
to the number of apoptotic cells. Apoptosis was measured as
the percentage of Mutu binding FITC-labelled Annexin V as
analysed by flow cytometry. The chemotaxis index is the fold
increase in the number of transmigrated macrophages com¬
pared to media (negative) control. Results from 23 separate
experiments are plotted. The Pearson correlation r = 0.81,
Student's /-test **><0.0001.
deficient in the phagocytic receptors CD 14 and CD36.
BMDM from CD14~'~ mice had no defect in chemo¬
taxis to apoptotic BL cells (Fig. 5B). Similarly, BMDM
from the CD36~'~ mouse showed no defect in chemo¬
taxis to apoptotic BL cells compared to wild-type
macrophages (Fig. 5C). Although important for apop-
totic-cell clearance, these results indicate that CD 14 and
CD36 are not necessary for macrophage chemotaxis to
apoptotic cells.
Discussion
The results presented here demonstrate monocyte and
macrophage chemotaxis to apoptotic BL cells in vitro
for the first time. Currently, we are investigating
whether apoptosis may also be a mechanism for
recruiting monocytes and macrophages to lymphomas
in vivo.
Tumour-associated macrophages have been described
as "benign" in standard pathology textbooks (Cotran
i
Fig. 3. Mononuclear phagocyte chemotaxis to apoptotic Mutu
BL cells. Apoptosis was induced by UV-light. Chemotaxis was
measured as the mean number of transmigrated cells counted
in ten high power fields: (A) Macrophage chemotaxis to
apoptotic Mutu BL cells. (B) Monocyte chemotaxis to
apoptotic Mutu BL cells. For A and B media alone was
the negative control and lOOng/ml CCL5 was the positive
control. (C) Absence of neutrophil chemotaxis to apoptotic
Mutu BL cells. Media alone was the negative control and
10~SM fMLP was the positive control. One representative
result from at least three separate experiments is shown. Data
represent means + SEM;
*><0.005,*/3<0.02.
Student's /-test ><0.0001,
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p = 0.56
et al., 1989) but they may influence the pathogenesis of
Burkitt's (and related) lymphomas by multiple means
including helping the tumour to avoid immune detection
as has been suggested for other malignancies (Manto-
vani et al., 2002). Our data shows that apoptotic tumour
cells can recruit monocytes and macrophages in vitro.
Once arrested in the tumour microenvironment, these
cells are likely to acquire an 'alternatively activated'
phenotype and engage in the engulfment of apoptotic
cells. The resulting anti-inflammatory effects, such as the
release of TGF-/? (Savill and Fadok, 2000), may aid
tumour growth through evasion of adaptive anti-
tumour immunity.
BL were not chemoattractive to neutrophils and
appeared to be capable of actively preventing neutrophil
transmigration, presumably through the release of
soluble inhibitory-factors. Failure of neutrophil chemo-
taxis to BL cells appeared to be independent of
apoptosis, since, Mutuftf/_2, with negligible apoptosis
and Mutuuv, containing large numbers of apoptotic
cells, both inhibited neutrophil chemotaxis. This was
reflected in the histological picture seen in Fig. 1, which
showed a paucity of polymorphonuclear cells infiltrating
BL. This observation requires further work although
one prediction might be that BL cells fail to secrete any
CXCL chemokines expressing the ELR (Glutamate-
Leucine-Arginine) tripeptide sequence, a chemokine
group that is known to attract neutrophils.
Infection of cells with Epstein-Barr virus (EBV) can
have profound immunomodulatory effects both in vitro
and in vivo. EBV-positive Hodgkin's lymphomas have
increased secretion of CCL5 and CXCL 10 (IP-10),
whereas mononuclear cells from EBV-infected indivi¬
duals produce no CCL3 (MlP-la) even after stimulation
with LPS (Jabs et al., 2002; Teruya-Feldstein et al.,
2000). Since Mutu is an EBV positive BL line, we
repeated our experiments in an EBV negative BL line,
BL2 (data not shown). Again, we demonstrated that
macrophages migrated preferentially to apoptotic BL2
Fig. 5. (A) Human macrophages that had migrated to
apoptotic cells expressed high levels of CD 14. Flow cytometric
histograms are shown of immunolabelled CD14-PE input
versus migrated macrophages. (B) Mouse BMDM from the
CD14~7~ mice had no defect in chemotaxis to apoptotic Mutu
BL cells. Media alone was the negative control and 1(V8M
fMLP was the positive control. Chemotaxis was measured as
the mean number of transmigrated cells counted in ten high-
power fields. One representative result from at least three
separate experiments is shown. Data shown are means±SEM;
Student's /-test p = 0.26. (C) Mouse BMDM from the
CD36~'~ have no defect in chemotaxis to apoptotic Mutu BL
cells. One representative result from at least four separate
experiments is shown. Data shown are means+ SEM;
Student's /-test p = 0.56.
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cells. This experiment excluded the possibility that EBV
itself had caused the macrophage chemotaxis.
We saw chemotaxis to both spontaneous and UV-
induced apoptotic cells. This suggests that chemotaxis
was to products released during the process of apoptosis
and was not dependent on the (UV) stimulus that
induced cell death. Macrophages were also able to
migrate to apoptotic cells that had been induced by
stimuli other than UV, like staurosporin and ionomycin
(data not shown). Stable transfection of Mutu BL cells
with bcl-2 reduced the high level of spontaneous
apoptosis in Mutu to low levels. It is conceivable that
bcl-2 acts by inducing chemokine expression by Mutu as
has been shown with bcl-xL in macrophages (Lakics
et al., 2000). However, even when Mutu M.2 data is
excluded, there remains a strong correlation between the
number of apoptotic cells and chemotaxis (when UV-
treated Mutu cells are compared to untransfected Mutu
cells) (Pearson's r = 0.73, ***/>< 0.001). BL that retain
the features of the tumour biopsy cells have high levels
of spontaneous apoptosis and so it proved impossible to
obtain a 100% pure population of live Mutu without
some contaminating apoptotic cells. Methods to remove
apoptotic cells such as density gradient centrifugation,
reduced the numbers of dead cells but were not as
effective as bcl-2 transfection. The question of whether
bcl-2 could inhibit chemotaxis in the current model
through mechanisms other than inhibition of apoptosis
deserves further attention.
Although CD 14 and CD36, lipid-binding receptors of
macrophages that are known to function in apoptotic
cell clearance, are not members of the chemokine
receptor family, the discovery of a lipid chemokine
factor secreted from apoptotic cells (Lauber et al., 2003)
led us to rationalise that these receptors may play a role
in macrophage chemotaxis towards such cells. Integrin
signalling is important in the firm adhesion of migrating
cells to the endothelium during chemotaxis and macro¬
phages combine CD36 together with the integrin av/fi 'n
a complex to phagocytose apoptotic cells (Audran et al.,
1996; Savill et al., 1992). CD14 is a glycophosphatidy-
linositol-linked receptor with no intracellular domain
and so needs to cooperate with receptors like Toll-like
receptor 4 and CD1 lb in order to signal, (Ingalls et al.,
1998; Jiang et al., 2000). However, co-localisation of
CD 14 with a classical chemokine receptor has not been
described to date. We observed that transmigrated
macrophages expressed high levels of CD 14 compared
to the input population. This may represent either up-
regulation of CD 14 during chemotaxis, or the specific
migration of the CD14-high macrophage subset towards
the apoptotic cells. Study of human monocyte subsets
showed that CD14-high monocytes expressed CCR2
and moved towards CCL1 (MCP-1) (Weber et al., 2000)
and CD14-low monocytes failed to respond to this
chemokine but moved preferentially to CX3CL1 (frac-
talkine) (Ancuta et al., 2003). Murine homologues of the
CD14-high and low subsets have been described which
also have distinct migratory properties (Geissmann et al.,
2003). It is tempting to speculate that the CD 14 on the
migrated macrophages is up-regulated in readiness for
efficient corpse recognition and removal.
Despite observing that transmigrated human macro¬
phages expressed high levels of CD 14, we saw no
chemotactic defect in macrophages from CD14~'~ mice.
Although CD 14 is a marker for monocytes with distinct
migratory potentials, our results show that CD 14 is not
required for macrophage chemotaxis to apoptotic cells.
In vivo studies of bacterial peritonitis have also shown
that F4/80-positive monocytes in CD14~'~ mice were
recruited as efficiently as wild-type controls (Henneke
et al., 2002). Similarly, macrophages from the CD36_/~
mouse also had no chemotaxis defect, migrating equally
well towards apoptotic BL cells as wild-type controls.
In conclusion, the in vitro results presented here
demonstrate that apoptotic tumour cells have the
potential to play a key role in recruiting the macro¬
phages that constitute a substantial proportion of the
cell mass in BL. If this proves to be the case in vivo, this
will have important implications for the role of both the
apoptotic tumour cell and the macrophage in BL
pathogenesis. Although "eat-me" signals displayed by
dying cells have been well described, apoptotic-cell "find
me" signals are mostly unknown to date. Towards the
end of its life, a dying cell may well release lipids to
attract phagocytes but our results have shown that
macrophage chemotaxis to an apoptotic cell does not
require the 'phagocytic lipid receptors' CD 14 and CD36.
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